Spinal cord grey matter pathology in multiple sclerosis by Gilmore, Christopher Patrick
Gilmore, Christopher Patrick (2008) Spinal cord grey 
matter pathology in multiple sclerosis. DM thesis, 
University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/10496/1/Gilmore_-
_Spinal_Cord_Grey_Matter_Pathology_in_Multiple_Sclerosis.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Thesis submitted to the University of Nottingham
For the degree of Doctorate of Medicine
June 2008 by
Christopher Patrick Gilmore
BMedSci, BMBS, MRCP (UK)
Spinal Cord Grey Matter Pathology in Multiple Sclerosis
2Table of Contents
Table of Contents..................................................................................................2
Figures and Tables ...............................................................................................7
Abstract.................................................................................................................8
Publications and presentations related to thesis ...................................................9
Abbreviations ......................................................................................................13
Acknowledgments...............................................................................................15
Chapter 1: Introduction ....................................................................................16
1.1 Overview .........................................................................................................................16
1.1.1 Epidemiology............................................................................................................16
1.1.2 Genetic Studies ........................................................................................................16
1.1.3 Aetiology...................................................................................................................16
1.1.4 Clinical Course .........................................................................................................17
1.1.5 Diagnosis and Management.....................................................................................18
1.2 The Pathology of MS  the White Matter plaque.............................................................19
1.2.1 Inflammatory cell infiltration ......................................................................................19
1.2.2 Demyelination and oligodendrocyte pathology .........................................................20
1.2.3 Evidence of Heterogeneity in MS lesions .................................................................21
1.2.4 Gliosis.......................................................................................................................22
1.2.5 Remyelination...........................................................................................................22
1.2.6 Axonal loss ...............................................................................................................22
1.3 The pathological substrate of clinical disability in MS......................................................24
1.4 GM Pathology in MS .......................................................................................................25
1.5 Thesis Outline .................................................................................................................30
Figures ..................................................................................................................................31
Chapter 2: Regional variations in the extent and pattern of grey matter
demyelination in Multiple Sclerosis - a comparison between the
cerebral cortex, cerebellar cortex, deep grey matter nuclei and the
spinal cord.........................................................................................................33
2.1 Introduction .....................................................................................................................33
2.2 Materials and methods....................................................................................................36
32.2.1 Clinical material ........................................................................................................36
2.2.2 Preparation of the sections.......................................................................................37
2.2.3 Immunohistochemistry..............................................................................................37
2.2.4 Assessment of GM and WM lesions.........................................................................37
2.2.5 Statistical analysis ....................................................................................................39
2.2.6 Reproducibility of measurements .............................................................................39
2.3 Results ............................................................................................................................40
2.3.1 Lesion counts and morphology.................................................................................40
2.3.2 Demyelination is more extensive in the GM than the WM ........................................41
2.3.3 Regional differences in the extent of demyelination .................................................41
2.3.4 Influence of age and disease duration on extent of demyelination ...........................42
2.4 Discussion.......................................................................................................................42
2.4.1 Demyelination in the cerebral cortex ........................................................................45
2.4.2 Cerebellar Demyelination .........................................................................................46
2.4.3 Spinal Cord Demyelination .......................................................................................48
2.4.4 Thalamic Demyelination ...........................................................................................49
2.4.5 Influence of disease duration and MS subtype .........................................................50
2.5 Conclusion ......................................................................................................................51
Figures ..................................................................................................................................52
Chapter 3: The extent and pattern of Grey Matter demyelination in the
spinal cord in Multiple Sclerosis .....................................................................61
3.1 Introduction .....................................................................................................................61
3.2 Materials and methods....................................................................................................62
3.2.1 Clinical material ........................................................................................................62
3.2.2 Preparation of the sections.......................................................................................62
3.2.3 Immunohistochemistry..............................................................................................62
3.2.4 Histochemical Staining .............................................................................................63
3.2.5 Measurement of GM and WM lesions ......................................................................63
3.2.6 Statistical analysis ....................................................................................................63
3.3 Results ............................................................................................................................63
3.3.1 PLP Immunohistochemistry ......................................................................................63
3.3.2 Lesion counts ...........................................................................................................64
3.3.3 Demyelination is more extensive in the GM than the WM of the spinal cord ............64
43.3.4 Influence of age, sex and disease duration on extent of demyelination....................65
3.3.5 Lesion morphology ...................................................................................................65
3.3.6 GFAP expression within GM and WM plaques.........................................................66
3.3.7 The sensitivity of Luxol Fast Blue for detecting GM demyelination...........................66
3.4 Discussion.......................................................................................................................66
3.5 Conclusion ......................................................................................................................73
Figures ..................................................................................................................................74
Chapter 4: Spinal Cord atrophy in Multiple Sclerosis - relative
contributions of white matter and grey matter tissue loss............................91
4.1 Introduction .....................................................................................................................91
4.1.1 Evidence of GM atrophy in the brain in MS ..............................................................91
4.1.2 Atrophy in specific GM structures .............................................................................91
4.1.3 Mechanisms of GM atrophy in MS ...........................................................................92
4.1.4 Clinical relevance of GM atrophy..............................................................................93
4.1.5 Spinal cord atrophy in MS ........................................................................................94
4.2 Materials and methods....................................................................................................94
4.2.1 Clinical material ........................................................................................................94
4.2.2 Preparation of the sections.......................................................................................94
4.2.3 Measurements of GM and WM areas.......................................................................95
4.2.4 Validation and reproducibility of methods .................................................................96
4.2.5 Statistical analysis ....................................................................................................96
4.3 Results ............................................................................................................................96
4.3.1 WM area measurements ..........................................................................................96
4.3.2 GM area measurements...........................................................................................97
4.4 Discussion.......................................................................................................................97
4.4.1 WM atrophy is restricted to the upper cord...............................................................97
4.4.2 Spinal cord GM volume is preserved in MS..............................................................99
4.4.3 Influence of disease duration..................................................................................101
4.4.4 Limitations of our study...........................................................................................102
4.5 Conclusion ....................................................................................................................103
Figures ................................................................................................................................104
5Chapter 5: Neuronal Pathology in Multiple Sclerosis ..................................106
5.1 Introduction ...................................................................................................................106
5.1.1 Evidence of neuronal pathology secondary to GM demyelination ..........................106
5.1.2 Neuronal loss may occur within GM plaques via a number of mechanisms ...........108
5.1.3 Neuronal pathology secondary to axonal injury in distant WM lesions ...................110
5.1.4 MRS studies suggest there is substantial neuronal pathology in MS .....................114
5.1.5 Aims .......................................................................................................................115
5.2 Methods ........................................................................................................................115
5.2.1 Clinical Material ......................................................................................................115
5.2.2 Assessment of neuronal number and size..............................................................115
5.2.3 A note on profile based counting techniques and the Abercrombie correction .......117
5.3.4 Assessment of demyelination.................................................................................117
5.3.5 Statistics .................................................................................................................118
5.3 Results ..........................................................................................................................118
5.3.1 Neuronal counts .....................................................................................................118
5.3.2 Measurements of neuronal size .............................................................................119
5.4 Discussion.....................................................................................................................120
5.4.1 Evaluation of study methodology............................................................................121
5.4.2 There is substantial neuronal loss in the spinal cord in MS, particularly within
GM plaques .....................................................................................................................126
5.4.3 MS-related changes in neuronal size .....................................................................129
5.4.4 Clinical significance ................................................................................................130
5.5 Conclusions and future work.........................................................................................130
Figures ................................................................................................................................131
Chapter 6: The sensitivity of 4.7 Tesla MRI for detecting spinal cord
grey matter demyelination in Multiple Sclerosis - a post-mortem MRI-
histopathological correlative study...............................................................135
6.1 Introduction ...................................................................................................................135
6.2 Materials and methods..................................................................................................138
6.2.1 Clinical material ......................................................................................................138
6.2.2 MR Imaging Protocol ..............................................................................................138
6.2.3 Histological evaluation............................................................................................139
6.2.4 Immunohistochemistry............................................................................................139
66.2.5 Antibodies...............................................................................................................139
6.2.6 Histological Assessment.........................................................................................139
6.2.7 Assessment of lesion activity..................................................................................139
6.2.8 Image analysis .......................................................................................................140
6.2.9 Statistical analysis ..................................................................................................140
6.3 Results ..........................................................................................................................140
6.3.1 MBP Staining..........................................................................................................140
6.3.2 Lesion counts .........................................................................................................141
6.3.3 MHC class II and GFAP expression .......................................................................141
6.3.4 MRI.........................................................................................................................141
6.4 Discussion.....................................................................................................................142
6.4.1 Post-mortem MRI is highly sensitive for detecting spinal cord GM involvement
in MS ...............................................................................................................................142
6.4.2 Spinal cord GM plaques may be detected on MRI more readily than brain
lesions .............................................................................................................................143
6.4.3 Limitations of the study...........................................................................................145
6.5 Conclusion ....................................................................................................................146
Figures ................................................................................................................................147
Chapter 7: Summary of Results.....................................................................159
References ......................................................................................................162
7Figures and Tables
Figure 1.1 ........................................................................................................................ 31
Figure 2.1 ........................................................................................................................ 52
Figure 2.2 ........................................................................................................................ 54
Figure 2.3 ........................................................................................................................ 56
Figure 2.4 ........................................................................................................................ 58
Table 2.1.......................................................................................................................... 59
Table 2.2.......................................................................................................................... 60
Figure 3.1 ........................................................................................................................ 74
Figure 3.2 ........................................................................................................................ 75
Figure 3.3 ........................................................................................................................ 77
Figure 3.4 ........................................................................................................................ 79
Figure 3.5 ........................................................................................................................ 81
Figure 3.6 ........................................................................................................................ 82
Figure 3.7 ........................................................................................................................ 83
Figure 3.8 ........................................................................................................................ 85
Figure 3.9 ........................................................................................................................ 87
Figure 3.10 ...................................................................................................................... 89
Figure 4.1 ...................................................................................................................... 104
Figure 4.2 ...................................................................................................................... 105
Figure 5.1 ...................................................................................................................... 131
Figure 5.2 ...................................................................................................................... 132
Figure 5.3 ...................................................................................................................... 134
Figure 6.1 ...................................................................................................................... 147
Figure 6.2 ...................................................................................................................... 149
Figure 6.3 ...................................................................................................................... 151
Figure 6.4 ...................................................................................................................... 153
Figure 6.5 ...................................................................................................................... 155
Figure 6.6 ...................................................................................................................... 156
Table 6.1........................................................................................................................ 158
8Abstract
Background:
Traditionally, Multiple Sclerosis (MS) has been considered to be a predominantly white
matter (WM) disease. More recent studies have revealed considerable grey matter (GM)
involvement in the brain. However there is a paucity of literature examining GM pathology
in the spinal cord.
Objectives and methods:
We use human post-mortem material to explore various aspects of spinal cord GM
pathology in MS including (i) the extent and pattern of spinal cord demyelination, (ii) the
relative contributions of GM and WM volume loss to spinal cord atrophy, (iii) the extent of
neuronal pathology within the spinal cord and (iv) the sensitivity of post-mortem MRI for
detecting spinal cord GM plaques.
Results:
Within the spinal cord, GM demyelination is more extensive than WM demyelination with
many lesions showing a novel morphological pattern whereby the plaque borders
maintain a strict respect for the GM/WM boundary. Demyelination is more extensive in the
spinal cord GM than in other brain regions examined. Post-mortem MR imaging at 4.7
Tesla is highly sensitive for detecting the spinal cord GM plaques.
We demonstrate substantial neuronal loss in the spinal cord in MS, observing reductions
in both interneuron and motoneuron numbers. This neuronal loss occurs predominantly
within GM plaques. We also observe reductions in interneuron size, both within plaques
and in the myelinated GM. Despite this, we find no evidence of spinal cord GM atrophy.
Conclusions:
This study represents the first detailed examination of spinal cord GM involvement in MS.
We demonstrate substantial GM pathology in the spinal cord, further challenging the
concept that MS is a predominantly WM disease. A greater understanding of this
pathology may provide important insights into MS pathogenesis and mechanisms of
disability in the disease.
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Chapter 1: Introduction
1.1 Overview
Multiple Sclerosis (MS) is a chronic inflammatory disease of the Central Nervous System
(CNS) characterised by multifocal demyelinated sclerotic plaques. MS is the most
common chronically disabling neurological condition affecting young adults in the UK,
where it affects approximately 90,000 people1.
1.1.1 Epidemiology
The prevalence of MS varies considerably, being highest in northern Europe, southern
Australia and North America2. There is a latitudinal gradient in prevalence, independent of
genetic factors, with rates increasing as one moves away from the equator2. Migration
studies demonstrate that those who emigrate from an area of low-prevalence to an area
of high-prevalence remain at low risk if they move after 15 years of age3. Latitudinal
gradients are even described within the UK, with the highest rates being observed in
Scotland and Northern Ireland. The overall prevalence in the UK is 100-150/100,000 with
an annual incidence of approximately 7/100, 0004. Overall MS affects twice as many
women as men. The disease usually presents in the third or forth decade of life;
presentation before adolescence and beyond the age of 60 is uncommon.
1.1.2 Genetic Studies
Family studies reveal that MS has a concordance rate of 31% among monozygotic twins,
in comparison to 5% in dizygotic twins, highlighting a substantial influence of genetic
factors5. Genetic studies demonstrate weak associations with multiple genes including
certain Human Leucocyte Antigen (HLA) haplotypes (reviewed by Dyment et al6) and
polymorphisms in two non-HLA genes, the interleukin-2 receptor Į gene and the
interleukin-7 receptor Į gene298.
1.1.3 Aetiology
The aetiology of MS remains unknown. Several lines of evidence suggest it is an immune-
mediated disorder. These include observations related to genetic studies, animal studies,
immunosuppressive medications and histological assessments of MS plaques7. It is
hypothesised that the activation of CD4+ Th1 cells - sensitised to a self-antigen in the
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CNS - is an important early step in the disease process476. The oligodendrocyte-myelin
complex appears to be the principal target of this immune attack7. A single
oligodendrocyte can myelinate up to 3040 axons8; each myelin sheath consists of layers
of specialised oligodendrocyte plasma membrane wrapped in a spiral around the axon.
This multilamellar myelin sheath is composed of lipids and a number of myelin proteins
including MBP (myelin basic protein), PLP (proteolipid protein), MAG (myelin-associated
glycoprotein), MOG (myelin-oligodendrocyte glycoprotein) and CNP (23-cyclic nucleotide
3-phosphodiesterase)8. It is speculated that one of these proteins, or some other CNS
antigen, may be targeted by the immune system in MS. One proposed mechanism for this
loss of immunological tolerance is molecular mimicry, whereby exposure to an
environmental agent containing epitopes similar to self-antigens results in the generation
of activated, auto-reactive T cells. Candidate agents include the infections Ebstein Barr
Virus, Chlamydia Pneumonia and Human Herpes Virus 69.
It is suggested that these auto-reactive T cells then migrate into the CNS parenchyma
through a disrupted Blood Brain Barrier (BBB) where they recognise their target antigen,
processed by Antigen Presenting Cells such as macrophages and microglia.
Lymphocytes and macrophages subsequently secrete a range of substances which
mediate tissue damage and further propagate the inflammatory response. However, it is
important to note that recent studies argue against a primary role for CD4+ T cells in the
initiation of demyelination, reporting that these cells are scarce in very early MS lesions10,
11.
1.1.4 Clinical Course
80% of MS patients present with relapsing remitting (RR) symptoms12. The clinical
features of the relapse reflect the anatomical location of the demyelinated plaque, with
symptoms frequently resulting from plaques in the anterior visual pathway, the brainstem
and cerebellum, and the spinal cord. The degree of functional recovery following a
relapse is variable. Complete clinical recovery is frequently seen early in the disease
course, while at later stages there is often a persistent neurological deficit. In general,
relapse frequency declines over time. However, the majority of patients (approximately
80% after 20 years) enter a secondary progressive (SP) phase of disease, characterised
by a gradual accumulation of disability with or without superimposed relapses13. Even a
substantial proportion of patients labelled as having a benign disease course after 10
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years, will eventually develop progressive disability13, 14. 20% of patients present with
Primary Progressive MS (PPMS), characterised by a progressive course from onset
without relapses. In contrast to relapsing disease, PPMS usually presents with a chronic
progressive myelopathy, affects males and females equally and has an older mean age of
onset. Fixed disability in MS can therefore be acquired by two mechanisms; incomplete
recovery from relapse and disease progression. Overall 50% of MS patients require a
walking aid within 15 years of disease onset13.
1.1.5 Diagnosis and Management
The diagnosis of MS is made on clinical grounds, often supported by paraclinical
investigations such as Magnetic Resonance Imaging (MRI), evoked potential studies and
cerebrospinal fluid (CSF) examination. The diagnosis hinges on the ability to demonstrate
the dissemination of lesions in both time and space; that is to establish that two or more
episodes of demyelination have affected separate sites within the CNS at separate times.
Over 95% of MS cases have hyperintense lesions on T2 weighted MRI. Imaging can also
provide evidence of dissemination of lesions in space and time and is useful in excluding
conditions which mimic MS15. In over 90% of cases CSF examination demonstrates
oligoclonal IgG bands or increased IgG levels, providing evidence of intrathecal synthesis
of immunoglobulins. Visual and somatosensory evoked potential studies frequently
provide neurophysiological evidence of dysfunction of the optic nerves and sensory
pathways.
The mainstay of management remains symptomatic treatment for sensory disturbance,
spasticity, sphincter disturbance, fatigue and depression. Corticosteroids, for example
intra-venous methyl prednisolone, are frequently used to hasten recovery following a
disabling relapse although they do not significantly alter the ultimate recovery from an
attack16. Disease modifying immunomodulatory therapies (Interferon ȕ and glatiramir
acetate) result in a substantial reduction in the development of new gadolinium-enhancing
MRI lesions and reduce relapse frequency by approximately 30%, but appear to have little
impact on the progressive phase of the disease17. More powerful therapeutic options
include Natalizumab (an Į4-integrin antagonist), Alemtuzumab (Campath-1H, an anti-
CD52 monoclonal antibody) and Mitoxantrone which are more efficacious but have less
favourable side-effect and safety profiles18-20.
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1.2 The Pathology of MS  the White Matter plaque
The pathological hallmark of MS is the demyelinated white matter (WM) plaque, a sharply
demarcated oval-shaped lesion which may reach several centimetres in diameter. The
initial event in the formation of the demyelinated plaque is unknown, as are the factors
governing plaque topography. They may occur anywhere in the CNS with predilection
sites including the periventricular WM, optic nerves, cerebellum, cervical cord, brainstem
and leucocortical junction21-25. Plaques are generally centred on one or more small veins
or venules, sometimes displaying finger-like projections (Dawsons fingers) along the
course of the vessel21, 25. At the histological level the WM plaque is characterised by BBB
breakdown and inflammatory cell infiltration, demyelination and variable degrees of
remyelination, astroglial scar tissue, and axonal loss:
1.2.1 Inflammatory cell infiltration
Under healthy conditions immune cell invasion across the BBB is highly restricted, with
only a small proportion of leukocytes participating in immunological surveillance within
the CNS477, 478. However, post-mortem studies reveal extra-vascular deposition of serum
proteins within MS plaques, indicating BBB breakdown in the disease state26, 27. A number
of molecules are involved in effecting BBB breakdown and the recruitment of
inflammatory cells to the MS plaque. For example T cell migration is facilitated by (i) the
up-regulation of adhesion molecules on the luminal surface of cerebral blood vessels as a
result of inflammatory mediators activating endothelial cells28, (ii) chemokines which
promote macrophage trafficking29, and (iii) matrix metalloproteinases (MMPs, produced by
macrophages) which degrade the extracellular matrix, further aiding entry of inflammatory
cells into the brain tissue30.
Macrophages make up the majority of inflammatory cells in the WM plaque25. A proportion
of macrophages are derived from blood-borne monocytes, while others stem from
resident microglia. Under non-pathological conditions microglia are incapable of acting as
Antigen Presenting Cells. However, during CNS inflammation they become activated,
expressing MHC class II and co-stimulatory molecules essential for optimal antigen
presentation to T cells, and may also adopt a macrophagic morphology.
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The inflammatory activity of lesions can be categorised according to the extent and
distribution of MHC class II-expressing cells (i.e. activated microglia and macrophages)31.
Active lesions contain an abundance of activated macrophages (both in the brain
parenchyma and the perivascular spaces of blood vessels), a variable number of
activated T lymphocytes (predominantly perivascular CD4+ and CD8+ T cells) and a
smaller number of B cells. A proportion of active plaques show evidence of ongoing
demyelinating activity, identified by the presence of myelin degradation products within
macrophages; the frequency of these plaques is low in patients with chronic MS32. The
most commonly encountered lesions at autopsy are chronic inactive, which contain
smaller numbers of inflammatory cells. Other lesions are described as chronic active,
with the plaque borber demonstrating a prominent inflammatory infiltrate, while there is a
paucity of inflammatory cells in the centre.
The inflammatory process in MS is not restricted to the demyelinated plaques. A range of
pathological abnormalities have also been described in the non-demyelinated,
macroscopically normal-appearing WM25, 33. Changes include gliosis, inflammatory cell
infiltration, microglial activation, axonal loss, thickening of blood vessel walls, perivascular
deposits of lipofuscin, the expression of inflammatory mediators and subtle BBB changes
(e.g. abnormal tight junction proteins on vascular endothelia with evidence of
extravascular fibrinogen leakage)30, 34-39. One study reported some degree of histological
abnormality in 72% of the macrocopically normal appearing WM examined34. Meningeal
inflammation is also well recognised in MS40, 41.
1.2.2 Demyelination and oligodendrocyte pathology
Injury to the myelin-oligodendrocyte complex is likely to occur via a number of
mechanisms, although the relative importance of these processes is poorly understood.
MHC class II-restricted interactions between CD4+ T cells and antigen-presenting
macrophages are likely to be important in inducing the inflammatory reaction which
ultimately results in oligodendrocyte damage25. T cells and macrophages secrete
numerous cytotoxic products which have been implicated in oligodendrocyte injury; CD8+
T cells release perforin42 and lymphotoxin43, 44 while macrophages produce reactive
oxygen45 and nitrogen species46, 47, proteases, excitatory amino acids48 and cytokines
HJ71)ĮDQG,)1Ȗ49, 50). Oligodendrocyte apoptosis may also be mediated via the Fas-
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Fas ligand pathway, which involves interaction between the molecules Fas (expressed by
the oligodendrocyte) and Fas ligand (on macrophages and CD8+ T cells) 51-53.
The role of B cells and autoantibodies in MS is uncertain54, 479. B cells and plasma cells
are observed in the perivascular spaces and meninges, with parenchymal infiltration
being less common. Actively demyelinating plaques may contain immunoglobulins (mainly
IgG) and complement components which are either produced locally (by B cells and
macrophages / microglia respectively) or enter through the leaky BBB. Antibody-
mediated processes may contribute to demyelination, with antibody-opsonized myelin
being destroyed by activated macrophages or through complement activation54, 55, 479.
1.2.3 Evidence of Heterogeneity in MS lesions
It has been suggested that active MS plaques can be classified into one of four types56, 57.
All four patterns show T cell and macrophage infiltration. Demyelination in type I lesions
appears to be T cell mediated, while type II lesions also contain prominent deposition of
immunoglobulin and activated complement. Type III lesions show degenerative changes
in the distal processes of the oligodendrocyte with preferential loss of the myelin protein
MAG, and nuclear changes consistent with oligodendrocyte apoptosis. It has been
suggested that this pattern may occur secondary to viral or toxin-induced oligodendrocyte
injury. Type IV lesions show primary oligodendrocyte degeneration followed by myelin
destruction. Only small numbers of type IV lesions have been described to date, all in
PPMS. Despite this inter-individual heterogeneity there appears to be homogeneity within
individual patients; that is, all active plaques within a particular patient appear to exhibit
the same pattern, although it is unclear if new lesions that develop over time also follow
this pattern.
More recent studies have challenged this concept of lesion heterogeneity10, 11. Barnett
and Prineas have proposed that extensive oligodendrocyte apoptosis is the initial event in
the formation of the MS plaque, with the dying oligodendrocyte inciting a secondary
inflammatory response10. Studying cases of early MS who died of rapidly worsening
disease, they observed oligodendrocyte apoptosis in areas with only mild reductions in
myelin density and an absence of macrophages and T cells, suggesting that
oligodendrocyte pathology actually precedes leukocyte infiltration.
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1.2.4 Gliosis
Astrocytes become activated by a variety of pathological processes including CNS
inflammation. This process of reactive gliosis is characterised by astrocyte proliferation,
upregulation of intermediate filament proteins including glial fibrillary acidic protein
(GFAP) and morphological changes including cellular hypertrophy and the emission of
processes (stellation). The degree of gliosis is variable - in some plaques astroglial
processes occupy most of the space created by myelin loss, while in others there is
marked expansion of the extracellular space58. It is unclear whether gliosis is protective or
detrimental; astrocytes produce various neurotrophic factors and cytokines which may
contribute to remyelination and neurite outgrowth59. Alternatively the astroglial scar may
mechanically impede these processes60. In vitro, astrocytes have the ability to express
MHC class I and II, but whether they present antigen in vivo is controversial61, 62.
1.2.5 Remyelination
Remyelination is well recognised in MS. There is some evidence that early in the disease
course plaques contain high numbers of oligodendrocytes and show pronounced
remyelination32, while in later stages few oligodendrocytes are found and remyelination is
either absent or restricted to the lesion border63. In contrast Patrikios et al report extensive
remyelination in a subset of patients with chronic MS64.
There is much debate as to whether remyelinating cells are derived from
oligodendrocytes that survive the demyelinating attack, or if they are recruited from a pool
of glial progenitors32, 65, 66. Several studies suggest that oligodendrocytes which survive in
the vicinity of a demyelinated area do not divide and are incapable of forming new myelin
sheaths67, while glial progenitors are able to divide and migrate to repopulate a
demyelinated region68, 69. The myelin sheaths in remyelinated lesions are uniformly thin
and have shorter internodes70, showing reduced staining intensity with myelin stains.
Lesions which show complete remyelination are termed shadow plaques.
1.2.6 Axonal loss
Post-mortem studies demonstrate extensive axonal loss in MS, not only in WM plaques
but also the peri-plaque WM and the so-called normal appearing WM71-73. Further
evidence for axonal loss comes from Magnetic Resonance Spectroscopy (MRS) studies.
MRS provides quantitative indices of several tissue metabolites including N-
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acetylaspartate (NAA), a putative index for axonal injury or loss in vivo, and significant
reductions in NAA have been reported both within MS plaques74 and in the normal
appearing WM75.
Axonal degeneration occurs early in the disease course73, 76. Small calibre axons appear
to be more susceptible to injury than larger fibres which are relatively well preserved77-79.
The mechanisms of axonal loss remain speculative80. Axonal damage is greatest in areas
of high inflammatory content with lesser degrees of injury being observed in inactive
lesions and the peri-plaque WM71, 73, 81-83. In particular, acute axonal injury correlates with
the number of CD8+ T cells and activated macrophages, suggesting a role for these
cells73, 83. CD8+ T cells have been shown to transect axons in vitro84-86 while macrophage
products such as Nitric Oxide87, TNFĮ88, 89 and proteases90 may also induce axonal injury.
Autoantibodies against neuronal proteins have been identified in sera and CSF from MS
patients, raising the possibility of antibody-mediated axonal injury 91-94. The demyelinated
axon may be particularly vulnerable to immune-mediated injury, while remyelination may
afford some protection against axonal degeneration, with less axonal damage being
observed in remyelinated lesions in comparison to demyelinated plaques71, 73.
It has been proposed that axonal degeneration in chronic inactive plaques occurs
secondary to a mismatch between energy supply and demand (i.e. a state of virtual
hypoxia) 80, 95. Rather than being restricted to the nodes of Ranvier, Na+ channels
become distributed diffusely along the chronically demyelinated axon, increasing Na+
influx. However, mitochondrial function may be compromised in MS96, 97, impairing the
ATP-dependant Na+/K+ pump which normally restores this ion gradient. Instead, the
energy-independent Na+/Ca2+ pump exchanges Na+ for extracellular Ca2+, disrupting Ca2+
homeostasis and activating Ca2+-dependant proteases which degrade the axon
cytoskeleton. Low levels of inflammatory mediators and the removal of neurotrophic
support (i.e. normally provided by the myelinating oligodendrocytes) may also contribute
to axonal loss in chronic plaques53, 71, 98, 99.
Following axonal transection in an MS plaque, the distal portion of the axon undergoes
Wallerian degeneration and is phagocytosed by macrophages100. Retrograde
degeneration of the proximal axon may also occur. These processes are generally
considered to account for the extensive axonal loss reported in the normal appearing
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WM, although evidence is somewhat conflicting72, 101. Evangelou et al reported a strong
correlation between lesion loads in the cerebrum and axonal number in the corresponding
area of the corpus callosum72. In contrast DeLuca et al found little correlation between
plaque loads and axonal loss in the spinal cord, suggesting a neurodegenerative process,
independent of inflammatory / demyelinating activity, may contribute to axonal loss in
MS101.
1.3 The pathological substrate of clinical disability in MS
The symptoms of an MS relapse are believed to predominantly reflect inflammation and
demyelination. The axons ability to conduct nerve impulses in the normal saltatory
manner is compromised in the demyelinated state, leading to slowing or blockade of
conduction102. Functional impairment will occur if a significant proportion of nerve fibres in
a clinically eloquent site are affected. The anatomical site of the lesion determines
symptomatology, although the majority of lesions cannot be linked to clinical symptoms4.
Demyelinated axons may also discharge spontaneously and show increased mechanical
sensitivity leading to paroxysmal symptoms including Lhermittes phenomenon (sensory
disturbance travelling down the spine on neck flexion). Incomplete demyelination may
result in intermittent conduction block, for example conduction failure in association with a
rise in temperature (Uhtoffs phenomenon). Animal studies suggest that disability can
result from inflammation in the absence of demyelination480, 481. This may partly reflect
Nitric Oxide production, which potentially contributes to conduction block103.
Axonal degeneration has been proposed as a major cause of irreversible and progressive
neurological disability in MS patients53. Axonal loss occurs in the very early stages of
disease76, 104, but may not cause clinical symptoms due to a functional reserve of axons
and other compensatory mechanisms. However when axonal loss in a clinically eloquent
tract reaches a threshold, it leads to permanent disability. This axonal hypothesis is
supported by MRS studies suggesting that NAA levels are a better predictor of clinical
disability than conventional MRI lesion loads75, 105, 106. Imaging studies also demonstrate
significant atrophy in various CNS structures in MS107-110, even in the early stages of
disease111-113. Although direct evidence is lacking, this tissue loss is assumed to mainly
reflect axonal loss. Importantly, several studies report that atrophy rates correlate with the
accumulation of disability110, 114-120.
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Several mechanisms are likely to contribute to functional recovery following relapse. In
the early stages removal of inflammatory mediators such as nitric oxide may reverse
conduction block, while the resolution of oedema may relieve mechanical pressure on
fibre tracts. Electrical conduction may be restored by both remyelination and by the
insertion of voltage-gated Na+ channels along the internodal membrane of the denuded
axon121, 122. Compensatory adaptive changes in the cerebral cortex may further facilitate
recovery123. Failure of these mechanisms with time (e.g. exhaustion of the
oligodendrocyte progenitor pool) may explain the observation that recovery from relapse
tends to be incomplete in the later stages of the disease. Cumulative axonal loss -
following repeated inflammatory attacks  and gliotic scarring are also likely to contribute
to incomplete remission.
1.4 GM Pathology in MS
CNS tissue can be divided into WM and grey matter (GM). The WM consists of axonal
tracts, with the high proportion of myelinated axons giving the WM its colour, while the
GM - where the neuronal cell bodies reside - appears grey on account of the high density
of neuronal nuclei. In comparison with WM, the myelin content of GM is reduced.
However, although the dendritic tree and the neuronal cell body is unmyelinated, many
myelinated fibres do enter and leave the GM and many regions of GM contain large
numbers of myelinating oligodendrocytes124, 125. A proportion of oligodendrocytes within
GM - so-called satellite or perineuronal oligodendrocytes - lie opposed to the perikarya of
neurons and are believed to play an important role in maintaining neuronal
homeostasis125, 126.
MS is traditionally described as a disease of WM. While it was acknowledged that the
pathological process was not limited to the WM, only a modest degree of GM involvement
was recognised21-23. However this has been called into question over recent years with
the realisation that GM demyelination is grossly underestimated by conventional staining
and imaging techniques127-129. In light of this, it is essential that GM pathology in MS is re-
assessed.
Several post-mortem studies  using more sensitive staining techniques  have identified
the cerebral cortex as a predilection site for demyelination127, 130-134. Like WM plaques,
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cortical lesions are characterised by sharply demarcated areas of complete myelin loss
associated with substantial neuronal/axonal injury130, 132. However they show a number of
striking differences in comparison with their WM counterparts, for example they contain
minimal inflammation and gliosis, and often display a distinct morphology which is not
perivenous in distribution127, 130, 132, 135-137. Furthermore the extent of cortical
demyelination correlates poorly with the degree of WM demyelination suggesting that
different pathological processes may be responsible for myelin loss in the two different
tissue compartments129, 133 .
Numerous MRI studies demonstrate significant GM atrophy in the brain138-140. Several
other studies report abnormalities in quantitative MRI parameters in GM brain structures
related to Magnetisation Transfer141-145, Diffusivity and Fractional Anisotropy144, 146-149, T1
Relaxation time150-152 and MRS153-159. While the precise pathological correlate of these
imaging changes are poorly understood they indicate the presence of tissue damage
beyond the resolution of conventional MRI, and further support the notion that there is
substantial GM pathology in MS.
1.4.1 GM pathology may be an important contributor to clinical disability in MS
It has been suggested that GM pathology contributes to fatigue, depression and cognitive
problems in MS134, 152, 160. All of these symptoms are common, frequently manifesting
early in the disease course and causing substantial morbidity161:
- Fatigue has been reported to occur in 78% of MS patients162, with one study
suggesting that fatigue was the earliest symptom in 31% of patients and the most
troublesome symptom in 28%163.
- The lifetime prevalence of depression approaches 50% in the MS population, with
major depression occurring in over 25%164, 165. While a reactive depression may
represent a psychological reaction to chronic disability, there is growing evidence
that MS-related depression has an organic component, for example reflecting
pathology in the frontal lobes. Both fatigue and depression are predictors of
impaired quality of life in MS, independent of physical disability166, 167. There is
also an increased risk of other psychiatric disorders including bipolar affective
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disorder, euphoria and psychotic symptoms, which have even been described at
disease onset168, 169.
- Cognitive impairment affects approximately 40% of MS pateints170. Typically the
dementia is of a subcortical pattern, with prominent defects in attention and
executive function, although a smaller number demonstrate neuropsychological
deficits typical of cortical dementia such as dysphasia, dysgraphia and
dyslexia171. A minority of patients may even present with cortical MS,
characterised by predominantly neuropsychological or cognitive deficits or distinct
syndromes (anomia, agraphia, aphasia, alexia, alien hand) consistent with
cortical dysfunction 171, 172
- The prevalence of epilepsy in MS is estimated to be increased three- to six-fold in
comparison with the general population173
Juxtacortical lesion load has been correlated with a number of clinical features including
physical disability, epilepsy, cognitive dysfunction and depression174-180. However MRI
does not detect the vast majority of GM plaques so the pathological substrate of these
symptoms - including the relative importance of GM and WM pathology - is unclear.
Imaging studies suggest that cognitive dysfunction and mood disturbance in MS may be
related to GM brain atrophy180-185, and fatigue has been linked to subcortical GM
pathology, as evidenced by studies using both quantitative MRI, functional MRI and 18F-
fluorodeoxyglucose Positron Emission Tomography152, 160, 186, 187. Cortical demyelination -
particularly within the cingulated gyrus, insular cortex and temporobasal cortex - may
result in cognitive deficits134. However it has also been suggested that WM lesions may
cause disruption of (i) subcortical U fibers and other intra- and interhemispheric
connections between different cortical areas and (ii) cortico-subcortical circuits, linking the
cortex with the basal ganglia and the thalamus, leading to fatigue, depression and
cognitive impairment160, 170, 172, 175-177, 188, 189 , 190.
GM pathology may also contribute to a number of symptoms classically attributed to WM
disease, including motor disability, sensory symptoms and ataxia. Extensive cortical
demyelination may be an important pathologic correlate of irreversible disability in
progressive forms of MS133. Indeed the failure of conventional MRI to adequately detect
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GM pathology is likely to contribute to the clinico-radiological paradox, that is the poor
correlation between MRI lesion load measures (i.e. which will largely reflect WM disease)
and disability. In contrast several groups have noted correlations between measures of
physical disability and both GM atrophy191-196 and quantitative MRI measurments related
to GM141, 197-199.
1.4.2 The spinal cord is ideally suited for quantitative post-mortem studies
The spinal cord resides in the spinal canal of the vertebral column, extending from the
medulla caudally to the level of the lower thoracic or upper lumbar vertebrae. It is
suspended by the denticulate ligaments (which attach to the lateral surfaces of the cord)
and is separated from the CSF-filled subarachnoid space by the Pia mater, the innermost
meningeal layer that adheres to the cord surface. The average length of the adult cord is
45cm in males and 42cm in females200. The cord is divided into 8 cervical, 12 thoracic, 5
lumbar, 5 sacral and 1 coccygeal segmental levels, corresponding to the attachment of 31
pairs of spinal nerves and it is thickest at the cervical and lumbosacral enlargements (C4-
T1 and L2-S3 respectively).
The cord is composed of a central core of GM, surrounded by WM (figure 1.1). The
relative proportion of GM to WM varies between levels200. The WM consists of three
columns or funiculi  the ventral, lateral (containing the descending corticosinal tracts)
and dorsal columns. The GM is butterfly-shaped in transverse section and has a
distinctive configuration at each spinal level, with the cross-sectional area being greatest
in the cervical and lumbosacral enlargements. Rexed divided the spinal GM into 10 zones
or laminae on the basis of cytoarchitectonic features, although it is often not possible to
identify these laminae on human post-mortem material201. The GM is composed of a pair
of dorsal (posterior) and ventral (anterior) horns - primarily concerned with sensory and
motor function respectively - linked by the GM commissure, which contains the central
canal. In the thoracic and upper lumbar segments there are small lateral horns, which
contain sympathetic efferent neurons.
Few post-mortem studies have assessed GM pathology outside of the cerebral cortex in
MS. There is a particularly striking paucity of literature examining GM pathology in the
spinal cord. The spinal cord is well suited for post-mortem examination on account of its
well characterised, relatively simple anatomy with readily identifiable structures202. The
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cord is an extremely relevant site to study MS pathology, for a number of reasons: Firstly,
MS plaques commonly affect the spinal cord21, 24, 79, 203; one autopsy series reported
spinal cord plaques in 48 out of 59 MS cases (81.4%), periventricular lesions surrounding
the lateral ventricles in 98 out of 126 (77.7%), and optic nerve lesions in 11 out of 20
(55%)204. Secondly, these plaques frequently result in clinical symptoms205, 206.
Characteristically spinal cord lesions cause a partial myelitis, with patchy, asymmetric
motor and sensory symptoms, and often bladder involvement. More rarely a complete
cord syndrome (i.e. transverse myelitis) is observed207. In a cross-sectional population-
based study of 301 MS patients in South Glamorgan physical examination revealed
sensory, motor or reflex changes consistent with a spinal cord lesion in 74% of cases208.
In comparison 92% of patients had visual pathway involvement, 55% had brainstem or
cerebellar dysfunction and 40% had evidence of cerebral impairment. Cord involvement is
also prevalant in African and asian populations, where optico-spinal MS is the
predominant disease phenotype209. Finally, substantial axonal loss occurs in the spinal
cord, both within WM plaques and myelinated WM76-79, 210 and may be an important
contributor to clinical disability in SP and PP disease, both of which are typically
characterised by a progressive myelopathy110, 203, 205, 210-218.
Due to its small cross-sectional area, the resolution of current MRI scanners is not
sufficiently high to study the spinal cord GM in vivo. Post-mortem examination is therefore
essential, although a number of factors require consideration when interpreting autopsy
studies. Firstly, in contrast to imaging studies, post-mortem examinations only provide a
snap-shot at a single time-point, and do not allow us to study the temporal evolution of
pathology. Secondly, the great majority of MS plaques found at autopsy are longstanding.
Acute lesions are rarely fatal and so examination of the initial stages of the disease
process is rarely possible. Biopsy material is enriched in early lesions, but is virtually
exclusively sampled from the brain rather than the spinal cord. Thirdly, severe, disabling,
long-standing MS cases are likely to be over-represented in an autopsy series25. Cases
with short disease durations that come to autopsy tend to be particularly aggressive;
whether the histopathological features of these atypical cases are fully representative of
MS is questionable36. Finally, detailed clinical information is rarely available at or shortly
before the time of death, so it is difficult to investigate the functional significance of
pathological changes.
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1.5 Thesis Outline
Only a small number of post-mortem studies have examined GM involvement in MS, with
the majority of these focusing on the cerebral cortex. To our knowledge this study
represents the first detailed examination of spinal cord GM involvement in MS. A greater
understanding of GM pathology in this clinically eloquent site may provide insight into the
pathophysiology of MS and mechanisms of disability in the disease. We use post-mortem
material to explore various aspects of spinal cord GM pathology in MS. The specific aims
of the study are as follows:
1. To compare the extent of GM and WM demyelination between different regions of
the CNS by examining tissue from the cerebral cortex, cerebellar cortex,
thalamus and spinal cord, assessing the proportion of WM that is demyelinated
and the proportion of GM that is demyelinated in each area.
2. To assess the extent and pattern of GM and WM demyelination in the spinal cord,
surveying the cord at multiple levels.
3. To examine the relative contributions of GM and WM volume loss to spinal cord
atrophy in MS.
4. To assess the extent of neuronal pathology  changes in both neuronal number
and neuronal size  within the spinal cord GM, both in relation to demyelinated
plaques and the myelinated GM.
5. To assess the sensitivity of post-mortem MRI for detecting spinal cord GM
plaques.
These aims are addressed in chapters 2-6, respectively. The autopsy material is derived
from a number of sources: the Netherlands Brain Bank, the UK Multiple Sclerosis Brain
Bank and the neuropathology department, Oxford Radcliffe NHS Trust, which we believe
to be the largest collection of spinal cord autopsy material in MS. The local research
ethics committee approved the study.
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Figures
Figure 1.1
Palmgren silver-stained transverse sections of the spinal cord at the upper cervical (A),
lower cervical (B), upper thoracic (C), lower thoracic (D) and lumbar levels (E) (Palmgren
silver stain). The butterfly-shaped grey matter (GM) has a distinctive morphology at each
spinal level, with the GM cross-sectional area being greatest in the lower cervical and
lumbosacral regions. The white matter (WM) consists of three columns  the anterior,
lateral and dorsal columns (AC, LC and DC respectively). The GM is composed of a pair
of dorsal horns (DH) and anterior horns (AH) linked by the GM commissure (GMC), which
contains the central canal (CC). In the thoracic segments there are small lateral horns
(LH). DR  Dorsal root.
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Chapter 2: Regional variations in the extent and pattern of
grey matter demyelination in Multiple Sclerosis - a comparison
between the cerebral cortex, cerebellar cortex, deep grey
matter nuclei and the spinal cord
2.1 Introduction
The factors influencing plaque topography in MS are not fully understood. MS plaques
may appear anywhere in the CNS but particular sites are preferentially involved. Studies
using conventional myelin staining techniques indicate that the majority of WM plaques
occur in a perivenular distribution21, 23, 219-221, with areas containing a high density of small
veins and venules - such as the periventricular WM, leucocortical junction and the WM
tracts of the brainstem and spinal cord - showing a preponderance for demyelination22, 23,
25, 222. The perivenular distribution of plaques has also been demonstrated in vivo by MR
venography223. A smaller proportion of WM plaques do not show a perivenous
distribution, indicating that additional factors influence plaque morphology21, 25, 57, 95, 219, 224.
Several observations suggest that the perivascular space (also known as the Virchow-
Robin space) is the focus of the MS plaque, rather than the blood vessel per se225. This
space - which is continuous with the potential subpial space - is lined internally by the
outer surface of the blood vessel and externally by the basement membrane of the glia
limitans, extending as far as the capillaries on both the arterial and venular sides of the
vascular tree226. The Virchow-Robin space is an important site for immunological
reactions to take place. It contains resident perivascular macophages which can present
antigen to blood-derived lymphocytes; the space may subsequently become engorged
with inflammatory cells which then migrate into the brain parenchyma226. Cuffs of
inflammatory cells in Virchow-Robin spaces are prominent features of acute MS
plaques226. Interestingly lymphoproliferative tumours that propagate within perivascular
spaces show a similar topography to MS plaques with the subependymal region and the
corpus callosum being frequently affected227.
Several groups have used conventional myelin staining techniques to assess the
frequency of MS plaques in the cerebral cortex22, 23, 222. These studies suggest that the
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majority of GM lesions involve the leucocortical junction22, 23, 222. Brownell and Hughes
described the distribution of macroscopically visible lesions in 22 MS brains, reporting that
17% of these plaques affected the leucocortical junction while only 5% of plaques were
restricted to the cortex alone22. Similarly Kidd et al, who assessed cortical pathology in 12
MS brains using Luxol Fast Blue (LFB) and Heidenheins myelin stain, observed that 76%
of cortical lesions involved the subcortical WM, while 24% exclusively involved the
cortex222. 7 distinct patterns of cortical lesions were described, the majority of which arose
within the territory of a principal cortical veins or one of its branches222.
A number of histochemical staining techniques are available for detecting myelin, each
with its relative merits and pitfalls228. LFB has an affinity for the phospholipids in myelin229
and is a particularly popular stain because - in contrast to many traditional myelin staining
methods (e.g. Weigert's230, Weil's231 and Heidanhain's stains232) - it can be applied to
formalin fixed tissues without requiring the use of a mordant (i.e. a substance used to set
the stain). LFB is frequently used in conjunction with Cresyl Violet233, a counter-stain that
binds the nuclei, the Nissl substance and the LFB anions present in the myelin. Additional
techniques are available to demonstrate degenerated myelin on frozen sections, including
Marchis stain234 and oil-soluble dyes such as Oil Red O235 which stains degraded myelin
within macrophages.
While conventional staining techniques such as LFB are satisfactory for identifying MS
lesions within the heavily myelinated WM, they are suboptimal for visualising the fine
myelinated fibres of the cerebral cortex127, 129, 228. The poor sensitivity of LFB for detecting
cortical demyelination is in part due to the practice of de-staining the sections (i.e.
washing the sections in a mixture of 70% ethanol and lithium carbonate to remove non-
specific background staining) until the normal cortex is no longer blue130, 236, although a
considerable proportion of plaques remain undetected when this step is omitted (personal
communication, Lars Bö). Therefore previous studies are limited by the techniques used
to identify cortical plaques, which are likely to have grossly underestimated the extent of
GM demyelination.
The current gold standard technique for detecting GM demyelination is myelin protein
immunohistochemistry (IHC), using antibodies against myelin components such as MBP,
PLP, MAG, MOG and CNP127, 132, 237, 238. In contrast to conventional myelin stains (e.g.
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LFB and Heidenhains stain), this technique is highly sensitive for detecting GM
demyelination127, 132.
A number of studies have used myelin protein IHC to demonstrate that substantial cortical
demyelination occurs in MS127, 130-134. Indeed Bö et al reported demyelination was more
extensive in the cerebral cortex (mean 26.5% demyelinated, median 14%) than in the
subcortical WM (mean 6.5%, median 0%)127.
Bö et al described four patterns of cortical plaque127: Type I lesions are located at the
leucocortical junction, extending across both WM and GM. Type II lesions lie completely
within the cortex and do not extend to the pial surface of the brain or the subcortical WM.
Type III and IV lesions extend from the pial surface of the brain into the cortex; type III
lesions extend partly into the cortex, often reaching cortical layer 3 or 4, while type IV
lesions extend through the full width of the cortex, without involvement of the subcortical
WM. In contrast to type I and II plaques, subpial lesions (i.e. type III and IV lesions) do not
appear to occur in a perivenous distribution, frequently spanning extensive areas of
cortex, sometimes affecting multiple adjacent gyri. Overall subpial lesions accounted for
67% of the cortical lesions, and 84% of the demyelinated cortical area127. 5 of the 20 MS
cases examined by Bö et al exhibited extensive subpial demyelination in widely spaced
cortical areas, suggesting that a pattern of general cortical subpial demyelination occurs
in a subgroup of cases. In these cases 57% of the cortex was demyelinated in
comparison with only 2.2% of the subcortical WM127. Subpial lesions have also been
described in animal models of MS239, 240. Merkler et al injected the pro-inflammatory
F\WRNLQHV 71)Į DQG ,1)Ȗ LQWR WKH FHUHEUDO FRUWH[ RI 02*-immunised Lewis rats
producing areas of demyelination with a striking similarity to MS lesions, with extensive
subpial plaques accounting for 90% of the demyelinated cortex240. Similarly Pomeroy et al
reported that subpial plaques accounted for 88% of the demyelinated cortical area in
marmosets with MOG-induced Experimental Autoimmune Encephalomyelitis (EAE)239.
Fewer studies have examined demyelination in the deep GM structures of the brain.
Brownell and Hughes estimated that 4% of MS plaques in the brain affect the central
GM22. Lumsden reported that 6.8% of plaques were located within the Basal Ganglia, and
2% were in the Thalamus23. Adams examined deep GM structures in 63 MS cases,
identifying plaques in the caudate, thalamus and putamen in 10 cases, 6 cases and 8
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cases respectively204. Deep GM pathology has not been assessed in detail using myelin
protein IHC; Vercellino et al detected deep GM plaques in 3 out of 6 MS cases132, while
Geurts et al examined 9 cases of chronic MS, observing only 8 deep GM plaques in
comparison with 70 WM and 90 cortical lesions128. Huitinga et al used LFB-staining to
identify hypothalamic lesions in 15 out of 16 MS cases241. The authors suggest such
lesions may be clinically significant, impairing activation of the corticotrophin releasing
hormone system  and the subsequent production of endogenous corticosteroids - in
response to an MS relapse. To our knowledge, only one study has used myelin protein
IHC to assess demyelination in the cerebellar cortex, while no study has quantified GM
demyelination in the spinal cord242.
A number of studies have compared the frequency of MS plaques within different CNS
regions22, 23, 204, 243. However the myelin staining techniques employed in these studies
are recognised as being insensitive for detecting GM demyelination127, 132. Therefore it is
unclear whether GM demyelination is more prominent in the spinal cord, the cerebral
cortex or other GM structures. In this study we use myelin protein IHC to make within-
subject comparisons of the extent of WM and GM demyelination in the cerebral cortex,
cerebellum, spinal cord and thalamus, allowing us to explore the relationship between
pathology at these different sites. We have therefore included areas where MS lesions
frequently result in neurological deficits (e.g. the spinal cord and the cerebellum), areas
where neuronal loss and GM atrophy has been demonstrated (i.e. the cerebral cortex and
the thalamus), and areas previously considered to be predilection sites for WM and GM
lesions. We hypothesise that subpial areas (i.e. the cerebral cortex and the cerebellar
cortex) will show a preponderance for GM demyelination, while the thalamus and the
spinal cord will contain a relative paucity of lesions.
2.2 Materials and methods
2.2.1 Clinical material
Autopsy material was obtained from 14 pathologically confirmed MS cases and 3 controls.
This material was aquired from the Multiple Sclerosis Brain Bank, London. The MS
patients (1 male, 13 female) were aged 44-81 years (mean 56.6 years, median 56 years)
with disease durations of 6-32 years (mean 23.7 years, median 22 years). 11 cases had
SPMS, 2 had PPMS and 1 had RR disease. The controls (2 females aged 69 and 73, 1
male aged 35) had no clinical or pathological evidence of neurological disease. The
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material was fixed in 4% paraformaldehyde for 2 - 3 weeks before being embedded in
paraffin.
2.2.2 Preparation of the sections
5ȝm sections were taken from 7 predetermined areas of the CNS, irrespective of
macroscopic appearance; the motor cortex, cingulated gyrus, cerebellar cortex (cut in the
plane of the dentate nucleus), thalamus and spinal cord (transverse sections from the
cervical, thoracic and lumbar levels).
2.2.3 Immunohistochemistry
Sections were stained for Proteolipid Protein (PLP) using the EnVision method (DAKO
EnVision kit, MCA839G, Dako, Denmark), a system based on a Horse Radish Peroxidase
(HRP)-labelled polymer conjugated to secondary antibodies. Sections were
deparaffinated in a series of xylene, 100%alcohol, 96%alcohol, 70%alcohol and water,
washed with phosphate-buffered saline (PBS). Endogenous peroxidase activity was
quenched by treating the specimens for 5 minutes with DAKO Peroxidase Block before
incubation with the primary antibody for 60 minutes at room temperature. After washing in
PBS the sections were incubated for 30 minutes with the pre-diluted Envision-HRP
complex and washed again in PBS. The sections were then developed for 10 minutes
with diaminobenzidine (DAB, dilution 1:50), washed in tap water, dehydrated in alcohol
70% to 100%, and xylene and finally stained for 1 minute with haematoxylin and washed
in tap water until the nuclei stained blue. The primary antibody used was mouse anti-
Myelin PLP (IgG2a, clone number plpc1, dilution 1:3000, MCA839G, Serotec).
2.2.4 Assessment of GM and WM lesions
The PLP-stained sections were scanned in a slide scanner (Nikon Super Coolscan 4000,
Nikon UK Ltd., Kingston upon Thames, UK) to produce a digital image on which the MS
lesions and the GM/WM boundary were manually outlined using image analysis software
(AnalySIS Pro running SIS software, Olympus UK Ltd., Southall, UK). The PLP-stained
sections, examined via microscopy (10x, Leitz Dialux 20EB microscope), were used as a
reference to aid the identification of these regions, and the control cases was used to
establish the normal regional variations in myelin staining density between the different
CNS structures.
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The number of demyelinated plaques in each region was counted, with areas of WM and
GM demyelination being scored separately. Plaques in the cerebral cortex were classified
as type I, II, III or IV lesions according to the system of Bö et al, as described above127.
Outside of the cerebral cortex, plaques were scored as pure WM lesions, pure GM lesions
or mixed GM/WM lesions. By measuring the total GM area, total WM area and the cross-
sectional area of plaques, the proportion of GM that was demyelinated (PGMd) and the
proportion of WM that was demyelinated (PWMd) was calculated.
Material from the control cases was used to establish the normal regional variations in
myelin staining density between the different CNS structures. In control cases the myelin
staining density is low in the superficial layers of the cerebral cortex (layers I-III), the
cerebellar cortex and the GM commissure and Substantia Gelatinosa of the spinal cord
(figure 2.1A, 2.2A, 2.3F). Within these structures lesions were defined as sharply
demarcated areas showing a complete loss of myelin. In the remaining regions, where the
density of myelin is usually much higher, lesions were defined as sharply demarcated
areas, characterised by either complete myelin loss or markedly reduced myelin density
on the PLP-stained sections.
GM structures were identified by the presence of neurons and by the reduced myelin
staining intensity in comparison with the WM. Additional morphological characteristics
were used to identify the GM / WM boundary more precisely, particularly in the
demyelinated state:
Cerebral Cortex; radially orientated myelinated fibres are seen within the normal cerebral
cortex, running perpendicular to the cortical surface. These fibres are clearly visible to the
point where they reach the leucocortical junction, allowing the GM/WM boundary to be
identified (figure 2.1D). Type I cortical lesions are generally small and do not interfere
with reliable identification of the GM/WM boundary.
Cerebellar Cortex; the cerebellar cortex has three layers; an outermost molecular layer,
a middle Purkinje layer and an innermost granular layer (figure 2.2A-D). The molecular
layer is devoid of myelin, even in control cases, consisting of the extensive dendritic tree
of the Purkinje cells and the unmyelinated axons of the granule cells. The middle layer,
which contains the large Purkinje cells, is a single cell thick and contains only small
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amounts of myelin. In view of the paucity of myelin in these two outermost layers,
measurements of PGMd were restricted to the granular layer. The GM/WM boundary in the
cerebellum is readily identified - both in the myelinated and demyelinated state - on
account of the distinctive appearance of the dense network of granule cells whose round
nuclei appear blue on the haematoxylin counterstained sections.
Thalamus; the thalamic nuclei are interspersed with large amounts of WM and the myelin
staining intensity is similar in the GM and WM, so the GM/WM boundary is not striking
(figure 2.3A). The sections were therefore examined at high magnification and the tissue
classified as GM if neurons were visible. In general the WM of the thalamus was seen to
be composed of anisotropically arranged fibre bundles, aiding identification of the GM/WM
boundary.
Spinal Cord; when the transverse sections are examined by microscopy  even in the
demyelinated state  the axons of the WM tracts are readily identified running
perpendicular to the plane of section.
2.2.5 Statistical analysis
Paired t tests were used to compare PGMd with PWMd. Correlations between PGMd and PWMd
were assessed using Spearmans ranked test. Multiple regression analyses were used to
examine the influence of age, anatomical location and disease duration on PGMd and PWMd
(Stata version 9, StataCorp, Texas USA). As the sample contained only 2 PP and 1 RR
case, and only 1 male case, MS subtype and gender were not included in the regression
analysis.
2.2.6 Reproducibility of measurements
To evaluate intra-observer reproducibility 16 sections (4 cerebral cortex, 4 thalamus, 4
cerebellar cortex, 4 spinal cord) were selected at random and PGMd and PWMd were
measured by an observer (ID) on two separate occasions, with a one month interval
between measurements (coefficient of variation for GM measures = 4.7%; 6.8% for WM
measures). These measurements were repeated by a second observer (CPG) in order to
assess the inter-observer reproducibility (coefficient of variation for GM measures = 3.2%;
1.5% for WM measures).
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2.3 Results
2.3.1 Lesion counts and morphology
The number of areas of GM and WM demyelination in each of the CNS areas is shown in
table 2.1. Within the cerebral cortex and the thalamus the majority of GM plaques (95.8%
and 87.5% respectively) were restricted to the GM and did not impinge on the WM. In the
cerebellum 51% of areas of GM demyelination were restricted to the GM. In contrast only
16.7% of spinal cord GM plaques involved the GM exclusively.
Cerebral Cortex (figure 2.1); In the sections from the cingulate gyrus 20 areas of
demyelination were detected in the GM (1 type I, 3 type II, 15 type III, 1 type IV) while the
motor cortex contained 27 GM lesions (9 type II, 18 type III). Therefore we observed a
total of 47 GM lesions in the cerebral cortex (1 type I, 12 type II, 33 type III, 1 type IV).
The majority of cortical lesions were subpial (i.e. type III and IV) in location (72% by
number, 96% by area). In several cases these involved extensive lengths of the cortical
ribbon.
Cerebellar Cortex (figure 2.2); All of the pure GM lesions within the cerebellar cortex
involved the full thickness of the granular cell layer, with apparent sparing of the digital
WM, and frequently extended over multiple folia. While we restricted our assessment of
PGMd to the innermost granule cell layer of the cerebellar cortex, we note that
demyelination in the granular cell layer was invariably accompanied by myelin loss in the
purkinje cell layer. Similarly it was extremely rare to see loss of myelin in the purkinje cell
layer with preserved myelin in the granular layer.
Thalamus (figure 2.3 A - D); the borders of MS plaques within the deep GM structures
did not appear to show any respect for the GM/WM boundary. A number of periventricular
plaques were observed within the GM of the Thalamus. In some cases these lesions
appear to extend from the ventricular ependyma, into the thalamic GM to a relatively
constant depth.
Spinal cord (figure 2.3 E - G); In a number of cases a proportion of the border of the GM
plaque maintains a strict respect for the GM/WM boundary. This pattern of plaque
morphology is examined in detail in Chapter 3.
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2.3.2 Demyelination is more extensive in the GM than the WM
Overall, PGMd (mean 28.8%) was significantly greater than PWMd (15.6%) (p < 0.001).
There was a significant correlation between PGMd and PWMd (r = 0.7621, p < 0.001).
PGMd was greater than PWMd in the motor cortex (3.9% versus 0.5%, p = 0.0128),
cerebellar cortex (43.7% versus 8.7%, p = 0.0055), cervical cord (44.2% versus 35.3%, p
= 0.0464) and thoracic cord (55.5% versus 38.0%, p = 0.0082). There was not a
statistically significant difference between PGMd and PWMd in the lumbar cord (40.8%
versus 29.3%, p = 0.0693), the cingulate cortex (16.0% versus 6.5%, p = 0.1185) and the
deep GM nuclei (7.1% versus 4.0%, p = 0.3885). These results are summarised in figure
2.4.
2.3.3 Regional differences in the extent of demyelination
To examine for regional differences in the extent of GM demyelination, PGMd was
regressed on anatomical location controlling for age and disease duration. In comparison
with the cervical cord, PGMd was significantly reduced in the motor cortex (coefficient of
regression = -0.4703, p < 0.001, that is, controlling for other variables, PGMd was on
average 47% greater in the cervical cord than the motor cortex), the cingulate (coefficient
of regression = -0.3220, p = 0.001) and the thalamus (coefficient of regression = -0.4449,
p < 0.001). PGMd was not significantly different in the cerebellum (coefficient of regression
= -0.0217, p = 0.875), thoracic cord (coefficient of regression = 0.0984, p = 0.416) or
lumbar cord (coefficient of regression = -0.0829, p = 0.538) in comparison with the
cervical cord. PGMd was greater in the cingulate gyrus (mean 16.0%, median 11.4%) than
in the motor cortex (mean 3.9%, median 2.0%) (p = 0.013).
The correlation between PGMd and PWMd varied between the different anatomical sites,
being greatest in the spinal cord (e.g. thoracic cord; r = 0.908, p < 0.001) and thalamus (r
= 0.569, p = 0.042). In contrast, the two variables did not correlate in the cerebral cortex
(e.g. cingulate gyrus; r = 0.161, p = 0.6). The correlation approached statistical
significance in the cerebellum (r = 0.534, p = 0.060). PGMd in the cingulate cortex
correlated significantly with PGMd in the cerebellar cortex (r = 0.745, p = 0.003), but not
with PGMd in the spinal cord (e.g. thoracic cord; r = 0.407, p = 0.214).
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PGMd was significantly greater in the cerebellar cortex than in the cingulate gyrus (p =
0.01). However when we compared the proportion of the surface of the cingulate gyrus
that was demyelinated (mean 36.1%) with the proportion of the surface of the cerebellar
granular layer that was demyelinated (mean 43.6%) there was no significant difference (p
= 0.491).
In comparison with the lumbar cord, PWMd was reduced in the WM adjacent to the motor
cortex (coefficient of regression = -0.2975, p = 0.003), cingulate (coefficient of regression
= -0.2499, p = 0.014), thalamus (coefficient of regression = -0.2548, p = 0.021) and
cerebellum (coefficient of regression = -0.1982, p = 0.053). PWMd was not significantly
different in the cervical (coefficient of regression = -0.0829, p = 0.538) or thoracic cord
(coefficient of regression = 0.0984, p = 0.416) in comparison with the lumbar cord. The
extent of demyelination  for each of the regions examined  is summarised on a case-
by-case basis in table 2.2.
2.3.4 Influence of age and disease duration on extent of demyelination
Age (coefficient of regression = -0.0134, p = 0.004) appeared to have a significant
influence on PGMd, with younger patients having greater GM demyelination. Disease
duration did not appear to influence PGMd (coefficient of regression = 0.0091, p = 0.179).
Both age (coefficient of regression = -0.0100, p = 0.003) and disease duration (coefficient
of regression = 0.0092, p = 0.049) appeared to have a significant influence on PWMd with
more extensive demyelination being observed in younger patients and those with longer
disease durations.
We were unable to examine the influence of gender on the extent of demyelination as the
MS cohort only contained 1 male patient.
2.4 Discussion
Numerous studies have examined the distribution of MS plaques within the CNS using
histochemical myelin stains21-23. This work suggests that MS is predominantly a disease
of WM, although it has long been recognised that it may also involve GM structures21-24,
204, 222, 241. However, these studies are likely to have substantially underestimated the
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extent of GM pathology due to limitations in the staining techniques employed127, 129, 132. In
light of this, it is essential that the extent and pattern of demyelination in MS be re-
evaluated using more sensitive methods of lesion detection.
Previous studies have used myelin protein IHC, the gold standard technique for
detecting GM demyelination, to demonstrate substantial cortical involvement in MS127, 131-
133. In contrast, GM pathology in the spinal cord, cerebellar cortex and thalamus has
received relatively little attention132, 242. Our current study is the first to compare the extent
and pattern of GM demyelination between these four regions within the same patient
group. Rather than simply reporting the absolute numbers of plaques in each site - which
provides a rather crude measure of the extent of demyelination - we have calculated the
proportion of GM and WM tissue that is demyelinated in each region.
We have defined MS plaques as sharply demarcated areas, characterised by either
complete myelin loss or markedly reduced myelin density on sections stained with the
anti-PLP antibody. PLP, a component of compact myelin, links the exoplasmic surfaces of
the multi-lamellar myelin sheath8. However we stress that the pattern of myelin loss that
we observe is not unique to this particular myelin antibody; identical results are produced
with anti-MBP, -MAG, -MOG and -CNP antibodies (personal communication, Lars Bö).
Interestingly McNally and Peters report that DAB may be used to stain myelin on tissue
sections that have been treated with horse serum244. The resulting myelin staining is faint
but can be enhanced using a silver intensification procedure and is said to be particularly
useful for examining myelinated fibres in GM. The mechanisms of binding of the horse
serum to the myelin and the subsequent deposition of DAB at the binding sites are
unclear. However the method could not be used on paraffin-embedded material.
Furthermore the specificity of the PLP IHC was checked in the current study by omitting
the primary antibody; when the tissue was exposed to DAB in the presence of the
secondary antibody, but not the anti-PLP antibody, staining was blank.
Lucchinetti et al reported four distinct subtypes of active MS plaques57, 95. In the early
stages of plaque development, type 3 lesions show a preferential loss of MAG, while
other myelin proteins (including PLP, MBP and CNP) persisted within the partly damaged
myelin sheaths. It is therefore feasible that PLP IHC may fail to detect a small number of
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MS plaques. However, actively demyelinating plaques make up a small proportion of
lesions in chronic MS32, and in patients with disease durations greater than one year, type
3 lesions only make up a small proportion of actively demyelinating lesions (2 out of 27
actively demyelinating lesions examined by Lucchinetti et al)57. It should also be noted
that selective loss of MAG has yet to be confirmed by other groups245.
Perhaps surprisingly, few studies of MS have compared the extent of demyelination -
either GM or WM demyelination - in intracranial structures with that in the spinal cord204,
243. None of these studies have assessed GM demyelination in detail. Numerous other
groups have examined pathology in the brain or the cord but comparisons between
studies are likely to be confounded by differences in MS subtype, disease course, disease
duration, age, gender etc. Examining 70 MS cases, Ikuta et al reported extensive
demyelinated plaques within the spinal cord, cerebrum and cerebellum in 53%, 51% and
19% of cases respectively243. In another large study Adams observed periventricular
plaques in 78% of cases, while 22% contained plaques in the cerebral cortex and 81%
contained spinal cord plaques204. Spinal cord GM plaques were reported in only 3.4% of
cases, further highlighting the limitations of conventional staining techniques. Neither
study provides detailed information on the extent or pattern of demyelination in these
sites. In the current study we observe a striking preponderance for WM demyelination in
the spinal cord in comparison with the other WM structures examined. GM demyelination
is also much greater in the spinal cord than in the cerebral cortex and deep GM
structures. However, in contrast to the situation in the WM, the extent of GM
demyelination in the cerebellar cortex is comparable to that in the cord. Interestingly we
find that PGMd is greater than PWMd in all of the regions studied; these differences are
statistically significant in the motor cortex, cerebellar cortex and throughout the spinal
cord.
Plaques which cause particularly disabling symptoms  such as brainstem, cerebellar and
the spinal cord plaques - are likely to be over-represented in an autopsy series25.
Therefore, while anatomical factors  such as a high density of post-capillary venules 
may indeed predispose to MS plaques in these areas, this may be exaggerated
somewhat in autopsy studies. This potential source of sampling bias must be considered
when interpreting our results. We also acknowledge that our sampling regimen is by no
means exhaustive. Several WM areas have not been sampled, most notably the
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periventricular region, brainstem and optic nerves; therefore we cannot conclusively state
that demyelination is more extensive in the GM than in the WM. In a study of 6 MS cases,
Vercellino et al quantified demyelination in a single coronal section of the brain - cut in the
plane of the thalamus and basal ganglia, but also including the periventricular WM -
reporting greater demyelination in the WM than the GM (mean 21.75%, median 11%
versus mean 14.8%, median 3.25%)132. However it is important to note that we have
included material from the spinal cord, the subcortical WM, the corpus callosum (present
on all of the cingulate gyrus sections) and the cerebellum, all of which are considered to
be predilection sites for WM plaques25.
2.4.1 Demyelination in the cerebral cortex
We report that the majority of plaques in the cerebral cortex (72% by number, 96% by
area) are subpial in location. Previous studies also indicate that cortical demyelination
predominantly occurs in a subpial distribution127, 129, 131-134. Consistent with Kutzeligg et
al133, we find no correlation between PGMd and PWMd in the cerebral cortex, suggesting that
cortical demyelination  in particular subpial demyelination  occurs by an independent
mechanism to WM demyelination.
It has been suggested that subpial demyelination is mediated by a soluble factor, diffusing
inward from the surface of the brain41, 127, 130, 134. Such a myelinotoxic factor may spread
from remote areas of the CNS via the CSF or be generated by meningeal inflammation.
The CSF in MS often contains raised number of inflammatory cells, particularly in acute
disease246. The majority of these cells are T lymphocytes, some of which are specific for
putative myelin autoantigens247-250. B cells secreting IgG antibodies against the myelin
proteins MOG249, 251, PLP 248, 252, MBP253, 254 and MAG255 have also been detected in the
CSF in MS. Although the pathogenic role of autoreactive B cells is unclear246, several
lines of evidence suggest that antibody-mediated processes contribute to demyelination in
MS57, 256, 479 and EAE257. Other CSF factors may contribute to subpial demyelination
LQFOXGLQJ71)ĮDQG,)1ȖERWKRIZKLFKPD\EHUDLVHGLQWKH&6)LQ06247, 258, 259. ,)1Ȗ
augments antibody-mediated demyelination when injected into the CSF of rats in
combination with anti-MOG antibodies257, while TNFĮ has been shown to induce
oligodendrocyte apoptosis in vitro43, 260.
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Meningeal inflammation is well recognised in MS and may be important in mediating
subpial demyelination40, 41. Kutzelnigg et al reported that T cells, B cells and plasma cell
infiltrates are invariably seen in the meninges overlying subial plaques134. Similarly
Pomeroy et al observed increased numbers of B cells, T cells and macrophages in the pia
mater overlying subpial plaques in an animal model of MS239. 239. Lymphoid follicle-like
structures have been described in the leptomeninges of both MS patients and mice with
EAE41, 261. These structures contained proliferating B-cells, in addition to T-cells, plasma
cells and a network of follicular dendritic cells, suggesting that they represent ectopic B-
cell follicles with germinal centres, sites where activated B cells undergo clonal expansion
and selection to differentiate into plasma cells secreting high affinity antibodies. In
keeping with this hypothesis, B cells at various stages of maturation have been identified
in the CSF of MS patients, including centroblasts, cells that are exclusively found inside
secondary lymphoid organs262.
Previous work has suggested that there is considerable regional variability in the degree
of demyelination in the cerebral cortex127, 132-134. Several studies demonstrate that the
cingulate gyrus is a predilection site for cortical demyelination, both in MS and EAE127, 132,
134, 239. For example Bö et al observed more extensive demyelination in the cingulate in
comparison with other cortical areas (mean 43.8%, median 49.4% versus mean 11.5%,
median 2.2% in the parietal lobe)127. Likewise we find greater demyelination in the
cingulate than the motor strip. The mean 16% demyelination that we observe in the
cingulate is similar to the 19.4% reported by Vercellino et al132. Kutzelnigg et al found
subpial demyelination to be most pronounced within the bases of sulci and within deep
invaginations of the cortex, notably the cingulate gyrus, insular cortex and temporobasal
cortex134. The preponderance for these areas may reflect regional differences in CSF
flow, with extensive demyelination occurring in areas of CSF stasis134, 239 .
2.4.2 Cerebellar Demyelination
Few studies have examined GM demyelination in the cerebellar cortex in MS204, 242. Using
conventional staining techniques Adams assessed cerebellar pathology in 102 MS cases,
detecting cortical demyelination in only a single case204. Considering the low myelin
density within the healthy granular cortex (figure 2.2, A-D), it is perhaps not surprising
that demyelination in this area is not detected with histochemical stains. However myelin
protein IHC reveals that the cerebellar cortex is actually a predilection site for
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demyelination in MS, with PGMd exceeding 70% in 6 of the 13 cases examined in the
current study. The cerebellum also showed the greatest difference between PGMd (mean
43.7%) and PWMd (mean 8.7%). Our findings are consistent with a recently published
study by Kutzelnigg et al who examined cerebellar pathology in 40 MS cases and 8
controls, demonstrating extensive demyelination of the cerebellar cortex affecting all
cortical layers in a band-like manner242. This pattern of demyelination was exclusive to
MS subjects and was not observed in non-MS controls, including cases with cerebellar
hypoxia.
We are confident that the sharply demarcated areas of complete myelin loss that we
observe in the cerebellar cortex do indeed represent MS lesions, rather than Wallerian
degeneration. Tract degeneration would be expected to result in poorly demarcated areas
of incomplete myelin loss64. Furthermore, the efferent projections of the purkinje cells -
which pass through the granular layer - are myelinated, as are their recurrent collateral
branches; tract degeneration within the afferent connections of the cerebellum would not
result in a loss of this myelin263.
While demyelination in the cerebellar GM consistently involves the full thickness of the
cortex, the great majority of cerebral subpial plaques are limited to the superficial cortical
layers; therefore a greater proportion of the cerebellar cortex is demyelinated (43.7%
versus 16% in the cingulate gyrus). Interestingly, when we analysed the proportion of the
cortical surface that was demyelinated, the cerebellum and the cingulate showed similar
degrees of involvement (43.7% versus 36.1%). We note that Kutzelnigg et al occasionally
observed demyelination of the cerebellar cortex both (i) in a perivenous distribution and
(ii) extending a variable depth into the granular layer242, patterns of demyelination that we
did not detect (i.e. lesions invariably affected the full thickness of the cerebellar cortex in
our study). Like the subpial plaques of the cerebral cortex, the subpial GM lesions in the
cerebellum are extensive, typically involving long stretches of cortex so that multiple folia
may be completely demyelinated. PGMd in the cingulate cortex correlated significantly with
PGMd in the cerebellar cortex (further supporting the work of Kutzelnigg et al who found a
correlation between cortical demyelination in the cerebellum and the forebrain242), but not
with PGMd in the spinal cord, further suggesting that subpial demyelination occurs by a
different mechanism to demyelination in other sites. Kutzelnigg et al found no correlation
between GM and WM demyelination in the cerebellum, while we find a trend towards
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significance242. However, in agreement with their findings, we do observe some subjects
with extensive cerebellar cortical demyelination in the near absence of WM lesions.
2.4.3 Spinal Cord Demyelination
It is important to note that despite our speculations that subpial demyelination is mediated
by a factor related to the CSF, GM demyelination is even more extensive in the spinal
cord where the GM is surrounded by WM. Animal studies indicate that there are marked
differences between the GM of the brain and spinal cord in terms of their response to
injury, with inflammation being more pronounced in the spinal cord GM in comparison to
the striatum following either traumatic injury or the injection of pro-inflammatory
cytokines264, 265. Similar differences between sites may result in regional differences in the
extent of GM demyelination.
While the subpial WM of the spinal cord is a predilection site for lesions in particular
models of EAE266, this is not the case in MS where the subpial WM does not appear to be
any more susceptible to demyelination than the deeper tissue. Indeed areas of extensive
demyelination are frequently observed with sparing of a narrow rim of preserved myelin in
the subpial margin of the cord (see figure 3.4H, figure 3.8A, I and figure 3.9K from
Chapter 3 for examples)204. We occasionally observe demyelination limited to the subpial
WM of the spinal cord, but this is an infrequent finding (figure 2.3G). Although we
frequently see demyelination in the central portion of the spinal cord, this does not appear
to be centred on the central canal per se, but rather involves the GM commissure -
sometimes selectively, with sparing of the adjacent WM tracts (see figure 3.4H-K and
figure 3.9K-L). Such a pattern of demyelination is unlikely to be mediated by a
myelinotoxic factor in the CSF. The lumen of the central canal remains patent, allowing
the flow of CSF, in newborns and young children, but often closes in later life. Yasui et al
examined the anatomy of the central canal using autopsy material from 158 autopsy
cases ranging in age from only 1 week to 116 years267. While the patency rate under 1
year of age was almost 100%, cases in which the canal was occluded at all segmental
levels appeared in the second decade, with their number increasing with advancing age.
By the fourth decade the majority of cases were occluded at all cord levels.
A proportion of GM plaques in the spinal cord show a strict respect for the GM/WM
boundary. In this respect they show similarity to the subpial lesions in the cerebellar
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cortex and the type IV plaques which involve the full-thickness of the cerebral cortex, but
do not impinge on the subcortical WM. Only a single type IV cortical lesion was observed
in the current study, most likely reflecting the fact that we have examined relatively small
areas of cortex, but more gross examples are well described in the literature127, 132. It is
possible that these three lesion patterns - which clearly challenge our current
understanding of the factors that determine plaque morphology - share a common
pathogenic mechanism. This concept is explored in detail in Chapter 3. We note that the
converse pattern of demyelination (i.e. demyelinated WM, with sparing of the adjacent
GM) was not observed in any of the regions.
2.4.4 Thalamic Demyelination
Consistent with previous studies128, 132 we detect a modest degree of demyelination in the
thalamus, observing thalamic plaques in 9 out of 13 MS cases, with a mean 7.1% being
demyelinated. The nuclei of the thalamus are interspersed with a substantial amount of
WM and we did not observe lesions respecting the GM/WM boundary. Although the
ependymal surface was not identifiable on all of the sections, subependymal GM plaques
were present in a number of cases, sometimes extending over a relatively large area
(figure 2.3C, D).
It is well recognised that the periventricular WM is a predilection site for MS plaques. It is
unclear whether subependymal thalamic plaques share a common pathogenic
mechanism with these lesions. Adams et al examined the periventricular region in 129 MS
cases, observing periventricular plaques in 82% of these224. In the majority of cases the
plaque topography was most consistent with a perivenular origin224. Furthermore 84% of
active periventricular lesions showed a discrete perivenular distribution in comparison to
53% of chronic lesions, suggesting that over time discrete perivenular lesions coalesce to
form the characteristic pattern of periventricular demyelination. However, a smaller
number of periventricular WM plaques appear to arise from the ependymal surface of the
ventricle itself25, 224.
It has been suggested that inflammatory cells or a demyelinating factor within the
ventricular system may contribute to periventricular demyelination25, 268. Like the outer pial
surface of the brain, the inner ependymal surface is permeable, potentially permitting the
diffusion of a myelinotoxic agent from the ventricular CSF into the periventricular tissue269,
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270. In guinea-pigs with chronic relapsing EAE, a proportion of plaques appear to be
primarily related to the ventricular surface268. Numerous supraependymal macrophages
and lymphocytes overlie these lesions, suggesting that inflammatory cells within the
ventricular system may mediate periventricular demyelination268. Further work is required
to examine the relationship between periventricular GM plaques and subependymal veins
in MS and to compare the extent of periventricular demyelination between GM and WM
structures.
2.4.5 Influence of disease duration and MS subtype
In agreement with previous work, we find no correlation between disease duration and the
extent of GM demyelination127, 133, 242. However, disease duration was less than 10 years
in only one subject, indicating that studies on patients with shorter disease durations are
required to determine whether GM demyelination is an early or late event.
Bö et al found no statistical difference in the degree of demyelination in the cerebral
cortex between MS subtypes, although there was a trend towards more extensive
demyelination in progressive disease forms (16% in RR, 23% in SP, 37% in PP)127. A
large post-mortem study of 52 MS cases reported greater cortical demyelination in
patients with PP or SPMS (median 13% of cortex demyelinated) than in acute or RR
cases (0% and 3% respectively), suggesting that a high degree of cortical demyelination
may be a pathological correlate of disease progression133. WM lesion loads were similar
in the different clinical subgroups. Similarly Kutzelnigg et al reported that cortical
demyelination in the cerebellum was extensive in progressive MS, but sparse in acute
and RR disease242.
Due to a paucity of PP and RR cases in our study we have been unable to investigate the
influence of MS subtype on the extent of demyelination in the cerebral cortex and other
GM structures. We note that, in the single RR case (case 6, table 2.2) 18.7% of the
cingulate cortex was demyelinated, suggesting that extensive cortical demyelination is not
exclusively a feature of progressive disease. Interestingly no cerebral cortical plaques
were detected in the two PPMS cases (cases 11 and 14), while two of the cases of
progressive MS (cases 5 and 14) showed no demyelination of the cerebellar cortex.
However we acknowledge that, in comparison with other studies, we have examined
smaller areas of cortex.
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Due to a lack of detailed clinical information we are unable to explore the functional
consequences of GM plaques. It has been suggested that GM plaques in the cerebral
cortex may play a role in mood disturbance, cognitive impairment, fatigue and  less
commonly  seizures in MS129, 132, 134, 271. Similarly lesions in the cerebellar cortex and the
spinal cord may be relevant clinically. It is not uncommon to observe striking cerebellar
ataxia in the absence of prominent MRI changes272, a phenotype that could potentially
reflect extensive demyelination in the GM of the cerebellum, with relative sparing of the
WM. More sophisticated in vivo imaging techniques are required in order to explore the
clinical correlates of these GM lesions in more detail.
2.5 Conclusion
We demonstrate substantial variation in the extent of both GM and WM demyelination
between different regions of the CNS. Of the areas examined, GM demyelination was
most extensive in the spinal cord and cerebellum, while WM demyelination was most
prominent in the spinal cord. Demyelination was greater in the GM than in the WM at
each of the anatomical sites. Further work is required to better characterise these GM
plaques in order to understand both the factors that influence lesion topography and the
apparent preponderance for GM demyelination in MS.
52
Figures
Figure 2.1
Paraffin sections from control (A, C) and MS cerebral cortex (B, D-F),
immunohistochemically stained with anti-Proteolipid Protein antibodies. A, C - Myelin
staining in the motor cortex of a control; staining is reduced in the cortical grey matter
(GM) in comparison to the subcortical white matter (WM), particularly in the superficial
cortical layers, seen more clearly at higher magnification (C). B  Type III subpial lesion
extending over the majority of the cingulate gyrus (open arrows indicate lesion border). D
 A different type III plaque at high magnification demonstrating complete myelin loss in
the subpial tissue. In comparison to subpial lesions, type I (E) and type II (F) lesions are
generally smaller and often perivenular in distribution. The dashed lines represent the
GM/WM boundaries. Scale bars (C-F) represent 500ȝm.
53
54
Figure 2.2
Paraffin sections from control (A - D) and MS cerebellar cortex (E - I),
immunohistochemically stained with anti-Proteolipid Protein antibodies. A, B - Myelin
staining in a control case; in comparison with the white matter (WM) of the cerebellum,
there is a relative paucity of myelin within the granular cell (Gr) and purkinje (Pu) layers of
the cerebellar cortex, while the outermost molecular (Mo) layer is devoid of myelin, even
in the non-diseased state. C, D  Myelin staining density in the Pu (C) and Gr (D) layers
at higher magnification. E  Mixed grey matter (GM) / WM lesions in the cerebellar cortex
of an MS case; a similar plaque viewed at higher magnification (F) shows demyelination
of both the digital WM and the cortical GM of a folia. G, H  A proportion of cerebellar
plaques are characterised by a complete loss of myelin within the cortex, with sparing of
the adjacent subcortical WM, so that the lesion boundary shows a strict respect for the
GM/WM boundary. I  demyelination in the Gr layer is invariably accompanied by myelin
loss in the Pu layer, and vice-versa. The scale bars in B, F and G represent 500ȝm; in C,
D, H and I they represent 50ȝm.
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Figure 2.3
Paraffin sections from the thalamus (A  D) and the spinal cord (E  G) stained with anti-
Proteolipid Protein antibodies. A  Control case, showing gray matter (GM) nuclei
interspersed with white matter (WM). B  G MS cases. B  multiple demyelinated
plaques, largely within the GM. C  subependymal periventricular plaque lying within the
GM, also seen at higher magnification (D); the morphology is somewhat reminiscent of
the type III cortical plaques. E  two mixed GM/WM plaques in the cervical cord, both
display a complete disregard for the GM/WM boundary. There is a paucity of myelin
staining within the Substantia Gelatinosa, which is also observed in the non-diseased
state (not shown). F, G - A proportion of plaques within the spinal cord maintain a strict
respect for the GM/WM boundary. At higher magnification (G) a thin layer of
demyelination is seen affecting the subpial WM at the periphery of the cord (open arrows).
The dashed lines represent the GM/WM boundaries. Scale bars (D, G) represent 500ȝm.
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Figure 2.4
Bar chart illustrating the proportion of grey matter (GM) that is demyelinated and the
proportion of white matter (WM) that is demyelinated at the different CNS sites. Values
represent mean ± standard error. Spinal cord values represent the pooled results from
the three cord levels.
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Table 2.1
Frequency of lesions in the five anatomical regions. Spinal cord values represent the
pooled results from the three cord levels. *Pure GM lesions; i.e. lesions that are restricted
to the GM and do not impinge on the adjacent WM. **Tissue sections consist of cerebral
cortex and subcortical WM. GM = grey matter, WM = white matter.
Areas of GM demyelination Areas of WM demyelinationLocation Tissue
sections
examined
Number Proportion that
are pure GM
lesions*
Number Proportion that
are pure WM
lesions
Cingulate** 13 20 90% 9 77.8%
Motor cortex** 12 28 100% 2 100%
Deep GM 13 36 87.5% 13 61.5%
Cerebellum 13 79 50.6% 41 56.1%
Spinal Cord 37 42 16.7% 70 14.3%
Case Age Gender Disease MS Motor cortex Cingulate Cerebellum Thalamus Spinal cord
Duration Subtype
% Demyelinated
Area
% Demyelinated
Area
% Demyelinated
Area
% Demyelinated
Area
% Demyelinated
Area
GM WM GM WM GM WM GM WM GM WM
1 62 F 22 SP 11.5 0 11.4 14.0 23.6 2.2 NA NA 26.1 32.7
2 81 F 37 SP NA NA 8.8 9.1 7.4 0 0 0 25.9 15.6
3 56 F 25 SP 5.0 0 34.4 0 90.2 2.6 14.1 0 49.3 26.8
4 45 F 16 SP 8.9 0 24.3 0.1 100 59.1 6.0 0 NA NA
5 58 F 22 SP 0 0 0 0 0 0 0 0 49.9 21.5
6 46 F 6 RR 0 0 18.7 0 0 0 18.1 0 NA NA
7 59 F 20 SP 0 0 0 0 74.8 8.3 0.4 0 13.6 2.2
8 70 F 26 SP 6.0 0 41.7 0 77.2 1.9 11 21.0 52.7 30.0
9 44 F 18 SP 1.6 0 20.8 12.4 85.3 24.1 27.0 26.7 70.6 48.7
10 71 F 32 SP 2.4 0.2 0.5 0 12.0 12.1 0.6 0 0 0
11 56 F 33 PP 0 0 0 0 2.7 3.2 0 0 100 94.6
12 48 F 32 SP NA NA NA NA NA NA 0 0 90.4 53.3
13 44 M 19 SP 10.9 5.5 46.8 15.7 94.5 0 10.7 4.7 72.6 70.1
14 53 F NA PP 0 0 0 33.7 0 0 4.7 0 0 0
Table 2.2
The proportion of GM that is demyelinated and the proportion of WM that is demyelinated in each region in the 14 MS cases examined. Spinal cord values
represent the pooled results from the three cord levels. GM = grey matter, WM = white matter, SP = secondary progressive, RR = relapsing remitting, PP =
primary progressive, NA = information not available.
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Chapter 3: The extent and pattern of Grey Matter demyelination in
the spinal cord in Multiple Sclerosis
3.1 Introduction
The spinal cord is a predilection site for demyelination in MS21, 24, 204, 243. For example, in an
MRI study of 80 MS patients, 74% were found to have spinal cord lesions205. Furthermore, the
cord is a common site for MS relapses, with lesions more frequently resulting in clinical
symptoms than brain lesions206. Involvement of this clinically eloquent area also contributes
substantially to motor, sensory and sphincter disturbance in progressive forms of the disease.
The topographic distribution of MS plaques in the spinal cord has been examined in detail
using histochemical staining techniques21, 24. These studies suggest that plaques occur
throughout the length of the cord, particularly at the cervical level24. Fog described three
characteristic patterns of plaque corresponding to the three WM columns21 (figure 3.1).
Posterior column lesions typically involved the central portion of the WM, with sparing of the
lateral portions of the tract and the cord surface. The dorsal region of the lateral column was
also reported to be a predilection site for plaques, where lesions often had a wedge-shaped
outline in transverse section and extended to the pial surface of cord, involving the pyramidal
tracts. Oppenheimer hypothesised that these plaques may be precipitated by mechanical
stresses, transmitted to small vessels of the cord through the dendiculate ligaments24.
Involvement of the anterior WM tracts was relatively infrequent with the exception of
symmetrical areas of demyelination on either side of the anterior median fissure21.
According to Fog, many spinal cord plaques arose on the course of small veins and venules21.
At the point of maximal cross-sectional area plaques typically surrounded a radial vein,
involving both WM and GM. From here the plaque followed the ascending and descending
tributaries of the vein which coursed vertically within the WM; as it extended in cranial and
caudal directions the plaque tapered and became limited to the WM. Therefore, while plaques
predominantly affected the WM, they often impinged on the GM, displaying a total disregard for
anatomical boundaries, including the GM / WM boundary21, 24, 204. However spinal cord GM
demyelination was not examined in detail.
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We have previously demonstrated that the spinal cord GM is a predilection site for
demyelination in MS, suggesting that the conventional myelin staining techniques used in
previous studies substantially underestimated GM involvement. In this much larger study we
perform a more extensive and detailed assessment of spinal cord pathology in MS, using PLP
IHC to assess the extent and pattern of GM demyelination at five different cord levels. We
hypothesise that GM involvement parallels WM involvement, with the cervical cord showing
preferential involvement. Furthermore, we compare the utility of LFB staining with myelin
protein IHC in detecting myelin loss in this area.
3.2 Materials and methods
3.2.1 Clinical material
Human autopsy material was obtained from 36 pathologically confirmed cases of MS and 12
controls. This material was derived from the neuropathology department, Oxford Radcliffe NHS
Trust. The cases were selected at random from a collection of 55 MS cases and 33 controls
studied previously79, 101, 203. The MS patients (16 male, 20 female) were aged 32-79 years
(mean 59, median 58) with disease durations of 2-43 years (mean16, median 15). The controls
(6 male, 6 female), aged 33-77 years (mean 59, median 63), had no clinical or pathological
evidence of neurological disease.
3.2.2 Preparation of the sections
For each of the MS and control cases 6ȝm formalin-fixed paraffin-embedded transverse
sections were taken from 5 predetermined levels of the spinal cord, irrespective of macroscopic
appearance (upper cervical, lower cervical, upper thoracic, lower thoracic and lumbar levels).
3.2.3 Immunohistochemistry
Sections were stained using the EnVision method as described in Chapter 2.2.3. The primary
antibodies used were mouse anti-Myelin Proteolipid Protein (IgG2a, clone number plpc1,
dilution 1:3000, MCA839G, Serotec) and rabbit anti-human GFAP (dilution 1:4000, Z0334,
DAKO).
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3.2.4 Histochemical Staining
In order to compare LFB- and PLP-staining for detecting GM demyelination in the spinal cord,
30 sections were stained with LFB Cresyl Violet using a protocol described previously273.
3.2.5 Measurement of GM and WM lesions
The PLP-stained sections were scanned in a slide scanner (Nikon Super Coolscan 4000) to
produce a digital image. Using these images the MS lesions were manually outlined using
image analysis software (AnalySIS Pro running SIS software). Lesions were defined as
sharply demarcated areas, characterised by either complete myelin loss or markedly reduced
myelin density on the PLP-stained sections (figure 3.2). Areas of demyelinated GM and WM
were measured separately (figure 3.3). In addition, the cross-sectional areas of the spinal
cords and the cross-sectional GM areas were measured in order to calculate the proportion of
GM that was demyelinated (PGMd) and the proportion of WM that was demyelinated (PWMd). The
PLP-stained sections, examined via microscopy (10x, Leitz Dialux 20EB microscope), were
used as a reference to help identify the MS lesions and the GM boundaries.
3.2.6 Statistical analysis
Paired t tests were used to compare PGMd with PWMd. Correlations between PGMd and PWMd were
assessed using Spearmans ranked test. Multiple regression analyses were used to examine
the influence of age, sex, cord location and disease duration on PGMd and PWMd (Stata version
9, StataCorp, Texas USA).
3.3 Results
3.3.1 PLP Immunohistochemistry
The distribution of myelin in the GM of the non-diseased human spinal cord has been
described using histochemical staining274. Consistent with this study we found considerable
regional variation in myelin density within the GM, with a paucity of myelinated fibres in the
Substantia Gelatinosa of the dorsal horns, the GM commissure and  in the thoracic cord  the
lateral GM column (figure 3.4 A-G). Between controls there was a degree of inter-individual
variability, particularly within the GM commissure (figure 3.4 B, G).
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3.3.2 Lesion counts
In the 150 sections studied from the 36 MS cases, 262 areas of demyelination were detected in
the WM and 194 areas were detected in the GM. 86 of the 262 WM lesions (33%) were
restricted to the WM and did not impinge on the GM. 43 of the 194 GM lesions (22%) were
restricted to the GM and did not involve the WM. It has previously been reported that the vast
majority of lesions in this spinal cord material are inactive101. In keeping with this we observed
evidence of ongoing demyelination (i.e. macrophages containing LFB- or PLP-inclusions) in
only four lesions (two WM lesions and two mixed WM/GM lesions).
3.3.3 Demyelination is more extensive in the GM than the WM of the spinal cord
Overall, PGMd (mean 33.3%) was significantly greater than PWMd (19.7%) (p < 0.0001). Similarly,
when the 5 cord levels were analysed separately, PGMd was greater than PWMd at the upper
cervical (p = 0.0247), upper thoracic (p = 0.0001), lower thoracic (p = 0.0003) and lumbar (p =
0.0021) levels (figure 3.5). The difference did not reach statistical significance at the lower
cervical level (p = 0.0751). There was a significant correlation between PGMd and PWMd (r =
0.8316, p < 0.0001).
PWMd was highest at the upper cervical level (31.8%). To examine this further PWMd was
regressed on the cord level controlling for age, sex and disease duration. In comparison with
the upper cervical level, PWMd was significantly reduced at the lower thoracic (coefficient of
regression = -0.1514, p = 0.036, that is, controlling for other variables, PWMd was on average
15% greater at the upper cervical than the lower thoracic level) and lumbar (coefficient of
regression = -0.2163, p = 0.001) levels. In addition there was a trend towards significant
reductions at the lower cervical (p = 0.054) and upper thoracic (p = 0.053) levels.
In comparison to the upper cervical cord, and controlling for other variables, cord level did not
appear to have a significant influence on PGMd (lower cervical p = 0.079, upper thoracic p =
0.759, lower thoracic p = 0.471, lumbar p = 0.198).
Similar results were obtained when we considered only the areas of complete demyelination
(i.e. when areas of markedly reduced myelin density were excluded from the statistical
analysis). The proportion of completely demyelinated GM (28.4%) was greater than the
proportion of completely demyelinated WM (17.5%) (p < 0.001). When the 5 cord levels were
analysed separately, the proportion of completely demyelinated GM was greater at the upper
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cervical (p = 0.0275), upper thoracic (p = 0.0001), lower thoracic (p = 0.0018) and lumbar (p =
0.0034) levels (figure 3.6). The difference did not reach statistical significance at the lower
cervical level (p = 0.1856).
There is considerable variation in both the total cross-sectional area and the WM:GM ratio
between the different levels of the spinal cord275. We have controlled for this variation by
assessing the proportion of the tissue that is demyelinated, rather than the absolute area. We
note that the absolute area of demyelinated WM is greater than the area of demyelinated GM,
simply reflecting the substantially greater volume of WM in the cord.
3.3.4 Influence of age, sex and disease duration on extent of demyelination
Age (coefficient of regression = -0.0095, p < 0.001) appeared to have a significant influence on
PWMd, with younger patients having greater WM demyelination. There was a trend for gender to
influence PWMd, with demyelination being more extensive in males (coefficient of regression =
0.08695, p = 0.055). Disease duration did not significantly influence PWMd (p = 0.140).
Both age (coefficient of regression = -0.0087, p = 0.001) and gender (coefficient of regression =
0.1326, p = 0.043) appeared to have a significant influence on PGMd, while disease duration did
not (p = 0.225).
3.3.5 Lesion morphology
A large number of WM lesions show a similar morphology to those described previously using
conventional staining techniques21, 24. Predilection sites include the central portion of the
posterior columns and the lateral columns, where the plaques frequently have a wedge-shaped
outline in transverse section and impinge on the GM (figure 3.7).
Within the GM, plaques showed no obvious preponderance for any particular region; lesions
frequently involved the anterior horns, posterior horns and the GM commissure, often in
combination. In a number of cases a proportion of the border of the GM plaque maintains a
strict respect for the GM/WM boundary. This pattern of residual plaque morphology, which has
not been described previously, was observed in both mixed GM/WM lesions and pure GM
lesions (figure 3.8, A-H and figure 3.9, K-L). The myelin content of the WM immediately
adjacent to these demyelinated areas of GM appeared normal using both LFB- and PLP-
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staining, even when examined at high magnification. Conversely, we did not observe areas of
demyelinated WM with sparing of the adjacent GM.
In a number of other cases, completely demyelinated areas of GM were observed adjacent to
areas of WM with an obvious reduction in myelin staining density with PLP and LFB-staining
(figure 3.8, I-K). Overall, out of the 105 sections that contained at least one GM plaque, 55
contained a GM plaque where a proportion of the plaque border maintained a strict respect for
the GM/WM boundary. Such plaques were observed in 22 of the 36 cases, with disease
durations ranging from 5 years to 34 years.
3.3.6 GFAP expression within GM and WM plaques
GFAP staining within demyelinated areas is highly variable. Staining density was increased in
some GM and WM plaques; in other plaques staining was reduced in comparison with
corresponding areas of myelinated tissue. GM plaques frequently showed evidence of
astrocytic activation (figure 3.9). Gliosis is further discussed in Chapter 6.
3.3.7 The sensitivity of Luxol Fast Blue for detecting GM demyelination
For a number of the PLP-stained sections (n = 30), adjacent sections were stained with LFB to
evaluate the utility of this stain for detecting GM demyelination in the spinal cord. These
sections were selected to include a range of patterns of demyelination as demonstrated using
the PLP staining. Lesion morphology was more readily appreciated using myelin protein IHC,
which provides greater contrast between the myelinated and demyelinated tissue. However all
of the areas of GM demyelination were detected by thorough examination of the LFB-stained
sections at high magnification, particularly when informed by the PLP-stained sections (figure
3.10).
3.4 Discussion
Detailed post-mortem studies have used conventional histochemical myelin stains to examine
the topology of MS plaques within the spinal cord, demonstrating that the cord is a predilection
site for demyelination, which generally occurs in a peri-venular distribution21, 24. We re-
evaluate pathology in this clinically eloquent site, using myelin protein IHC to assess the extent
and pattern of GM demyelination. In comparison with the previous work - Fog examined 8 MS
cases, while Oppenheimer studied 18 - we have used autopsy material from 36 MS cases,
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examining pathology at five different cord levels. We have also studied a large number of
control cases. Considerable variations in myelin density were observed in these subjects, both
between individuals and between the different GM laminae, highlighting the importance of
using control material to define the normal limits of myelin content.
While Oppenheimer simply reported the frequency of MS plaques at various levels of the spinal
cord24, we also evaluate the extent of WM and GM demyelination. Lesion number is a crude
measure of MS pathology, particularly when comparing WM and GM involvement; simply
reporting lesion number is likely to underestimate the degree of GM pathology as lesions
frequently fuse in the GM, often in the vicinity of the central canal21. For example, using our
system for counting lesions, the section in figure 3.3C would be scored as containing 3 WM
lesions and one GM lesion.
We demonstrate that the proportion of GM that is demyelinated is greater than the proportion of
WM that is demyelinated throughout the spinal cord, further challenging the view that MS is a
predominantly WM disease. Although we do not have detailed clinical information regarding
disability, it is possible that these GM plaques have substantial functional consequences,
contributing to motor, sensory and bladder dysfunction. Animal studies demonstrate that GM-
specific injuries in the spinal cord can result in substantial deficits, including paraplegia276 and
pain syndromes277, even in the absence of damage to the WM tracts.
We have scored the material for MS plaques by visually inspecting the sections, both at low
and high magnification, rather than using an automated intensity-based technique whereby an
MS plaque is defined as an area with a myelin staining intensity below a particular threshold.
While an automated method is likely to be less subjective and more time-efficient, there are
potential limitations. As discussed previously, there are regional variations in myelin density
within the GM. Furthermore, given the marked reduction in axonal density in the MS cases79,
one may expect the staining intensity of the normal appearing tissue to be reduced in these
sections. Both of these factors should be considered when inspecting for areas of
demyelination, but are difficult to accurately incorporate into a threshold-based technique.
Finally it is not always possible to identify the GM/WM boundary using an intensity threshold-
based technique, particularly in the demyelinated state.
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We note that we occasionally observe areas of WM with more subtle reductions in myelin
densities that do not fulfil our criteria for an MS plaque. These changes were extensive in
several cases and were most evident on inspection of the WM at high magnification (figure
3.2, H-K). We have not attempted to quantify these changes, largely because they could reflect
any one of a number of different pathological changes. We have previously reported a 30%
reduction in corticospinal tract axonal density in this MS cohort79. These measurements were
made outside of MS plaques79. Such reductions in axonal density are likely to result in
secondary reductions in myelin staining density. However, numerous other pathological
abnormalities are observed in the non-lesioned WM, including gliosis, inflammatory cell
infiltration and oedema, all of which may result in a reduction in myelin staining density25, 30, 33-
35, 37-39, 133. Interpretation of the staining pattern is further complicated by the fact that  as a
result of axonal loss and tissue atrophy  the myelin staining density may actually pseudo-
normalise. Finally the staining intensity will not necessarily be directly proportional to the
density of myelinated axons; Pistorio et al noted that myelin protein IHC saturates at a medium-
to-high concentration of myelin and therefore may not be optimal for looking for subtle degrees
of myelin loss outside of MS plaques278.
In some cases these areas of reduced myelin staining may be difficult to differentiate from MS
plaques with markedly reduced myelin density, which most likely represent partially
remyelinated lesions. Consequently, we may have either underestimated, or overestimated, the
extent of demyelination, particularly in the WM. However, in contrast to MS plaques, which
have sharply demarcated borders, we would expect areas of Wallerian degeneration to appear
as poorly demarcated areas of reduced myelin density with ill-defined contours64. Therefore we
are confident that these factors have not had a significant influence on our results. We note that
our measurements are highly reproducible (see Reproducibility of measurements, section
2.2.6). Furthermore, when we consider only the areas of complete myelin loss (i.e. there is
clearly less subjectivity in defining completely demyelinated lesions), we still observe a
preponderance for GM - rather than WM - demyelination.
The cervical cord is often described as a predilection site for MS plaques. Oppenheimer
reported that approximately 90% of sections from the upper and lower cervical cord show MS
lesions, in comparison with 46% of thoracic and 41% of lumbar cord sections24. The cross-
sectional area of the spinal cord is greatest at the lower cervical level; by correcting for this (i.e.
by considering the proportion of demyelinated WM) our results suggests that the lower cervical
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cord is no more extensively involved than other levels. The reason that the upper cervical cord
is preferentially involved is unclear. One contributing factor may be that extensive plaques in
this region tend to cause particularly disabling symptoms (i.e. quadraparesis) and may
therefore be over-represented in an autopsy series. We find no significant difference in the
extent of GM demyelination between cord levels.
Our results suggest that gender influences the extent of both WM and GM demyelination with
more extensive demyelination being evident in males. There is little evidence suggesting
differences in MRI lesion loads in the brain between male and female MS patients. In a study of
SPMS, Li et al reported that male patients had greater T2 lesion loads than females, although
females showed a greater accumulation of gadolinium-enhancing lesions over the subsequent
3 years279. MS tends to run a more aggressive course in male patients 280-282 and there is some
evidence from post-mortem studies that axonal loss in the spinal cord is more severe in males
77. However, interpretation of our finding is limited; owing to a lack of clinical information the
multiple regression analysis does not control for MS clinical subtype, which has been reported
to influence lesion loads in imaging studies215, 283-287.
Brain MRI lesion load measures are generally lower in PPMS than in other MS phenotypes215,
283-287. Fewer studies have compared lesion loads in the spinal cord between different MS
subtypes. Some imaging studies suggest that focal cord lesions are more frequently seen in
SPMS than in PP cases285, 288, while others report no differences between subtypes215, 287.
Examining a cohort of 19 patients with progressive MS (10 PPMS, 9 SP disease), Kidd et al
performed serial brain and spinal cord imaging over a 1 year period215. During this time 132
active brain lesions appeared (85% occurred in the SP group), in comparison with only 6 new
cord lesions (3 in each subtype). It has been reported that, in comparison with RR and SP
disease forms, PPMS patients often have extensive, diffuse MR abnormalities in the spinal
cord284, 288, 289. Nijeholt et al suggested that these diffuse changes correspond
histopathologically with areas of partial demyelination, but these have not been characterised
further289. Whether there are differences in the extent of spinal cord demyelination between
different MS subtypes is an important question, but one that we have been unable to address in
the current study.
It is likely that MS patients who die soon after diagnosis, or at a younger age, will tend to have
more aggressive disease. This may explain our observation that age appears to influence the
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extent of WM and GM demyelination, whereas disease duration does not. It is less likely that
spinal cord lesion load plateaus after a short time period following which disease duration has
little influence on demyelinated area; longitudinal imaging studies indicate that T2 lesion load
measures in the brain increase over time, even between 10 and 14 years disease duration290.
An additional consideration when interpreting post-mortem studies is that plaques may have
undergone several phases of evolution (i.e. demyelination, re-myelination and repeated
demyelination)291.
There are limitations to using single sections to examine lesion topology and it is possible that
a proportion of pure GM lesions expand into the WM as the plaque extends in cranial and
caudal directions. However, our study suggests that the majority of GM lesions in the spinal
cord are mixed GM/WM lesions. In contrast the majority of cortical lesions lie entirely within
GM127, 131-134. Consistent with these observations - and our previous study - we find a strong
correlation between the degree of GM and WM demyelination in the spinal cord while there is
no such correlation in the brain133. Spinal cord plaques may extend over a variable distance,
ranging from only a few millimetres to several spinal segments in length225. Further studies 
using either serial sections or potentially post-mortem MRI - are required to examine the three-
dimensional topology of spinal cord plaques in more detail.
Many MS plaques are seen on the course of small veins and venules21. However we
demonstrate that in many cases a proportion of the border of the GM plaque maintains a strict
respect for the GM/WM boundary. This pattern of plaque morphology, which has not been
described previously, does not appear to occur in a purely perivenular distribution. These
plaques show similarities to the type IV lesions of the cerebral cortex127 and the extensive
areas of demyelination that we frequently observe in the cerebellar cortex, both of which are
characterised by full-thickness cortical demyelination, with sparing of the subcortical WM.
Therefore, in all three lesion patterns, a proportion of the lesion border corresponds exactly to
the GM/WM boundary, suggesting a common pathogenic mechanism. Unfortunately we have
little insight into plaque morphology during the early stages of lesion development, as the
majority of plaques in our post-mortem series are likely to be longstanding. We observe
evidence of ongoing demyelination in only two of the GM lesions; the plaque borders did not
respect the GM/WM boundary in either of these lesions. It is therefore unclear whether the
pattern of residual plaque morphology that we observe at autopsy reflects the morphology of
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the demyelinating lesion per se, or demyelination with subsequent remyelination of the WM, but
not the GM, portion of the lesion.
There may be differences in the glial-cell environment between GM and WM which predispose
to extensive GM demyelination with sparing of the adjacent WM. There are phenotypical
differences between inflammatory cells in WM lesions and those in the GM; the majority of
MHC class II-positive cells in active WM plaques are macrophages, while those in cortical GM
lesions have the morphology of microglia130. There are also phenotypical differences between
astrocytes in WM and GM (the GM contains protoplasmic astrocytes while the WM contains
fibrous astrocytes)292, 293 and differences related to the oligodendrocyte-myelin complex. For
example, a proportion of oligodendrocytes (so-called satellite or perineuronal oligodendrocytes)
are exclusive to the GM, where they lie opposed to the perikarya of neurons125, 126. There is
evidence that the topography of lesions in EAE is determined, in part, by the target
autoantigen. T-cells that recognise MBP or PLP induce disease predominantly affecting areas
with thick myelin sheaths, while MAG- or MOG-induced disease primarily involves areas
containing thinner sheaths25, 294. Interestingly, T cells specific for GFAP or the nonmyelin
autoantigen S100ȕ, a calcium binding protein expressed and secreted by astrocytes, mediate
inflammation which is more pronounced in the GM than the WM294, 295. Similarly, antigenic
differences between the GM and WM may render the GM more vulnerable to immune-
mediated attack in MS.
Bö et al suggested that demyelination in type IV lesions may be mediated by a myelinotoxic
factor in the interstitial fluid (i.e. the fluid that bathes the brain parenchyma) 127. Soluble factors
can exchange between the CSF, the perivascular (Virchow Robin) spaces and the interstitial
fluid via a number of pathways269, 270, 296. Drainage of a myelinotoxic factor along these
predetermined anatomical routes may influence plaque topography in MS240. In the cerebral
cortex interstitial fluid preferentially drains along perivascular channels to the CSF, while a
substantial volume of interstitial fluid in WM also spreads diffusely through the extracellular
spaces between the nerve fibres, draining into the ventricular CSF296. Therefore, interstitial fluid
 along with any myelinotoxic factor that it may contain  may be cleared more efficiently from
WM than from GM269, 270, 296. These differences may be further exaggerated in the diseased
state as BBB breakdown and oedema  which are more prominent in WM than GM plaques135,
136 - may facilitate the bulk flow of fluid out of the brain parenchyma297. Therefore GM/WM
differences in the clearance of a myelinotoxic agent may be expected to produce areas of GM
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demyelination with sparing of the adjacent WM, consistent with those observed in the spinal
cord, cerebral cortex and cerebellar cortex. A myelinotoxic substance originating in the
interstitial fluid could also potentially circulate within the Virchow-Robin space (resulting in
perivenular demyelination) and the CSF (mediating subpial and periventricular
demyelination)11.
Alternatively the GM may have a poor ability to remyelinate in comparison to the WM, due to
numerical or functional differences in oligodendrocyte precursors between GM and WM. The
spared WM immediately adjacent to the GM plaques appears normal on the LFB- and PLP-
stained sections (figure 3.8, A-H); if these areas of WM were remyelinated we may have
expected the LFB-staining to demonstrate abnormally thin myelin sheaths leading to an overall
reduction in myelin staining density36. However, we acknowledge that remyelination is more
reliably assessed using more sensitive techniques36. Consistent with this hypothesis we
observe that some plaques are characterised by completely demyelinated areas of GM
adjacent to areas of WM with reduced myelin density (figure 3.8, I-K). It is possible that these
areas of markedly reduced myelin density represent areas of remyelination, although there are
other potential explanations for this pattern of staining (e.g. extensive axonal loss, oedema etc.)
as discussed previously. Further work, using electron microscopy or Toluidine blue-stained
resin sections, is therefore required to look for evidence of remyelination in areas of WM
directly adjacent to demyelinated GM plaques which appear to respect the GM/WM boundary.
To our knowledge GM remyelinaton in MS has not been examined in detail. Merkler et al report
that following cortical demyelination in a rat model of MS, demyelinated areas are repopulated
with oligodendrocytes and extensive remyelination occurs within 2 weeks240. It is feasible that
the paucity of GM plaques observed in acute and RRMS133 actually reflects rapid and extensive
cortical remyelination early in the disease course, but that this remyelinating capacity becomes
exhausted with repeated episodes of demyelination240.
There is evidence that GM lesions show a reduced number of inflammatory cells in comparison
to WM plaques130, 135, 222, although this has not been demonstrated in the spinal cord
specifically. The induction of acute inflammation stimulates remyelination in animal models of
chronic demyelination299. Animal studies also suggest that both macrophages and lymphocytes
facilitate remyelination300, 301. Weerth et al have suggested that the complement factor C5
promotes remyelination following inflammatory-mediated injury, demonstrating that C5-deficient
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mice with chronic EAE show a reduced ability to remyelinate in comparison with control
animals302. Interestingly, Brink et al report that GM MS lesions in the cortex show markedly
reduced complement deposition in comparison to WM lesions137. It is therefore interesting to
speculate that the GM environment may be less conducive to remyelination than the WM in
MS.
In contrast to the highly-specific IHC staining there is a degree of background staining
associated with the LFB Cresyl Violet, resulting in less contrast between the myelinated and
demyelinated tissue. While GM demyelination was more readily appreciated using myelin
protein IHC, the great majority of plaques were also detected by LFB-staining. This is not the
case in the cerebral cortex where a significant proportion of GM plaques are not detectable
using conventional histochemical stains, even when inspected alongside the corresponding
IHC-stained sections127. This may reflect, in part, differences in myelin density between the GM
of the spinal cord and that of the cerebral cortex. Furthermore, identification of the GM portion
of the mixed GM/WM lesions  which constitute a large proportion of GM lesions in the cord - is
aided by following the plaque border from the WM portion of the plaque into the GM. The fact
that LFB, which stains the phospholipid component of the myelin sheath, reveals a similar
pattern of plaque morphology confirms that the staining pattern obtained with the IHC is not
unique to this particular PLP antibody.
3.5 Conclusion
We demonstrate extensive GM demyelination in the spinal cord in MS, with a proportion of
plaques showing a distinct morphology that has not been described previously. A greater
understanding of these GM plaques may provide important clues regarding MS pathogenesis
and mechanisms of disability in the disease. Further work is required to establish whether the
pattern of residual plaque morphology that we observe reflects differences in the extent of
demyelination between WM and GM in the cord or a relative failure of remyelination in the GM.
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Figure 3.2
Paraffin sections from MS (A-E, H-K) and control spinal cords (F-G), immunohistochemically
stained with anti-Proteolipid Protein antibodies (A-G, H, J) and Luxol Fast Blue (I, K). A 
Extensive demyelination in the lumbar cord. Areas of complete myelin loss (green box, also
shown at high magnification in B) and markedly reduced myelin density (red box, D) are
observed in the grey matter. Similarly, the white matter contains areas of complete myelin loss
(blue box, C) and markedly reduced myelin density (orange box, E).
F, G - Areas of grey matter (F) and white matter (G) in a control case demonstrating normal
myelin content.
H, I - Other areas of white matter show less striking reductions in myelin density that do not
fulfil our criteria for an MS plaque. J, K - Higher magnification images from panels H and I
(boxes) demonstrating these changes more readily.
Scale bars (B-G, J, K) represent 50ȝm.
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Figure 3.3
Paraffin sections from MS spinal cords, immunohistochemically stained with anti-Proteolipid
Protein antibody. A, C - Sections were scored for lesions, defined as sharply demarcated areas
characterised by either complete myelin loss or markedly reduced myelin density. Areas of
demyelinated grey matter and white matter were measured separately; according to this
system panel A contains two grey matter lesions and one white matter lesion, while panel C
contains one grey matter lesion and four white matter lesions. B, D  The lesions are shaded
(white and grey), and the grey matter / white matter boundary outlined (black lines).
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Figure 3.4
Paraffin sections from control (A-G) and MS (H-K) spinal cords stained with anti-Proteolipid
Protein (PLP) antibodies (A-H, J) and Luxol Fast Blue (LFB)(I, K).
A. Staining in the non-diseased cord demonstrating a paucity of myelin in the grey matter
commissure (solid box) and the Substantia Gelatinosa (dashed box), shown at a higher
magnification in panels B and C respectively. D. In the thoracic cord there is also a paucity of
myelin in the lateral horn of the grey matter. E - Higher magnification image from panel D (box).
F, G - Grey matter commissure in a different control demonstrating a reduction in myelin
density in comparison with panels A and B.
H-K. Sections from MS spinal cords stained with PLP antibodies (H) alongside an adjacent
section stained with LFB (I). J-K - Higher magnification images from boxes in panels H and I. A
number of pure GM plaques are characterised by a complete loss of myelin within the GM
commissure, which is more clearly delineated using PLP-staining.
Scale bars (B, C, E, G, J, K) represent 500ȝm.
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Figure 3.5
Bar chart of proportion of grey matter (GM) and white matter (WM) that is demyelinated at
different levels of the spinal cord. UC=upper cervical; LC=lower cervical; UT=upper thoracic;
LT=lower thoracic; Lum=lumbar. Values represent mean ± standard error.
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Figure 3.6
Bar chart of proportion of grey matter (GM) and white matter (WM) that is completely
demyelinated at different levels of the spinal cord. UC=upper cervical; LC=lower cervical;
UT=upper thoracic; LT=lower thoracic; Lum=lumbar. Values represent mean ± standard error.
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Figure 3.7
Paraffin sections from MS spinal cords, immunohistochemically stained with anti-Proteolipid
Protein antibody. Many MS plaques show a similar morphology to those described previously
using conventional staining techniques for myelin. The principal predilection sites for white
matter (WM) plaques are the central portion of the posterior columns (A) and wedge-shaped
plaques in the lateral columns which frequently extend laterally to the pial surface of the cord
and medially to the grey matter (GM), displaying a complete disregard for the GM/WM
boundary (dashed line) (B). C - Involvement of the anterior WM tracts is relatively infrequent
with the exception of paramedian lesions, symmetrical areas of demyelination on either side
of the anterior median fissure. C - Lesions frequently fuse within the GM and show a striking
symmetry about the midline.
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Figure 3.8
Paraffin sections from MS spinal cords stained with anti-Proteolipid Protein (PLP) antibodies
(A, B, E-G, I, J) and Luxol Fast Blue (LFB)(C, D, H, K). A proportion of mixed GM/WM (A, C)
and pure GM lesions (E, G, H) appear to expand within the GM whilst maintaining a strict
respect for the GM/WM boundary. A, C - Lesion morphology demonstrated using both PLP-
and LFB-staining. B, D - Higher magnification images from panels A and C (boxes)
demonstrate complete demyelination of the GM commissure while the myelin in the adjacent
WM appears entirely normal using both LFB- and PLP-staining. E - Lesion involves the entire
right anterior horn, respecting the GM/WM boundary, and extends to the contra-lateral GM horn
via the GM commissure. F - High magnification image from panel E (box) demonstrating
sparing of the adjacent WM. G, H - The GM lesion on the left respects the GM/WM boundary. I
- In some cases, completely demyelinated areas of GM were observed adjacent to areas of
WM with subtle reductions in myelin staining density. J, K - PLP- and LFB-stained sections
corresponding to the area of reduced myelin staining intensity from panel I (box) at high
magnification. Scale bars (B, D, F, J, K) represent 150ȝm.
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Figure 3.9
Paraffin sections from MS (A - F, H, I, K, L) and control (G, J) spinal cords stained with anti-
Proteolipid Protein antibodies (A - C) and GFAP (D  F, corresponding to sections A - C
respectively, and G - L). GFAP staining in the myelinated white matter (WM) tracts  both in
controls (G) and MS cases (H, corresponding to panel D, black vertical arrow) - is
characterised by an abundance of GFAP staining due to a dense network of astrocytic
processes, the vast majority of which run longitudinally, buttressing the fibre tracts. I
(corresponding to panel D, black horizontal arrow) - there is a loss of the isotropic distribution of
glial filaments within the WM tracts in the demyelinated state , with a reduction in the density of
longitudinally orientated filaments and a substantial increase in the proportion of astrocytic
processes running radially in the plane of section (i.e. anisotropic gliosis).
The density of GFAP staining in both grey matter (GM) and WM lesions is extremely variable;
for example some GM lesions demonstrate an increase in GFAP staining (panel F, black
arrow) while others show reduced GFAP staining (panel E, arrow). This apparent reduction in
GFAP staining may represent dilution by some other process such as oedema or
inflammatory cell infiltration within the MS plaque. Note  the pale staining in the posterior
aspect of the spinal cord panel F is artefactual.
In comparison to the WM, glial filaments within the myelinated GM of controls (J) and MS
cases (K, corresponding to panel D, white arrow) are aligned haphazardly. There is evidence of
astrocytic activation within some GM plaques. For example in panel L (high magnification
image of GM plaque in panel F, white arrow) the astrocytes have larger cell bodies and more
conspicuous nuclei in comparison with myelinated grey matter (K). Scale bars (G-L) represent
50ȝm.
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Figure 3.10
Paraffin sections from MS spinal cords stained with anti-Proteolipid Protein (PLP) antibodies
(A, C, E, G, I, K) alongside adjacent sections stained with Luxol Fast Blue (LFB) (B, D, F, H, J,
L respectively). Lesion morphology is more readily appreciated using immunohistochemistry,
with the PLP-stained sections demonstrating greater contrast between the myelinated and
demyelinated grey matter (GM). C - F - Higher magnification images from solid (C, D) and
dashed (E, F) boxes in panels A and B. G, H - Pure GM plaque, also shown at high
magnification (I, J). K, L - Demyelination of the GM commissure is more clearly delineated
using PLP-staining. Scale bars (C-F, I, J) represent 500ȝm.
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Chapter 4: Spinal Cord atrophy in Multiple Sclerosis - relative
contributions of white matter and grey matter tissue loss
4.1 Introduction
Spinal cord atrophy in MS has been shown to correlate with clinical disability in both cross-
sectional and longitudinal imaging studies110, 212. However, the relative contribution of WM and
GM tissue loss to spinal cord atrophy has not been adequately examined. Characterising the
extent of GM atrophy in this clinically eloquent site is required in order to better understand
mechanisms of permanent disability in MS.
4.1.1 Evidence of GM atrophy in the brain in MS
A number of MRI-based techniques have been used to quantify GM volume loss in MS
including a variety of segmentation-based and automated registration-based methods303.
Different methods vary in terms of accuracy, reproducibility and efficiency with operator-
independent, automated techniques being highly reproducible and therefore particularly
suitable for longitudinal studies184, 195, 304-308.
A number of cross-sectional MRI studies have examined the relative contributions of WM and
GM volume loss to brain atrophy in MS, with some apparently inconsistent results. These are
likely to reflect a combination of methodological factors and differences between the patient
cohorts. A small number of reports suggest brain atrophy is attributable to WM - but not GM -
volume loss118, 309. Other studies indicate reductions in both WM and GM volumes139, 184, 192, 194,
310 while some groups report that brain atrophy is predominantly311 - or exclusively195, 312 - due
to GM volume loss. Consistent with this work, three longitudinal MRI studies have reported
progressive GM atrophy in the MS brain in the absence of WM volume loss138-140.
4.1.2 Atrophy in specific GM structures
Reductions in normalised cortical volumes have been reported in both RR and PPMS in
comparison to controls181, 185, 191. Sailer et al reported that cortical thinning predominantly
involves fronto-temporal regions, a finding supported by Prinster et al313. More disabled
patients and those with longer disease durations also showed thinning of the motor cortex314.
Somewhat consistent with these studies, Carone et al reported cortical atrophy predominantly
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involving frontal and parietal areas311. Cortical atrophy has also been reported in longitudinal
studies193, 196. For example, Chen et al demonstrated cortical thinning in patients with
progressive MS over a 1 year period with the parietal and precentral cortex showing the fastest
rates of atrophy193. Only one post-mortem study has examined cortical atrophy in MS; using
material from 21 MS cases and 16 controls, Wegner et al demonstrated a 10% reduction in
neocortical thickness in the MS cases, with thinning being most prominent in the motor
cortex131.
Atrophy has also been demonstrated in the thalamus, caudate and other deep GM structures,
both in cross-sectional157, 158, 304, 313, 315 and longitudinal imaging studies196, 316. In addition to
imaging the thalamus in vivo, Cifelli et al quantified thalamic pathology using post-mortem
material from 10 MS patients and 10 controls, reporting a mean 21% reduction in volume in the
medial dorsal nucleus in the MS cases157.
4.1.3 Mechanisms of GM atrophy in MS
The substrate of GM atrophy in MS is poorly understood. Loss of neuronal tissue  both
neuronal shrinkage and neuronal loss - is likely to contribute, as suggested by both post-
mortem157, 317 and MRS studies153, 154, 157, 158. Demyelination, gliosis and axonal / dendritic loss
may also contribute to volume loss130, 318.
One potential mechanism of atrophy is a direct effect of local GM demyelinating lesions. Myelin
loss alone is unlikely to explain the extent of atrophy given the small amounts of myelin in
GM314, 319; myelin has been estimated to constitute only 3-5% of the GM volume, in comparison
with 24% of the WM volume320, although this figure is likely to vary considerably between
different CNS structures. Cortical plaques appear to be associated with neuronal, axonal and
dendritic loss130-132. However there is little evidence that GM plaques directly cause atrophy;
Wegner et al found no correlation between neocortical thickness and extent of cortical
demyelination131.
Alternatively, GM atrophy may occur secondary to the effects of distant WM lesions, through
either retrograde or anterograde degeneration. It has been suggested that prominent atrophy of
the motor cortex may reflect axonal injury  with secondary retrograde neuronal degeneration 
in the corticospinal tracts131, 193, 314. The diffusion of neurotoxic factors (e.g. cytokines,
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chemokines, reactive oxygen and nitrogen species, excitatory amino acids or proteases), either
from nearby WM lesions or via the CSF, may also mediate neuronal pathology80.
Correlations between WM lesion loads and the extent of GM atrophy in MS vary greatly
between studies. Some cross-sectional studies suggest there is no relationship between lesion
load measures and GM volume loss183, 193, 315, while several others show moderate
correlations118, 139, 191, 194, 195, 310, 312-314, 321. For example, in a large study of 425 early RRMS
patients, Charil et al found significant correlations between WM lesion load measures and
mean cortical thickness, particularly in the cingulate, insula and associative cortical regions321.
Several studies suggest that lesion load measures correlate more closely to GM atrophy than
to WM atrophy118, 194, 310, 312. A number of longitudinal studies have reported correlations
between changes in GM volumes and changes in lesion loads138, 191 , 196, 316 while others have
failed to do so139, 140, 192. Overall, correlations are at best modest, suggesting that GM atrophy in
MS occurs at least partially independently of WM lesions. Potential mechanisms of neuronal
pathology in MS are further discussed in Chapter 5.
4.1.4 Clinical relevance of GM atrophy
A number of groups have observed correlations between GM volumes and disability
measures191-196, 321 while others have not118, 139, 312, 313, 315, 322. In some cases Expanded
Disability Status Scale appears to be more closely related to GM atrophy than to WM
atrophy194, 195.
GM atrophy may contribute to cognitive dysfunction and mood disturbance. Amato et al
demonstrated lower cortical volumes in cognitively impaired MS patients than in cognitively
preserved patients, despite no differences in lesion load measures or brain volume between
the two groups181, 185. Within the cognitively impaired patients, the cortical volume correlated
with scores of verbal memory, verbal fluency and attention. Morgen et al demonstrated
correlations between cognitive function and cortical atrophy, with cognitively impaired patients
showing more extensive volume loss in frontal, temporal and parietal regions183. Sanfilipo et al
also suggested that brain volume measures related to neuropsychological performance with
GM atrophy being the best predictor of verbal memory, euphoria, and disinhibition184, while
Feinstein et al reported that MS patients with major depression had reduced GM volume in
comparison to those without180.
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4.1.5 Spinal cord atrophy in MS
Spinal cord atrophy in MS has been reported in post-mortem studies203, 210 and in cross-
sectional205, 211-214 and longitudinal imaging studies110, 215-218. Atrophy occurs early in the
disease course203, 218, 323 and progressive cord atrophy has been detected over as little as 6
months110. A strong correlation between cervical cord volume and disability has been reported
in cross sectional studies108, 109, 205, 211-214, 216, 284. A number of longitudinal studies have found a
correlation between changes in cord area and disability scores110, 114, 115, although others have
not215-218.
It is unclear whether spinal cord atrophy in MS reflects tissue loss in the WM or GM
compartments. Due to the small cross-sectional area of the spinal cord GM, the resolution of
current MRI scanners is not sufficiently high to investigate spinal cord GM pathology in vivo.
Histopathological studies are therefore required. The aim of this post-mortem study is to assess
the relative contributions of WM and GM tissue loss to spinal cord atrophy in MS. In view of the
extensive GM demyelination in the cord we hypothesise that there will be substantial GM
atrophy.
4.2 Materials and methods
4.2.1 Clinical material
Human autopsy material was obtained from 55 pathologically confirmed cases of MS and 33
controls. This material was derived from the neuropathology department, Oxford Radcliffe NHS
Trust and comprised all of the MS and control cases available. The MS patients (29 male, 26
female) were aged 25-83 years (mean 57.5 years) with disease durations of 2-43 years (mean
17.1 years). The controls (15 male, 18 female), aged 31-81 years (mean 57.9 years), had no
evidence of spinal cord disease. This autopsy material has been used in previous studies79, 101,
203.
4.2.2 Preparation of the sections
For each of the MS and control cases formalin-fixed paraffin-embedded transverse sections
were taken from 5 levels of the spinal cord (upper cervical, lower cervical, upper thoracic, lower
thoracic and lumbar levels). 10ȝm thick sections were stained for neuronal elements with
Palgrem silver stain and 15ȝm sections were stained for myelin with LFB Cresyl Violet using a
protocol described by Lowe and Cox273.
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4.2.3 Measurements of GM and WM areas
384 Palmgren silver sections were digitally photographed at low power (Olympus DP10 camera
mounted on a Leica WILD MZ8 dissecting microscope). These sections were used to improve
the blinding of the observer (CPG) to the disease state, as the myelin-stained sections highlight
demyelination. Cases were coded to blind the observer to the clinical information. The cross-
sectional GM areas were traced manually on the digital images using image analysis software
(AnalySIS Pro running SIS software) (figure 4.1). The Palmgren silver sections, examined via
microscopy (10x, Leitz Dialux 20EB microscope), were used as a reference to help identify the
GM boundaries. The cross-sectional area of the spinal cord sections, measured previously203,
was used to calculate the WM cross-sectional area (i.e. total spinal cord area  GM area). A
shrinkage factor of 0.71, calculated in our laboratory in a previous study324, was applied to the
measured areas to correct for changes in tissue size as a result of fixation and embedding
processes. In this way comparisons can be made between our spinal cord areas, published
MRI studies and previous work using this post-mortem material79, 203.
It was not possible to accurately identify the GM boundaries on a few sections, either because
there was a tear in the section or there was gross disruption of the normal tissue architecture
secondary to an MS plaque. Measurements were made from 356 of the 384 Palmgren silver
sections. It was possible to make measurements from an additional 12 sections using the
myelin-stained material. In 16 cases it was only possible to measure the GM area on one half
of the section; in these cases this area was doubled to give an estimate of the GM area. It was
not possible to make measurements on the remaining 16 sections because the GM boundaries
could not be accurately identified.
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4.2.4 Validation and reproducibility of methods
To evaluate intra-observer reproducibility the GM areas of 45 randomly selected Palmgren
silver sections were measured on two separate occasions, 2 months apart (coefficient of
variation=1.36%)325, 326. To validate the use of the myelin stained sections for some of the
measurements, the GM areas of 15 Palmgren silver sections and the corresponding 15 Luxol
Fast Blue sections were measured (coefficient of variation=2.94%). 15 Luxol Fast Blue sections
were measured on two separate occasions (coefficient of variation=1.42%). Finally the GM
areas on the right hand sides of 15 sections were compared with the GM areas on the left hand
sides of the sections (coefficient of variation=4.00%), validating the use of "half-sections" to
make a small number of measurements as detailed above.
4.2.5 Statistical analysis
Multiple regression analyses were used to examine the influence of age, sex, cord location,
disease state and disease duration on cross-sectional GM and WM area. The regression
coefficient was calculated for each of these variables. We do not have detailed clinical
information regarding disability and are therefore unable to examine the correlation between
clinical disability (e.g. Expanded Disability Status Scale) and tissue atrophy.
4.3 Results
4.3.1 WM area measurements
The cross-sectional WM area of the spinal cord was significantly reduced in the MS cases
compared to controls, controlling for age, sex and cord location (coefficient of regression = -
5.80, p = 0.001, that is, controlling for other variables, the WM area is reduced in the MS cases
by an average of 5.80mm2). Specifically, the WM area was reduced at the upper cervical
(coefficient of regression = -12.17, p = 0.039), lower cervical (coefficient of regression = -10.47,
p = 0.035) and upper thoracic (coefficient of regression = -7.50, p = 0.021) levels in comparison
to controls, but not at the lower thoracic (coefficient of regression = 0.55, p = 0.836) or lumbar
(coefficient of regression = -1.55, p = 0.599) levels. These results are presented in figure 4.2A.
As expected from previous work203, the WM area in the MS cases is strongly influenced by the
disease duration (coefficient of regression = -0.71, p = 0.001).
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4.3.2 GM area measurements
In contrast to the WM area measurements, the cross-sectional GM area was not significantly
different between MS cases and controls (coefficient of regression = -0.15, p = 0.705).
Similarly, the GM area was not reduced at the upper cervical (coefficient of regression = -0.26,
p = 0.754), lower cervical (coefficient of regression = -0.27, p = 0.734), upper thoracic
(coefficient of regression = -0.04, p = 0.946), lower thoracic (coefficient of regression = 0.26, p
= 0.592) or lumbar (coefficient of regression = -0.51, p = 0.740) levels in the MS cases (figure
4.2B). The GM area in the MS cases was not significantly influenced by the disease duration
(coefficient of regression = 0.03, p = 0.13).
4.4 Discussion
There is evidence that the degree of spinal cord atrophy in MS correlates with clinical
disability108-110, 114, 115, 205, 211-214, 216, 284. Neuro-pathological and imaging studies suggests that
tissue loss in the brain is not restricted to the WM but also affects GM structures157, 158, 191, 310,
314. However, the relative degree of WM and GM atrophy has not been adequately assessed in
the spinal cord.
Our series represents the largest post-mortem study of spinal cord atrophy in MS. We use
material from 55 MS cases and 33 controls, measuring the cross-sectional GM and WM areas
at five different cord levels. The results demonstrate that spinal cord atrophy in MS is due to
WM, rather than GM, volume loss.
4.4.1 WM atrophy is restricted to the upper cord
Spinal cord WM atrophy in MS is likely to be driven by axonal loss, although other processes
such as myelin and oligodendrocyte loss may contribute318. The role of gliotic scarring in
atrophy has not been established; it is conceivable that gliosis either contributes to, or
counteracts atrophy. Post-mortem studies indicate that substantial axonal loss occurs in the
spinal cord in MS, both within WM plaques and myelinated WM76-79, 210. For example Lovas et
al estimated that 65% of the axons in the cervical cord are lost in SPMS, with small calibre
fibres being predominantly affected78.
Our finding of WM atrophy restricted to the upper regions of the spinal cord is consistent with
previous work using this post-mortem material79, 203. Evangelou et al reported that atrophy is
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seen in the upper, but not the lower regions of the spinal cord203, while DeLuca et al observed
reductions in the cross-sectional areas of the lateral and posterior WM columns in the upper
but not the lower cord79. In an attempt to explain this pattern of atrophy we shall consider the
distribution of WM plaques within the cord and their influence on tissue loss, both locally and in
the non-lesioned WM.
The cervical cord has a predilection for WM plaques, while fewer lesions are seen in the lumbar
and sacral levels24. Using the same autopsy material as the current study we have
demonstrated a relative paucity of WM demyelination in the lumbar cord (12.4% of the WM was
demyelinated, in comparison with 31.8% in the upper cervical level; see figure 3.6, Chapter 3).
However, Evangelou et al reported that tissue loss within MS lesions does not have a
significant influence on local cord atrophy203. Indeed, lesions at the thoracic level caused
significant cord expansion203. Bjartmar et al estimated that spinal cord plaques in severely
disabled patients showed between a 45% and 84% reduction in total axonal number210. Taken
together, these two studies suggest that the axonal and myelin loss within WM lesions is
countered by some other process, such as BBB breakdown, oedema, inflammatory cell
infiltration, gliosis or expansion of the extracellular space58. MRI studies also suggest that
tissue loss in MS may be confounded by inflammatory WM lesions. Tiberio et al assessed the
cerebral WM volume in MS patients over a two year period; a reduction in WM volume was
observed in patients exhibiting a reduction in Gadolinium-enhancing lesion volume over the
course of the study, while patients with an increase in Gadolinium-enhancing lesion volume
showed an increase in WM volume139.
While WM lesions appear to make a minimal contribution to local atrophy203, the distribution of
WM lesions within the cord may still influence the pattern of atrophy. Bjartmar et al analysed
axonal pathology using autopsy material from a patient with a 9 month history of MS who died
from a lesion at the cervicomedullary junction, but who had no other cord lesions76. They
observed a 22% loss of axons in the descending normal appearing WM tracts at the C7 level
of the spinal cord, consistent with axonal loss secondary to Wallerian degeneration. In contrast
the estimated axonal number in the ascending tracts at the same level was normal, suggesting
that substantial retrograde axonal degeneration does not occur in the spinal cord in MS.
Similarly DeLuca et al reported that both (i) the cross-sectional area of the posterior WM
columns and (ii) the total axonal number in this tract were only reduced in the upper cord;
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preservation of ascending WM tracts in the lower cord may reflect the relative paucity of WM
lesions in this region and explain, in part, the preservation of WM volume in the lower cord79.
It is perhaps surprising that we do not observe atrophy in the lower cord subsequent to axonal
loss in the descending tracts. DeLuca et al report that the volume of the lateral WM columns is
well preserved in the lumbar cord in MS, despite a significant reduction in axonal number79.
Ganter et al found no correlation between the size of the lateral columns and axonal density in
this tract77. It therefore appears that, as in WM plaques, axonal loss in the normal appearing
WM is not necessarily accompanied by atrophy. There is evidence from post-mortem studies
in MS that the myelin sheath surrounding degenerated axons may persist for some time,
helping to maintain the WM volume76. Indeed it may take months or even years to clear CNS
myelin debris following Wallerian degeneration327. Additional factors including inflammatory cell
infiltration and gliosis may also contribute to the maintenance of WM volume in the lower cord
in MS.
While we report substantial WM atrophy in the spinal cord, we note that several imaging
studies have failed to detect WM atrophy in the brain in MS195, 312. There are a number of
potential explanations for this apparent inconsistency. Firstly, the average disease duration in
our study is considerably longer than one would expect in an MRI study. Secondly, there is
likely to be fewer active inflammatory lesions (i.e. which may cause local swelling, confounding
tissue loss) in longstanding cases. Finally, the degree of atrophy is likely to vary between
different sites in the CNS108. This may relate to regional variations in (i) the number of plaques,
(ii) the inflammatory content of plaques, or (iii) anatomical factors328.
4.4.2 Spinal cord GM volume is preserved in MS
The well defined and simple anatomy of the spinal cord GM makes it ideally suited for
quantitative post-mortem studies202. In comparison, measurements of cortical thickness are
difficult to obtain due to its highly folded structure and considerable regional heterogeneity321,
329, while the boundaries of the thalamic nuclei may be ill-defined on autopsy material330. In
addition, the morphology of the cord is well preserved in formalin fixed, paraffin embedded
material and - in contrast with the cerebral cortex and the subcortical nuclei  sections are easy
to orientate anatomically202. There are additional technical difficulties associated with
measuring GM volumes in the brain by MRI. The complex anatomy and thinness of the
cerebral cortex (estimated at 2.5 to 4.4 mm on MRI193) makes it particularly susceptible to
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partial volume effects, either with the CSF or subcortical WM. It is also possible that cortical
demyelination, which is grossly underestimated by conventional MRI128, may cause subtle
changes in tissue signal intensity which affect GM / CSF segmentation, reducing the apparent
GM volume195, 303, 331. There are also challenges in examining deep GM structures on MRI. The
anatomical boundaries of the thalamus are frequently poorly defined on MRI313. Furthermore
the nuclei of the thalamus are interspersed with a substantial amount of WM; the thalamic
atrophy reported in imaging studies may therefore partly reflect WM tissue loss157, 158, 316.
To our knowledge only one other study has reported the relative degrees of GM and WM
atrophy in the spinal cord in MS. Bjartmar et al studied spinal cord material from 5 severely
disabled MS patients and 6 controls, demonstrating a reduced spinal cord cross-sectional area
in the MS cases210. The GM:WM ratio was similar in the cases and controls, suggesting that
atrophy affects both tissue compartments. In contrast, our study  which contains substantially
larger numbers of cases - suggests that GM volume is well preserved in MS.
MRI and post-mortem studies of the brain demonstrate significant reductions in cortical
thickness131, 314 and thalamic volume157, 158, 316 in MS patients. Several reports suggest that this
volume loss occurs early in the disease course138, 139, 181, 191, 192, 310, 322. Two previous autopsy
studies have examined GM atrophy in the MS brain, demonstrating a 10% reduction in cortical
thickness and a 21% reduction in the volume of the medial dorsal nucleus of the thalamus131,
157. Therefore there appears to be substantial regional heterogeneity in the degree of GM
atrophy.
Loss of neuronal tissue is likely to contribute to the substrate of GM atrophy in the brain, as
suggested by post-mortem studies131, 157, 317 and MRS studies demonstrating reductions in NAA
in the cerebral cortex and thalamus153-159, 320, 332, 333. However the mechanisms of this neuronal
pathology are poorly understood. One possibility is a direct effect of local GM demyelinating
lesions. Extensive GM lesions, as described in the cerebral cortex127, 130, could contribute to
GM atrophy via loss of myelin, transection of neurites or apoptotic neuronal death130. We have
demonstrated substantially greater GM demyelination in the spinal cord in comparison with the
cerebral cortex and the thalamus (see Chapter 2). Whether these plaques are associated with
neuronal and axonal loss requires further investigation. Another important consideration is the
degree of gliosis, which could potentially counter tissue loss within MS plaques. In contrast with
the lesions in the cerebral cortex and thalamus132, a number of spinal cord GM plaques appear
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to be associated with a significant gliotic reaction (figure 3.10, Chapter 3 and figure 6.4Q,
Chapter 6). Similarly inflammatory cell infiltration and oedema may act to preserve the GM
volume, and it is feasible that these processes are more pronounced in the spinal cord GM.
Alternatively, GM atrophy in the brain may occur as a consequence of distant WM lesions.
Transected axons in such lesions may result in neuronal pathology through retrograde or
anterograde transynaptic degeneration317. It has been suggested that the extensive
connections of the thalamus with other brain structures make it particularly sensitive to the
effects of pathology in distant sites157. Differences in the connectivity of the spinal cord GM and
the GM of the cerebral cortex and thalamus may leave the spinal cord GM less susceptible to
the effects of distant WM lesions. Further work is required to determine whether there is a
reduction in the number or size of neurons in the spinal cord, despite the preservation of GM
volume. Interestingly, Wenger et al reported a reduction in the thickness of myelinated cortex in
MS cases, despite finding no apparent decrease in neuronal or glial cell density - further
highlighting that GM atrophy is not synonymous with neuronal loss131. Similarly Bjugn et al
observed atrophy of the ventral horns in the lumbar spine following transection of the thoracic
cord in adult mice, despite no reduction in the number or size of neurons334. Conversely, our
observation of preserved GM volume in MS does not necessarily imply an absence of neuronal
pathology in the spinal cord GM.
4.4.3 Influence of disease duration
In the MS cases, WM area was strongly influenced by disease duration, while GM area was
not. Using the same post-mortem material, Evangelou et al observed that disease duration was
an important determinant of cord atrophy, with the rate of atrophy being particularly high in
early disease (3.5% per year in patients that died within 10 years of disease onset, in
comparison with 0.75% per year overall)203. However it is likely that MS patients who die soon
after diagnosis will tend to have more aggressive disease. Similarly DeLuca et al, observed
correlations between disease duration and the cross-sectional areas of the corticospinal tracts
and the posterior columns, although no correlation existed between disease duration and the
estimated axonal number in either tract79. Imaging studies also demonstrate correlations
between cervical cord area and disease duration108, 216.
Evangelou et al noted that age and gender did not influence whole cord atrophy in MS
cases203, while DeLuca et al reported that gender did not correlate with axonal density or cross-
102
sectional area in either the corticospinal tract or the posterior columns79. Similarly Ganter et al
found no gender difference related to corticospinal tract cross-sectional area, although axonal
density was reduced in males in comparison with females77.
4.4.4 Limitations of our study
There are a number of limitations to our study. In some of the MS cases disruption of the tissue
architecture was observed on the Palmgren silver sections, potentially interfering with blinding.
The use of a small number of myelin stained sections may also interfere with blinding. Despite
our efforts to measure the GM area on each of the sections, this was not possible in every
case, particularly when the GM boundaries were indistinct due to local inflammatory plaques.
This may bias the sample to include a greater proportion of normal appearing material.
However, given the large number of sections included in our study, we are confident that these
factors have not had a significant influence on our results.
There is considerable variation in spinal cord size, even between healthy subjects335. Imaging
studies frequently normalise brain or spinal cord volumes to intracranial volume, reducing the
effects of inter-individual variation and thereby increasing the power of the study318.
Unfortunately we are unable to normalise spinal cord areas to variables such as subject height,
or control for such variables in the statistical analysis. Furthermore we have been unable to use
tissue sections from precisely the same segmental levels in all the MS and control cases,
introducing further variability to our results and reducing our ability to detect small reductions in
the MS cases200. However it is questionable whether such subtle degrees of GM atrophy would
be of any functional significance.
Considerable dimensional changes occur in tissue post-mortem as a result of dehydration,
fixation, embedding and sectioning336, 337. Paraffin is the embedding material that induces the
largest degree of shrinkage, resulting in a volume reduction of approximately 10%336. Other
factors likely to influence the degree of shrinkage include the age of the subject, the nature and
duration of the terminal illness, the post-mortem delay and the length of fixation338. While our
cases are well matched for age we are unable to control for other variables such as post-
mortem interval and fixation time. Further work is required to establish if tissue shrinkage differs
between the healthy and diseased states - for example, due to the high water content
associated with MS plaques - and whether there is differential shrinkage of the GM and WM
compartments202, 337, 339.
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Our results suggest that previously observed correlations between spinal cord atrophy and
disability reflect WM, rather than GM, volume loss. However due to a lack of detailed clinical
information, we are unable to test this formally. Similarly we are unable to compare patterns of
atrophy between different MS subtypes. Cross-sectional immaging studies have failed to detect
spinal cord atrophy in RRMS patients in comparison with controls110, 213, 340, 341, despite
longitudinal reductions in spinal cord volumes being observed in this disease subtype110, 340.
Brex et al examined spinal cord atrophy in patients with a clinically isolated syndrome
suggestive of MS, observing reductions in baseline cord area in those with an abnormal brain
MRI in comparison to controls323. However no reductions in cord area were observed over the
following year, either in these patients or in those who developed clinical MS. One interpretation
of these findings is that cord area may actually increase in the very early stages of the disease
process, for example secondary to inflammation.
4.5 Conclusion
In this study - the largest post-mortem examination of spinal cord atrophy in MS - we
demonstrate that spinal cord atrophy in MS is due purely to WM volume loss, suggesting that
correlations between spinal cord atrophy and disability reflect WM, rather than GM atrophy. Our
observation of preserved GM volume is an important one, suggesting important differences
between the GM of the spinal cord and the GM structures of the brain. A greater understanding
of the mechanisms of GM atrophy is required to explain these differences.
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Figures
Figure 4.1
Transverse section of the spinal cord at the lumbar level (Palmgren silver stain). Grey matter
(white line) and total cord (black line) cross-sectional areas outlined in B.
A
B
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Figure 4.2
Bar chart of cross-sectional area of white matter (A) and grey matter (B) at different levels of
the spinal cord. UC = upper cervical; LC = lower cervical; UT = upper thoracic; LT = lower
thoracic; LUM = lumbar. Values represent mean ± standard error. * p < 0.05
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Chapter 5: Neuronal Pathology in Multiple Sclerosis
5.1 Introduction
Neuronal pathology may represent an important substrate of permanent disability in MS, along
with demyelination and axonal loss. MR Spectroscopy studies provide indirect evidence for
neuronal pathology in the brain, while post-mortem studies demonstrate reductions in neuronal
number and size in the cerebral cortex and thalamus131, 132, 153-159, 317, 320, 332, 333. It has been
proposed that these changes may occur either as a consequence of GM demyelination or
secondary to axonal injury in the WM, via retrograde or transynaptic degeneration. However
the relative importance of these processes is unclear. While a number of early post-mortem
studies report various pathological changes within neurons in MS220, 342, 343 few quantitative
studies have characterised these changes in detail, and these have contained relatively small
numbers of cases131, 132, 157, 317. To our knowledge no study has quantified neuronal pathology
in the spinal cord in MS.
5.1.1 Evidence of neuronal pathology secondary to GM demyelination
Neuronal injury in MS may occur as a direct consequence of local GM plaques. Examining 22
cortical lesions from 7 MS brains, Peterson et al demonstrated transected axons and dendrites
within cortical plaques, along with TUNEL-positive neurons, a marker of apoptotic death130.
Such changes were less prominent within myelinated cortex, suggesting a direct effect of the
cortical plaques in mediating neuronal injury. Vercellino et al studied neuronal pathology using
autopsy material from 6 MS cases; in the 2 cases with particularly extensive cortical
demyelination, a 20% reduction in neuronal density was observed within cortical plaques in
comparison with areas of myelinated cortex132. The authors also reported neuronal expression
of caspase-3  a major effector protease in apoptosis  within the cortical lesions, providing
further evidence of apoptotic neuronal death132. Comparisons in neuronal densities were not
made between MS and control cases.
Further evidence of neuronal loss within cortical plaques comes from Wegner et al who
performed neuronal counts in the deep cortical layers of the frontal lobe in 9 MS cases and 9
controls131. Examination of the GM portion of type I cortical lesions (i.e. mixed GM/WM lesions)
revealed reductions in the density of neurons (10% reduction, associated with a 9% reduction
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in neuronal size), glial cells (36% reduction) and synapses (suggested by reductions in the
synaptic proteins synaptophysin and GAP-43) in comparison with myelinated MS neocortex.
Myelinated neocortex did not show significant changes in neuronal density or neuronal size in
comparison with controls, although neurons were more circular in the MS cases, raising the
possibility of more subtle changes outside of the cortical plaques. Kutzelnigg et al
demonstrated neuronal pathology within the cerebellar cortex in MS; examining autopsy
material form 17 MS cases and 8 controls, they observed modest reductions in Purkinje cell
density in demyelinated areas in comparison with the myelinated cerebellar cortex of MS
patients and controls204, 242.
Neuronal pathology has also been reported in deep GM structures. Cifelli et al demonstrated
substantial neuronal loss in the medial dorsal nucleus of the thalamus in a post-mortem study
of 10 MS patients (1 RRMS, 6 SPMS, 3 PPMS) and 10 controls157. The volume of the nucleus
was reduced by 21% in the MS group, while neuronal density was reduced by 22%, giving an
estimated 35% reduction in total neuronal numbers in patients relative to controls. Neuronal
pathology in the thalamus has also been examined by Evangelou et al who - in a study of 8 MS
cases and 8 controls - demonstrated neuronal atrophy in the lateral geniculate nucleus (LGN)
in MS cases317. Neither study examined the influence of GM plaques on these neuronal
changes. However, in view of the relatively modest degree of GM demyelination that we
observe in the thalamus, it seems likely that additional mechanisms contribute to the
considerable neuronal pathology observed in this structure157, 317.
Neuronal pathology has not been extensively examined in the spinal cord in MS, although
abnormalities have been described in the cells of Clarkes column and in motoneurons220, 342,
343. While a small number of descriptive studies have reported a variety of pathologic changes
in relation to anterior horn cells lying within demyelinated plaques342, 343, the spinal cord has not
been the subject of more rigorous, quantitative studies. However there is evidence for
motoneuron pathology in EAE. Mice with MOG-induced EAE develop demyelination and
inflammation in the lumbosacral cord associated with perikaryal atrophy of local motoneurons,
dendritic pathology, but no reduction in motoneuron density344. Using a rat model of EAE,
Giardino et al demonstrated that spinal motoneurons undergo phenotypical changes indicative
of cellular stress including reductions in choline acetyl-transferase (ChAT) expression and
increases in calcitonin gene-related peptide (a trophic peptide for motoneurons) and p75LNGFR
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(a neurotrophin receptor that binds Nerve Growth Factor, Brain Derived Neurotrophic Factor
and neurotrophin 3-4)345.
5.1.2 Neuronal loss may occur within GM plaques via a number of mechanisms
The myelin-oligodendrocyte complex provides the neuron with important neurotrophic
factors346. The sub-population of satellite (perineuronal) oligodendrocytes which lie opposed to
the perikarya of neurons are likely to be particularly important in this respect, as well as having
additional roles in maintaining neuronal homeostasis125, 126, 346-348. Loss of this trophic support
following oligodendrocyte death may therefore lead to neuronal pathology within the GM
plaque349. Alternatively, a number of inflammatory factors are potential mediators of neuronal
injury:
T cell mediated neuronal injury
T cell mediated neuronal destruction has been implicated in a number of conditions including
Rasmussens encephalitis350 and several paraneoplastic neurological syndromes351. In the
healthy state CNS neurons express a minimal amount of MHC class I but expression may be
increased if the neuron is functionally compromised352, 353. For example, when electrically
paralysed hippocampal neurons are exposed to the pro-inflammatory cytokine IFN-Ȗ LQ YLWUR
MHC class I is dramatically upregulated rendering the neuron susceptible to attack by CD8+ T
cells353, 354. Similar conditions (i.e. blockade of electrical activity and high levels of IFN-ȖDUH
likely to be seen in the acute MS plaque. MHC restricted cytotoxicity may occur either via the
Fas / Fas ligand pathway, or the release of toxic granules containing perforins or granzymes. In
Rasmussens encephalitis CD8+ T cells may induce apoptosis in MHC class I+ neurons by
releasing the serine protease granzyme B350.
CD4+ and CD8+ T cells may also mediate cytotoxicity in cultured human neurons in a non-MHC
restricted fashion, again via the Fas / Fas Ligand pathway355. Studying living cortical slices
from mice, Nitsch et al observed that T cells mediate contact-dependent, MHC-independent
neuronal death, which could be prevented by blocking both perforin-mediated cytotoxicity and
glutamate receptors356. Smith et al reported a novel mechanism of neuronal loss in Lewis rats
with MBP-induced EAE357, whereby T cells were seen to attach to the cell membrane of spinal
motoneurons, becoming internalised and undergoing apoptosis; this sequestration of
lymphocytes resulted in neuronal degeneration, with a 30% reduction in neuronal density. This
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interaction between T lymphocytes and neurons is poorly understood and has not been
described previously in the context of EAE or MS.
Antibody mediated neuronal injury
Antibodies to gangliosides92, neurofilaments93 and other neuronal antigens have been
described in MS91, 94. For example Lily et al reported that a proportion of MS patients  mainly
with SP disease  express serum IgM antibodies that bind neurons in vitro94. Whether such
antibodies have any pathogenic significance is unclear; antibody mediated neuronal pathology
is not a well recognised phenomenon, although it has been implicated in mediating neuronal
pathology in Tropical Spastic Paraparesis, a myelopathy associated with Human T
Lymphotrophic Virus type 1358. This antibody - targeted against the neuronal antigen
heterogenous nuclear ribonuclear protein-A1 - appears to be biologically active, inhibiting the
firing of cultured rat neurons358.
Soluble factors
Neurons may also be susceptible to bystander injury secondary to a number of toxic products
secreted by activated microglia and macrophages:
- Pro-inflammatory cytokines such as TNFĮ can kill human neurons in vitro359, 360, as can
the chemokine CXCL10361, 362, which is expressed by macrophages in MS plaques 363.
There is also evidence that the death ligand tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) - secreted by or expressed on activated T cells - has a role in
neuronal death in EAE364.
- Reactive nitrogen and oxygen species may induce programmed neuronal death365.
Free radicals also oxidise the myelin breakdown product cholesterol to 7-
ketocholesterol. 7-ketocholesterol is elevated in the CSF of MS patients and within
acute MS plaques366 and may mediate neuronal injury directly366-369. Interestingly GM
hypointensities are commonly detected on T2-weighted MRI scans in MS, both in the
cortex and subcortical structures160, 370, 371. These changes are likely to reflect
pathologic iron deposition, although it is unclear whether this is simply a disease
epiphenomenon or if it contributes to neurotoxicity by promoting free radical
production160.
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- Glutamate-induced neuronal damage has been implicated in neuronal injury in a
variety of neurodegenerative conditions including spinal motoneuron loss in
Motoneuron Disease372. Neurons, activated inflammatory cells / microglia and injured
astrocytes may all release glutamate, and glutamate-mediated excitotoxicity is a
potential mechanism of oligodendrocyte and neuronal loss in MS. Groom et al reported
motoneuron loss in rats with EAE in association with changes consistent with
glutamate-mediated excitotoxic injury373.
- Finally, activated macrophages secrete proteases such as tissue plasminogen
activator and the matrix metalloprotease MMP-9, both of which are expressed in MS
plaques30, 374-377. Exposure to tissue plasminogen activator renders neurons more
susceptible to excitotoxic glutamate induced death378, while MMP-9 induces anoikis,
whereby the cell is detached from the extra-cellular matrix and undergoes apoptosis379
These soluble factors may originate from local GM plaques or nearby WM plaques.
Alternatively they may be generated in distant inflammatory plaques or areas of meningeal
inflammation and diffuse within the CSF, mediating neuronal pathology in the so-called normal
appearing GM. Alcazar et al demonstrated apoptotic death in cultured neurons exposed to
CSF from patients with aggressive PPMS, while CSF from patients with stable PPMS or non-
inflammatory neurological diseases did not induce neuronal apoptosis380. Furthermore Cid et al
reported apoptosis of cultured neurons following treatment with CSF from RRMS patients; the
degree of neuronal loss correlated with both lesion load measures and residual disability after
relapse381.
5.1.3 Neuronal pathology secondary to axonal injury in distant WM lesions
Additional factors, independent of local GM demyelinated plaques, may influence neuronal
pathology in MS. It is hypothesised that neuronal injury in myelinated GM may occur secondary
to axonal transection in distant WM plaques157, 317.
Retrograde degeneration
Following axonal transection the distal portion of the axon undergoes Wallerian degeneration.
In certain circumstances this will be accompanied by retrograde degeneration or shrinkage of
the cell body itself. Whether retrograde degeneration occurs following axotomy is influenced by
several factors including neuronal type, age at time of injury and the proximity of the injury to
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the neuronal body382. Axotomy-induced retrograde degeneration is most prominent in the
immature CNS but has been demonstrated in a number of neuronal systems in adult
animals383-385.
Animal studies demonstrate that axotomy may lead to considerable retrograde degeneration in
the spinal cord. For example thoracic cord transection in adult cats results in a 40% loss of
neurons within Clarkes nucleus at the lumbar cord level, with surviving neurons showing a
50% reduction in mean soma size384. However, there is little evidence for significant retrograde
axonal degeneration in MS, particularly in the spinal cord 76, 79. Bjartmar et al analysed axonal
pathology using autopsy material from a patient with a 9 month history of MS who died from a
lesion at the cervicomedullary junction76. Despite substantial axonal loss in the descending WM
tracts of the spinal cord, consistent with Wallerian degeneration, the estimated axonal number
in the ascending tracts was normal. Similarly DeLuca et al reported preservation of ascending
WM tracts in the lower cord despite multiple plaques at higher cord levels suggesting there is
little retrograde degeneration of these fibres79.
Retrograde degeneration has been demonstrated in an animal model of MS. Rats with MOG-
induced EAE develop optic neuritis accompanied by axonal transection, resulting in retrograde
degeneration and reductions in retinal ganglion cell density comparable to those seen after
surgical transection of the optic nerve386, 387. While retrograde degeneration is the predominant
mechanism of neuronal loss in this model, other processes appear to be important387. Early in
the disease course 73% of retinal ganglion cells are lost in comparison with only 55% of optic
nerve axons, suggesting a proportion of neurons die secondary to axonal demyelination per
se387. The electrical activity of the axonal membrane influences the expression of multiple
genes including those governing the synthesis of neurotrophins and their receptors388, 389. For
example depolarisation of retinal ganglion cells up-regulates the neurotrophin receptor TrkB,
increasing responsiveness to Brain Derived Neurotrophic Factor and improving cell survival390,
391. Conversely, electrophysiological dysfunction  secondary to demyelination - may result in
neurons becoming insensitive to endogenous trophic factors. Loss of electrical activity may
also render the neuron susceptible to MHC class I-mediated cytotoxicity as mentioned
previously. Alternatively, chronically demyelinated axons may degenerate as a result of virtual
hypoxia as described in Chapter 1.2.6.
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Transneuronal Degeneration
Neuronal survival in the adult CNS is maintained, in part, by trophic signals from both efferent
targets and afferent inputs. Loss of trophic signals from efferent targets is likely to be an
important trigger for retrograde neuronal degeneration following axotomy392. Similarly neurons
may degenerate or atrophy following interruption of their afferent connections (socalled
anterograde transneuronal degeneration) or after the death of the neurons upon which they
project (retrograde transneuronal degeneration)382. As is the case with retrograde
degeneration, susceptibility to transneuronal degeneration varies between different species and
different neuronal populations and occurs more commonly in the immature nervous system382.
Sequential transneuronal degeneration is also recognised382. For example, following
enucleation of the eye, anterograde transneuronal changes may occur not only in the LGN
(primary anterograde transneuronal degeneration) but also in the visual cortex (secondary
anterograde transneuronal degeneration). Likewise lesions of the limbic cortex may result in
retrograde degeneration in anterior thalamic nuclei followed by (primary) retrograde
transneuronal degeneration in the medial mammillary nucleus and (secondary) retrograde
transneuronal changes in the ventral tegmental nuceus of the midbrain.
Animal studies demonstrate anterograde and retrograde transneuronal degeneration in a
number of neuronal systems within the CNS382, 393. Anterograde degeneration is most clearly
observed in the LGN of the thalamus following degeneration of its retinal afferents88, 89. Such
changes have also been described in adult man secondary to ocular pathology394, 395. For
example Golby reported a 59 year old male who lost 50% of neurons in the right LGN following
enucleation of the left eye 40 years previously394. Kupfer et al examined 7 patients who died
between 1 month and 73 years after either the loss of an eye or the development of a macular
lesion; in cases that died within 2 years there was no evidence of cell loss in the LGN while
substantial neuronal loss was observed after longer survival periods394, 395. Both studies
suggest that the smaller parvocellular neurons of the LGN are more sensitive to deafferentation
and show a greater reduction in size than the larger magnocellular neurons394, 396. There is less
evidence for pronounced transneuronal retrograde degeneration in adult man, although Beatty
et al reported atrophy of the right LGN associated with axonal degeneration in the right optic
radiation and optic tract 40 years after surgical resection of the right occipital lobe395.
Quantitative MRI abnormalities have been reported in the posterior visual pathway following
isolated attacks of unilateral optic neuritis, possibly reflecting anterograde transynatic
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changes397, 398. Ciccarelli et al observed a reduction in connectivity  assessed by diffusion
tractography  in the optic radiations397 while Audoin et al detected a selective reduction in
MTR in the visual cortex398. In a post-mortem study of 8 MS patients and 8 controls,
Evangelou et al examined the cross-sectional area of neurons in the LGN; the parvocellular
neurons were significantly smaller in the MS group, while there was no difference in
magnocellular neuron size317. The parvocellular neurons receive input from small calibre axons
- known to be particularly susceptible to axonal injury in MS77-79 - while magnocellular neurons
receive input from larger axons. The axonal density in the optic tracts correlated with the extent
of parvocellular neuron atrophy, suggesting neuronal shrinkage may be secondary to
anterograde degeneration of axons that have received size related damage in the anterior
visual pathway. Alternatively there may be a size-related vulnerability to neuronal injury that is
independent of the calibre of the afferent or efferent connections or the presence of
demyelinated plaques in the visual pathways.
If anterograde transynaptic degeneration occurs in the spinal cord in MS we might expect to
observe similar mechanisms of neuronal death in animal studies and in other disease states.
There is conflicting evidence as to whether the transection of descending WM tracts induces
anterograde degeneration of ventral horn neurons in mature animals. Young et al observed
shrinkage of anterior horn cells in cats following cord transection399. Similarly Eidelberg et al -
studying adult rats - observed a 25% reduction in the number of lumbar motoneurons following
either thoracic cord transection or bilateral ablation of the motor cortex, with neuron loss being
detectable as early as day one400. However other groups have found no reduction in the
number or size of anterior horn cells following cord transection in rodents, even at 1 year
following injury334, 401.
There is a striking paucity of literature assessing the effect of corticospinal tract transection on
anterior horn cells in adult man. The few studies that have been performed fail to demonstrate
significant transynaptic changes402, 403. Kaelan et al found no reduction in motoneuron number
in 4 adults with long-standing transection of the spinal cord in comparison with 4 controls402.
Similarly there is little evidence of transneuronal degeneration as a consequence of stroke in
the adult literature. Terao et al studied 4 patients with severe hemiplegia who died 1 to 8 years
following a stroke; despite extensive axonal loss in the corticospinal tracts, the stoke cases
showed no reductions in anterior horn cell number or size in comparison with age-matched
controls404.
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5.1.4 MRS studies suggest there is substantial neuronal pathology in MS
MRS provides quantitative indices of several tissue metabolites including NAA, an amino acid
localised almost exclusively to neurons and neuronal processes in the adult brain405. NAA is
therefore used as an index for axonal / neuronal injury or loss in vivo, and has provided
substantial indirect evidence for neuronal pathology in MS. Significant NAA reductions have
been reported in cortical and subcortical GM structures in both relapsing and progressive
disease forms, even early in the disease course153-159, 320, 332, 333. A meta-analytic review
suggests these changes may be important clinically, providing some evidence for greater NAA
reductions in association with increased disease severity333.
However, there are a number of limitations to MRS studies. Firstly, one can only speculate on
the substrate of NAA reductions, which may reflect neuronal loss, atrophy of individual
neurons, axonal/dendritic loss, neuronal/axonal metabolic dysfunction or a combination of
these factors. Secondly, reversible reductions in NAA have been reported both in MS plaques
and in normal appearing WM, indicating that changes in NAA are not entirely specific for
neuronal/axonal loss406, 407 . Inhibition of the mitochondrial respiratory chain results in
reductions of NAA synthesis, suggesting mitochondrial dysfunction may produce potentially
reversible NAA changes408. Alternatively restoration of the NAA concentration may reflect
resolution of oedema or pseudo-normalisation as a consequence of atrophy74, 407. Thirdly, the
specificity of the NAA signal has been questioned by work demonstrating oligodendrocyte
expression of NAA in vitro409.
Numerous technical limitations further hamper the utility of MRS for examining neuronal
pathology. Due to the thin, highly folded nature of the cortex and the relatively large volume of
spectroscopic voxels, there will be significant partial volume contamination of cortical voxels
from both the CSF and the adjacent WM. Therefore NAA reductions in cortical voxels will in
part reflect brain atrophy (i.e. atrophy will increase the proportion of CSF in the voxels) and
axonal injury in the subcortical WM. To avoid spectral contamination by intense lipid signals
from subcutaneous adipose tissue and bone marrow, voxels must be placed away from the
skull, making most cortical GM difficult to access410. Such methodological issues may
contribute to apparent inconsistencies in the literature; for example, three studies have failed to
detect cortical NAA reductions, particularly in RR disease155, 159, 332. While the deep GM
structures are less susceptible to many of these technical problems the thalamic nuclei are
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interspersed with large amounts of WM, and the caudate and putamen are small and difficult to
delineate on MRI320.
5.1.5 Aims
The spinal cord is a predilection site for both WM and GM demyelination and a site of
substantial axonal loss in MS76-79, 101, 210. However no study has quantified neuronal pathology
in this clinically eloquent region. In this post-mortem study we investigate neuronal pathology in
the spinal cord in MS, comparing the number and size of motoneurons and interneurons
between MS cases and controls. We assess the extent of neuronal pathology, both within GM
plaques and in the myelinated GM.
5.2 Methods
5.2.1 Clinical Material
Human autopsy material was obtained from 37 pathologically confirmed cases of MS and 22
controls. This material was derived from the neuropathology department, Oxford Radcliffe NHS
Trust. The cases were selected at random from a collection of 55 MS cases and 33 controls
studied previously79, 203. For each of the MS and control cases formalin-fixed paraffin-
embedded transverse sections were taken from the upper cervical, upper thoracic and lumbar
levels of the spinal cord. Sections were cut at a microtome setting of 15 µm and stained for
Nissl substance and myelin with LFB Cresyl Violet. Corresponding PLP-stained sections were
available for a number of MS cases (n = 30).
5.2.2 Assessment of neuronal number and size
The sections were positioned on the microscope stage with the GM commissure orientated
parallel to the x-axis and the anterior median fissure parallel to the y-axis. Neuronal counts
were restricted to the anterior horn of the GM, defined - for the purposes of this study - as the
area ventral to the anterior border of the GM commissure (figure 5.1). The entire anterior horn
was systematically viewed using a video camera (KY-F55B 3-CCD JVC Color Video Camera)
linked to microscope (40x, Leitz Dialux 20EB microscope). Neurons were photographed and
counted if the nucleolus was visible in the plane of the section. A small number of sections
were excluded from the analysis because either the neurons were too darkly stained to identify
the nucleoli (n = 8 sections) or there was a tear in the section (n = 7 sections). A further 3
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sections from the UT cord were omitted because they were from the T1 spinal level, which has
a markedly different morphology in comparison with the other thoracic levels.
The Nissl stain readily differentiates between neurons and non-neuronal cell populations when
viewed at high magnification. Neuron are larger cells with a well defined nucleolus and a cell
body rich in endoplasmic reticulum while neuroglia are smaller with denser nuclei, less
conspicuous nucleoli and a greater nucleus: cytoplasm ratio. Where possible, we excluded
neurons from the intermediolateral column and Clarkes nucleus from the neuronal counts. In
general these neuronal populations are readily identified; the large neurons of Clarkes nucleus
are arranged in a well defined column within the thoracic cord, lying dorsolateral to the central
canal while the intermediolateral column is composed of large preganglionic autonomic
neurons, forming a well defined cluster in the lateral horn, most conspicuous from ~T1  L2.
The neuronal bodies and nucleoli were outlined manually using image analysis software
(AnalySIS Pro running SIS software). Neuronal processes were traced to include proximal
processes, but not the axon or the dendrites per se. The cross-sectional area of the neuron
was determined as was the maximum and minimum neuronal diameter (for neuron
classification), and the nucleolar diameter (for application of the Abercrombie correction), with
all measurements being made in the plane in which the nucleolus appeared largest. To
evaluate intra-observer reproducibility neuronal size measurements were made on two
separate occasions  2 months apart - using a randomly selected tissue section with 34
neurons (coefficient of variation=6.7%; inter-observer coefficient of variation=6.5%)325, 326.
Neurons were classified as motoneurons or interneurons according to size criteria; those with a
maximum diameter of at least 30ȝm and a minimum diameter of at least 13.5ȝm were
classified as motoneurons; all other neurons were classified as interneurons. Light levels were
adjusted for optimal viewing of the nucleolus allowing for section thickness and staining
intensity and avoiding optical bleaching of the tissue. Counts were performed on both anterior
horns of each section. Raw counts were converted using the Abercrombie formula. Section
thickness was measured at a workstation with a video camera (JVC TK-1380) attached to a
microscope (Olympus BX50 using x100 oil-immersion lens) with a motorised stage (Prior,
Fulbourm, UK) that controlled movements in the z-axis. This system was connected to a PC
running CAST software (Computer Assisted Stereological Toolbox, Olympus).
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On any given section, measurements (i.e. neuronal counts, size measurements and extent of
demyelination) were made for each anterior horn (i.e. right and left) separately.
5.2.3 A note on profile based counting techniques and the Abercrombie correction
When autopsy material is sectioned, structures are often cut and therefore appear on multiple
sections. If 5ȝm thick transverse sections are cut from the spinal cord, a large object such as a
motoneuron will appear on several adjacent sections (e.g. a 100ȝm tall motoneurnon will
appear on 20 consecutive sections) while a smaller object, such as an interneuron, will appear
on a smaller number of sections. Simple profile counts on single sections therefore over-
estimate the number of objects in a structure, with the size of the error depending on both the
section thickness and the height of the object being counted. The error is greatest when large
objects are counted in thin sections, but even a nucleolus will have an appreciable height in
relation to the thickness of the section411.
A variety of methods, including the Abercrombie method412, attempt to correct the
overestimates generated by raw counts of cellular profiles. The Abercrombie formula states:
Ht
tn
N 
 
5.3.4 Assessment of demyelination
The extent of demyelination within the anterior horn (expressed as the proportion of the total
area that was demyelinated) was assessed using the PLP-stained sections, which were
available for 30 of the MS cases. In the remaining 7 cases demyelination was assessed using
the LFB-stained sections. We have previously demonstrated that  in the spinal cord at least 
close inspection of LFB-stained sections at high magnification can reliably detect GM
demyelination.
n: number of objects counted in the sampled portion
N: estimate of true number of objects
t: section thickness
H: mean height of the object (i.e. nucleolus), which
we estimate by measuring the diameter in the xy
plane
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The influence of myelin loss on neuronal pathology was assessed in the MS cases by
comparing anterior horns that were completely myelinated (n = 81 hemisections, from 29 MS
cases) with those that were completely demyelinated (n = 33 hemisections, from 13 MS cases).
5.3.5 Statistics
Nonparametric statistical tests (unpaired Wilcoxon rank sum test) were used to compare
neuronal numbers between MS cases and controls, and between the myelinated and
demyelinated regions within the MS group. Unpaired t tests were used to make comparisons in
neuronal sizes. Multiple regression analyses were used to examine the influence of age, sex,
disease state and, in MS cases, disease duration and the extent of demyelination on neuronal
size and number (Stata version 9, StataCorp, Texas USA).
5.3 Results
5.3.1 Neuronal counts
Interneuron and motoneuron number is reduced in MS cases
Total neuron count was reduced in the MS cases in comparison with controls at the upper
cervical (p = 0.0024) and upper thoracic (p = 0.0145), but not the lumbar (p = 0.7158) level.
Similarly, in comparison to control cases, both interneuron and motoneuron number were
reduced in MS cases at the upper cervical (interneuron p = 0.0549; motoneuron p = 0.0073)
and upper thoracic (interneuron p = 0.0507; motoneuron p = 0.0144) but not the lumbar
(interneuron p = 0.6081; motoneuron p = 0.7931) level (figure 5.2). In keeping with these
results multiple regression analysis suggests that - controlling for age and gender - disease
state had a significant influence on total neuronal number at the upper thoracic level (p = 0.010,
with MS cases showing a 30.3% reduction in neuronal number). There was a trend towards
significance at the upper cervical level (p = 0.069; 23.8% reduction in MS cases), but not the
lumbar level (p = 0.632).
Neuronal loss is greater in plaques than in myelinated grey matter
Total neuronal count was reduced in the GM plaques in comparison with controls at the upper
cervical (p = 0.0018) and upper thoracic (p = 0.0043), but not the lumbar (p = 0.9652) level.
Similarly interneuron count was reduced in the GM plaques in comparison with controls at the
upper cervical (p = 0.0262) and upper thoracic (p = 0.0099), but not the lumbar (p = 0.7600)
level. Motoneuron count was reduced in the GM plaques at the upper cervical (p = 0.0021), but
not the upper thoracic (p = 0.1326) or lumbar (p = 0.3594) levels.
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Total neuronal count was not reduced in the myelinated GM of MS cases in comparison with
controls at any of the cord levels (upper cervical, p = 0.2530; upper thoracic, p = 0.0797;
lumbar, p = 0.7799). Similarly interneuron count was not reduced in the myelinated GM of MS
cases in comparison with controls at any of the cord levels (upper cervical, p = 0.9317; upper
thoracic, p = 0.2079; lumbar, p = 0.8459). Motoneuron count was reduced in the myelinated
GM of MS cases in comparison with controls at the upper thoracic (p = 0.0190) but not the
upper cervical (p = 0.1039) or lumbar (p = 0.7706) levels.
Within the MS cases, the total neuronal count was reduced within the GM plaques in
comparison to the myelinated GM at the upper cervical level (p = 0.0504) but not at the upper
thoracic (p = 0.2130) or lumbar (p = 0.9666) levels. There was a trend towards a reduction in
interneuron count within the GM plaques at the upper cervical (p = 0.0808) and upper thoracic
(p = 0.0915) but not the lumbar (p = 0.8672) levels. Motoneuron count was reduced within GM
plaques at the upper cervical (p = 0.0276) but not the upper thoracic (p = 0.4093) or lumbar (p
= 0.2097) levels.
5.3.2 Measurements of neuronal size
Interneuron cross-sectional area is reduced in MS cases in comparison with controls
The mean interneurons cross-sectional area was smaller in MS cases in comparison to
controls at all three cord levels (upper cervical, 147.4ȝm2 in MS cases versus 185.1ȝm2 in
controls, p = 0.0000; upper thoracic, 147.2ȝm2 versus 162.9ȝm2, p = 0.0002; lumbar, 186.8ȝm2
versus 193.9ȝm2, p = 0.0337) (figure 5.3A).
There was no significant difference in motoneuron size between MS cases and controls in the
upper cervical (p = 0.7416; 655.1ȝm2 in MS cases versus 645.9ȝm2 in controls) and upper
thoracic (p = 0.6426; 583.7ȝm2 in MS cases versus 570.9ȝm2 in controls) levels. However the
mean motoneuron size was greater in MS cases than controls at the lumbar level (p = 0.0059;
1001.0ȝm2 versus 908.4ȝm2) (figure 5.3B).
Multiple regression analysis also indicated that disease state had a significant influence on
neuronal size, with interneurons being smaller in the MS cases at the upper cervical and upper
thoracic levels (UC, p = 0.000; UT, p = 0.000; Lum, p = 0.404) and motoneurons being larger in
the MS cases at the lumbar level (UC, p = 0.461; UT, p = 0.706; Lum, p = 0.016).
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Interneuron cross-sectional area is reduced in both myelinated and demyelinated grey
matter
Mean interneuron size was reduced in the GM plaques in comparison with controls at the upper
cervical (122.8ȝm2 in GM plaques versus 185.1ȝm2 in controls, p = 0.0000), upper thoracic
(139.2ȝm2 versus 162.9ȝm2, p = 0.0004) and lumbar (173.6ȝm2 versus 193.9ȝm2, p = 0.0041)
levels. Motoneuron size was not significantly different between the GM plaques and the
controls at any of the cord levels (upper cervical, 633.7ȝm2 in GM plaques versus 645.9ȝm2 in
controls, p = 0.7555; upper thoracic, 531.9ȝm2 versus 570.9ȝm2, p = 0.3199; lumbar, 993.4ȝm2
versus 908.4ȝm2, p = 0.2958).
Interneurons within the myelinated GM of MS cases were significantly smaller than in controls
at the upper cervical (158.0ȝm2 in the myelinated GM of MS cases versus 185.1ȝm2 in
controls, p = 0.0000) and upper thoracic (149.8ȝm2 versus 162.9ȝm2, p = 0.0033), but not the
lumbar level (193.2ȝm2 versus 193.9ȝm2, p = 0.8694). Motoneuron size was not significantly
different between myelinated GM in MS cases and controls in the upper cord (upper cervical,
665.0ȝm2 in the myelinated GM of MS cases versus 645.9ȝm2 in controls, p = 0.5847; upper
thoracic, 598.6ȝm2 versus 570.9ȝm2, p = 0.3817), but was increased in the MS cases at the
lumbar level (1023.4ȝm2 versus 908.4ȝm2, p = 0.0025).
Within the MS cases, interneuron size was reduced within the GM plaques in comparison to the
myelinated GM at the upper cervical (122.8ȝm2 in GM plaques versus 158.0ȝm2 in myelinated
GM, p = 0.0000) and lumbar (173.6ȝm2 versus 193.2ȝm2, p = 0.0148) levels. There was no
significant difference at the upper thoracic level (139.2ȝm2 versus 149.8ȝm2, p = 0.1268). There
was no significant difference in motoneuron size between GM plaques and myelinated GM in
the MS cases (upper cervical, p = 0.4415; upper thoracic, p = 0.1144; lumbar, p = 0.7358).
5.4 Discussion
While previous studies have quantified neuronal pathology in relatively small numbers of MS
cases (n < 10)131, 132, 157, 317, we have examined autopsy material from 37 MS cases and 22
controls, making measurements from 8989 neurons. We have performed neuronal counts on
Nissl-stained sections, adjusting the raw counts using the Abercrombie correction. We
demonstrate substantial neuronal pathology in the spinal cord in MS, with changes being
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observed within both demyelinated plaques and in myelinated tissue. Our results suggest that
neuronal loss occurs predominantly within GM plaques.
5.4.1 Evaluation of study methodology
Previous studies have measured the number or density of neurons in the cerebral cortex and
thalamus in MS. Performing neuronal counts in the cerebral cortex is challenging on account of
its highly folded structure and considerable regional heterogeneity329 while the boundaries of
the thalamic nuclei may be ill-defined on autopsy material330. In both structures it is difficult to
obtain sections that are consistently cut in the same plane. In contrast the well defined, simple
anatomy of the spinal cord render it more suitable for quantitative studies202. The spinal cord is
particularly well suited to examine the influence of demyelination on local neuronal loss due to
the high frequency of GM plaques. However a number of issues need to be considered when
performing neuronal counts:
i. Post-Mortem changes in tissue
Considerable dimensional changes occur during the processing of tissue post-mortem, as
described in Chapter 4.4.4336, 337, 339. Due to a lack of detailed information we are unable to
control for variables such as post-mortem interval and fixation time. Tissue shrinkage may also
differ between the healthy and diseased states202, 337. Therefore shrinkage may be greater in
MS plaques in comparison with myelinated tissue due to a higher water content or a difference
in the integrity of the tissue.
ii. Identification of neurons
We use the nissl stain Cresyl violet to identify neurons within the anterior horns of the spinal
cord. A recent study has employed a similar technique to perform neuronal counts in the
cerebral cortex131. IHC stains, for example Neu-N, are available for the identification of
neurons. NeuN is a monoclonal antibody against a nuclear antigen and is a highly sensitive
and specific neuronal marker413, 414. However NeuN staining is often extremely variable when
used on formalin-fixed tissue, particularly when fixation times are long (personal
communication Christiana Wegner, Oxford, and Lars Bö, Amsterdam). Nissl stains such as
Cresyl violet are more robust when used on archival material and readily differentiate between
neurons and non-neuronal cell populations. There are additional merits to using conventional
staining techniques when performing measurements of neuronal number and size. NeuN is
predominantly a nuclear stain; staining of the perikaryal cytoplasm is not observed in all
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neuronal populations, limiting its use in the assessment of neuronal size414. There are also
disadvantages to applying IHC techniques when using relatively thick tissue sections, as used
in this study; incomplete penetrance of the stain is a particular problem for IHC procedures339.
Furthermore, because NeuN identifies nuclei  rather than nucleoli  even thicker sections
would have to be used in order to accurately apply the Abercrombie correction. We do
acknowledge however that the LFB stain interferes with blinding of the heavily demyelinated
sections.
For the purposes of performing neuronal counts, several groups have defined the anterior horn
as the area ventral to the central canal404, 415-418. However the intermediolateral column
frequently lies within this area, as does the anterior portion of Clarkes nucleus419. We were
keen to minimise contamination of our counts by these neuronal populations. In addition we
wished to exclude neurons from the GM commissure as these are smaller than ventral horn
interneurons and more difficult to distinguish from glia274. Therefore we restricted our neuronal
counts to the area ventral to the anterior border of the GM commissure, although we note that a
small number of motoneurons lie posterior to this area and will not be counted419.
iii. Distinction between motoneurons and interneurons
While neurons and non-neuronal cell populations are readily differentiated using the nissl stain,
distinguishing between motoneurons and interneurons may be less straightforward. Retrograde
labelling techniques, which are frequently used to identify motoneurons in animal studies,
cannot be employed post-mortem. The two cell types cannot be differentiated according to their
location within the anterior horn; motoneurons do not always appear in well demarcated,
discrete columns on transverse section and, even when they do, these columns also contain a
significant number of interneurons274. We are not aware of a marker that is 100% specific to
either neuronal subtype that can be reliably applied to formalin fixed material. The cholinergic
markers choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) have been used to
stain motoneurons420, 421. However AChE lacks specificity while ChAT is extremely sensitive to
fixatives and is poorly visualised in formalin-fixed material421, 422. IHC staining for non-
phosphorylated neurofilaments (e.g. using the antibody SMI-32) is a relatively reliable marker
of motoneurons with a similar efficacy to nissl staining although staining is less conspicuous
with prolonged formalin-fixed material421. The Calcium Binding Proteins calbindin, parvalbumin,
calmodulin and calretinin offer some promise as potential markers for particular subpopulations
of interneuron but are not sufficiently sensitive or specific423-426. All four proteins are also
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expressed by a proportion of motoneurons424, 427. Motoneuron expression is upregulated
following axonal injury, which is likely to further limit their use as interneuron markers in a
disease such as MS428.
Several groups have distinguished motoneurons and interneurons using size criteria404, 415-417,
429. Tomlinson et al defined cells as motoneurons if they were greater than 30ȝm in diameter
and fulfilled particular morphological criteria, namely a multipolar shape with 3-5 sides, a
centrally placed nucleus and a well defined nucleolus, 3-6 ȝm in diameter430. In reality a
multipolar neuron may appear circular, oval, unipolar or bipolar in cross-section. In view of this -
and in an effort minimise bias and improve efficiency - we were keen to adopt a less subjective
system of classification. We frequently observe thin bipolar interneurons that are greater than
30ȝm in diameter. We therefore defined motoneurons as cells with a maximum diameter of at
least 30ȝm and a minimum diameter of at least 13.5ȝm with all other neurons being classified
as interneurons. There are limitations to this system of classification. Firstly, there is some
overlap in size between motoneurons and interneurons, even in the non-diseased state274.
Secondly, if there is perikaryal atrophy of motoneurons in the diseased state a proportion of
pathologically shrunken neurons may be misclassified as interneurons.
iv. Neuronal Counts
The disector method is regarded by several groups as the most accurate method of estimating
cell density despite a distinct lack of evidence that it is superior in practice431. Whereas profile-
based counting techniques use single sections as counting probes, the physical disector uses
pairs of parallel sections, a reference section and a lookup section. Objects (e.g. nucleoli)
that appear in the reference section but not in the look-up section are counted; the number of
these objects divided by the volume of space bounded by the outer surfaces of the two
sections represents the density of objects. The two sections need not necessarily be adjacent,
but should be close enough so that no objects are lost between them. In addition it must be
possible to determine which profiles belong to the same object. Despite its theoretical
advantages, the disector method can be difficult to apply in practice. Serial sections are
required; therefore a number of valuable slide collections are unsuitable for such methods339,
432. Furthermore, cutting serial sections is time consuming and requires technical expertise.
The process of co-registering the section pairs is also labour intensive, particularly if performed
without expensive specialist equipment and will be associated with a degree of error339, 433.
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There is much debate as to the relative advantages and disadvantages of profile-based counts
in comparison with stereological-based methods such as the disector339, 411, 432-438. We have
performed counts of neuronal profiles using single sections, correcting these raw counts for
object size and section thickness using the Abercrombie formula. When applied appropriately
profile-based counts can provide extremely accurate estimates of neuronal number439. To avoid
bias the object height (H) should not exceed one third of the section thickness (t)411, 440. We
have therefore counted nucleoli (i.e. we have only counted neurons if the nucleolus can be
seen in the plane of the section) - rather than nuclei or neuronal cell bodies  because they
have a well defined shape and are small relative to the section thickness. In performing such
counts we assume that every neuron has one, and only one, identifiable nucleolus. It may not
be possible to recognise very small fragments of nucleoli that are sectioned by the microtome;
modifications of the Abercrombie correction address this problem of lost caps but the resulting
error is likely to be minimal and so was not applied in this study441.
In practice investigators often estimate H by measuring profile diameters in the xy plane, rather
than measuring it directly in the z-axis. In doing this we assume that the nucleloi are spherical,
or at least isotropically orientated (i.e. orientation in all possible axes is equally likely) so that
mean H and mean object length in the section plane are equal411. These are reasonable
assumptions although the mean nucleolar diameter - as measured - will be slightly less than
the true nucleolar diameter because a proportion of measurements will be made from nucleolar
fragments lying at the section surfaces411. However this error is unlikely to significantly bias our
results considering the small size of the nucleoli relative to the section thickness.
We make further assumptions when measuring the size (i.e. cross-sectional area) of the
neurons, specifically that the nucleolus is approximately in the centre of the neuron and its
position doesnt change in the diseased state. It is well recognised that axonal injury may lead
to chromatolysis, a retrograde reaction in the neuronal cell body characterised by swelling of
the neuronal cell body, peripheral displacement and deformation of the nucleus, and loss of
nissl substance from the central part of the cell. Eccentric placement of the nucleolus would
result in an apparent reduction in neuronal cross-sectional area as we have measured this
parameter in the plane of the nucleolus. However the light microscopy changes of
chromatolysis - best studied in nissl-stained sections - were not observed in this study and we
find no evidence suggesting that the nucleolus becomes eccentrically placed in the pathological
state.
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When applied appropriately, profile-based counts can be extremely accurate, producing results
within 2% of the counts obtained by complete 3-dimensional reconstruction from serial
sections, the gold standard technique for counting cells439. In contrast, the disector can be
inaccurate when compared against 3-dimensional reconstruction442-445. Furthermore, particular
morphological characteristics of the spinal cord were considered in planning the sampling
procedure; motoneurons are not distributed evenly throughout the ventral horn but form
aggregates, arranged in longitudinal columns, referred to as motor nuclei due to their
appearance in transverse section. There is evidence that the physical disector is particularly
inaccurate when applied to neurons distributed in such a non-uniform fashion. Popken et al
performed neuronal counts in the dorsal root ganglion of adult rats, an area showing a
markedly heterogenous distribution of neurons443. When the recommended sampling protocol
for the physical disector was employed (i.e. sampling 100-200 objects)446-449, estimates derived
from repeated measurements differed by over 50%. Comparisons between the physical
disector, profile-based counts and 3-dimensional reconstruction demonstrated that counts of
nucleoli profiles were more reliable than those derived from the physical disector443.
We have reported absolute counts, rather than neuronal densities, counting all neurons in the
anterior horn, regardless of the anterior horn volume. Cell density measurements can be
difficult to interpret if changes in the reference space may occur in the disease state338. For
example, neuronal density may be influenced by a variety of factors including oedema,
inflammatory cell infiltration and gliosis, in addition to neuronal loss per se58. Density
measurements may also be inaccurate if the neurons are arranged in clusters, as they are in
the spinal cord.
v. Sources of statistical variability
We perform neuronal counts at three spinal cord levels; upper cervical, upper thoracic and
lumbar. There is a considerable inter-individual variation in neuron number, even in the non-
diseased state450, 451. There is marked intra-individual variation in motoneuron number between
adjacent spinal cord segments, for example between L2 and L3450. However, the exact
segmental level is not known in all of our cases, making it difficult to control for this variability.
Even greater variability is observed when counts are performed on a single section 430. All of
these factors are likely to add substantial statistical noise to our results. Consequently subtle
differences in neuronal size or number between MS cases and controls may go unnoticed,
despite our relatively large sample size.
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5.4.2 There is substantial neuronal loss in the spinal cord in MS, particularly within GM
plaques
We observe substantial reductions in both motoneuron and interneuron number in the MS
cases in comparison with controls. Our results suggest that neuronal loss occurs predominantly
within GM plaques; neuronal counts in demyelinated tissue are reduced in comparison with
both control tissue and with the myelinated GM of MS cases. These changes only reach
statistical significance in the upper regions of the cord. The apparent preservation of neuronal
number in the lumbar cord may reflect a number of factors. Firstly, within the lumbar region,
relatively few sections demonstrate demyelination of the entire anterior horn (i.e. when
comparing neuronal counts between GM plaques and myelinated GM we consider only anterior
horns that are either completely demyelinated or completely myelinated). This is likely to reflect
(i) the relative sparing of the lumbar region in our cohort (we have previously reported that 42%
of the GM is demyelinated in the upper cervical level in comparison with 38% at the upper
thoracic and 28% at the lumbar level, although these differences do not reach statistical
significance, figure 3.5) and (ii) the GM cross-sectional area is considerably larger in the
lumbar cord, so the anterior horn is less frequently completely demyelinated at this level.
Secondly, there is a high degree of inter-individual and inter-level variability in neuronal number
in the lumbar cord450, so modest reductions in neuronal numbers may go undetected. Finally,
motoneurons are larger in the lumbar cord than at other levels (figure 5.3); if neuronal
susceptibility to injury is size-related, we may expect motoneurons in the lumber cord to be
relatively resistant to neuronal loss.
The mechanism of neuronal loss within GM plaques is poorly understood. Demyelination per se
may lead to neuronal injury, depriving the neuron of trophic support349. Alternatively, a number
of components of the inflammatory milieu are potential mediators of neuronal injury. For
example, lymphocyte-mediated neurotoxicity has been reported in a number of settings, via a
number of mechanisms350, 352-356. Neurons may also be susceptible to bystander injury
secondary to cytokines359, 360, 364, chemokines361, 362, reactive nitrogen and oxygen species365,
glutamate and proteases374, 378, 379.
Post-mortem studies suggest that cortical GM plaques show little inflammatory cell content135,
137. Whether inflammatory cells are present during the earlier stages of plaque genesis is less
clear; animal models of cortical demyelination suggest that transient inflammation may
occur240. The inflammatory content of spinal cord GM plaques has not been examined in detail,
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but at least a proportion of such lesions show an abundance of macrophages. Alternatively
soluble factors may diffuse from nearby WM plaques. This may be particularly relevant in the
spinal cord, where the majority of GM lesions are mixed GM/WM plaques.
Axonal loss in MS almost exclusively affects small calibre axons77-79. We do not observe such a
striking size-related susceptibility to neuronal injury, with similar proportions of interneurons and
motoneurons being lost. Given the magnitude of the anterior horn cell loss that we observe it is
perhaps surprising that we do not observe the classical signs of lower motoneuron pathology in
the clinical setting more frequently. However, it is estimated that 50% of motoneurons are lost
in Motoneuron Disease before muscle wasting and fasiculations are evident clinically452. Focal
muscular atrophy is a relatively uncommon but well recognised feature of MS, estimated to
occur in 6-7% of patients; In a study of 523 men in the armed forces, Kurtzke observed focal
muscle atrophy in 38 cases, while Fisher et al observed atrophy in 9 out of 150 patients453, 454.
The cause of this atrophy is unclear; several mechanisms have been proposed including
involvement of motoneurons or ventral exit zones by MS plaques, neuropathy secondary to
subtle abnormalities in peripheral myelin455 and peripheral nerve compression453. There is
some electrophysiological evidence that focal muscle atrophy is most consistent with injury at
the motoneuron or ventral exit zone level456, 457, although other studies disagree453. Two post-
mortem studies have directly implicated demyelinating plaques involving motoneurons in
muscle atrophy in MS, noting a variety of pathologic changes in the anterior horns (i.e. at the
level corresponding to the focal muscle atrophy), including neuronal shrinkage, central
chromatolysis and subjective reductions in neuronal numbers342, 343.
There appears to be minimal neuronal loss within myelinated regions of the spinal cord,
although we do detect a reduction in motoneuron number in the myelinated GM at the upper
thoracic level. Consistent with our work, Wegner et al found no evidence of neuronal loss within
the myelinated cortex of MS cases131. Even in the non-diseased state there is considerable
inter-individual variation in neuronal number450, 451. Therefore despite our relatively large
sample size, our study may lack the statistical power to detect subtle neuronal loss within the
myelinated GM.
Substantial neuronal loss has been reported in the thalamus in MS157, 317. Cifelli et al reported a
35% reduction in neuronal number in the medial dorsal nucleus in MS patients relative to
controls157. While the role of local GM plaques in mediating these changes has not been
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assessed in detail, it seems unlikely that the modest degree of thalamic demyelination (~ 7 %
according to our estimations, Chapter 2.3.3) could account for such marked changes. It has
been suggested that neuronal loss in the thalamus occurs secondary to the transection of
axons in distant WM lesions157. However we note that despite extensive axonal loss in the
corticospinal tracts in MS79, 101 we find little evidence for neuronal loss in the myelinated GM of
the spinal cord, suggesting that transneuronal degeneration is not a prominent mechanism of
neuronal death in this region. It is hypothesised that susceptibility to transneuronal
degeneration is dependent on the extent of collateral connectivity, with neurons possessing
relatively few sources of synaptic contact, such as those in the LGN, being particularly
vulnerable to injury following de-afferentation or de-efferentation334, 458, 459. In contrast many
spinal cord neurons are involved in complex neuronal networks, receiving multiple inputs and
synapsing on multiple targets. They may therefore derive trophic support from numerous
sources including propriospinal neurons within the cord, peripheral nerves and motoneurons, in
addition to descending tracts from the brain334, 402. Such an abundance of synaptic connections
may be sufficient to maintain neuronal survival, even following removal of descending afferents,
potentially explaining the apparent resistance of spinal neurons to transneuronal
degeneration334, 401-404, 459.
Taken together, these studies suggest there is marked regional heterogeneity both in the
extent of neuronal pathology in MS and in the mechanisms driving these changes. It appears
that neuronal loss is greater in the thalamus (35% reduction157) and the spinal cord (e.g. 24%
reduction in the upper cervical cord, 30% reduction in the upper thoracic cord) than in the
cerebral cortex (10% reduction within lesions, no loss within myelinated areas131), although
there are obvious limitations in comparing studies using different MS cohorts, different counting
techniques etc.. Such variability may reflect regional differences in (i) the extent of GM
demyelination and (ii) susceptibility to retrograde and transneuronal degeneration, which varies
considerably between neuronal populations382. Therefore, neuronal loss in the spinal cord and
the cerebral cortex occurs predominantly  if not exclusively - within local GM plaques while it
is likely that transneuronal degeneration is more prominent in the thalamus. It is also interesting
to note that despite substantial neuronal loss and myelin loss, the volume of the spinal cord GM
is well preserved in the MS cases. Conversely atrophy of the cerebral cortex occurs despite no
change in neuronal density131, highlighting the complex interaction between tissue loss and
atrophy in MS. Presumably loss of neurons  and myelin  within the spinal cord is countered
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by some other process such as oedema, gliosis or expansion of the extracellular matrix, thus
maintaining GM volume.
5.4.3 MS-related changes in neuronal size
In addition to reductions in neuronal numbers in the MS cases, we find significant differences in
neuronal sizes between MS cases and controls. The average interneuron cross-sectional area
is significantly reduced in the MS cases, suggesting there is shrinkage of these cells in MS.
While these changes appear to be most marked within demyelinated areas (e.g. interneurons
within GM plaques in the upper cervical cord show a 34% reduction in size in comparison with
controls), reductions in interneuron size are also observed within myelinated areas of the MS
cases. Again the mechanisms behind these changes are unclear. Evangelou et al suggested
that anterograde transneuronal changes - in particular atrophy of the parvocellular neurons -
occurs in the LGN of the thalamus secondary to axonal loss within plaques in the anterior
visual pathway317. Similarly interneuron shrinkage in the myelinated GM of the spinal cord may
reflect transneuronal damage following axonal injury in the WM tracts (the majority of
descending corticospinal and rubrospinal tract fibres synapse on interneurons rather than
motoneurons429).
There is some evidence that motoneuron size is increased in the MS cases in comparison with
controls. The difference only reaches statistical significance in the lumbar region. The
significance of this finding is unclear; changes in motoneuron size are particularly difficult to
interpret in the context of neuronal loss. An apparent increase in motoneuron size could result
from (i) pathological swelling of motoneurons (ii) a preferential loss of smaller motoneurons (i.e.
a size-related susceptibility to motoneuron loss) resulting in an increase in the average size of
remaining motoneurons, or even (iii) perikaryal shrinkage so that small motoneurons are
incorrectly classified as interneurons.
We have not examined for changes in neuronal shape or dendritic architecture. Spinal
motoneurons have extremely large dendritic trees, constituting 97% of the surface area and
75% of the volume of the neuron460. They frequently extend beyond the GM into the WM, and
may therefore be susceptible to injury secondary to WM and well as GM pathology460. Damage
to spinal motoneuron dendrites has been reported in EAE344, 461, but further work is required to
assess the extent of dendritic pathology in MS.
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5.4.4 Clinical significance
Axonal degeneration is commonly considered to be the major cause of permanent, progressive
neurological disability in MS patients53. Using the same spinal cord autopsy material, we have
reported a 41% reduction in axonal number in the corticospinal tract at the upper cervical level,
with a 26% reduction in the lumbar cord 79. In contrast we report a ~ 25% reduction in neuronal
number at the upper cervical level. It is therefore possible that this neuronal loss is a significant
contributor to permanent disability in MS, along with demyelination and axonal loss. The
substantial reduction in interneuron size may also be relevant clinically. Sastre-Garriga et al
observed correlations between disability scores and GM NAA concentrations in the brain156,
while other groups have found no relationship159, 320, 332. Due to a lack of detailed clinical
information we are unable to investigate the functional significance of neuronal pathology.
There are numerous subpopulations of interneurons with varying functions including the
processing of sensory information, modulating motoneuron activity and co-ordinating motor
activity between different spinal levels459. Interneuron pathology (i.e. reductions in the number
and size of interneurons) may therefore contribute to a number of MS-related symptoms
including motor and sensory disturbance. For example, it has been proposed that loss of dorsal
horn inhibitory GABAergic interneurons following peripheral nerve injury contributes to
neuropathic pain, resulting in a reduction in inhibition of nociceptors that terminate in the dorsal
horn462. Similarly, interneuron loss may contribute to spasticity, a commonly experienced
symptom in MS459.
5.5 Conclusions and future work
In summary, neuronal loss in the spinal cord appears to occur predominantly within GM
plaques, with both motoneurons and interneurons being affected. While we find little evidence
of neuronal loss within the myelinated GM, we do observe changes in neuronal size, indicating
that pathology is not exclusive to GM plaques. Further work is required to elucidate the
mechanisms of this neuronal injury. Additional studies are also required to establish whether
particular subpopulations of interneurons are more susceptible to neuronal injury than others.
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Figures
Figure 5.1
Paraffin sections from the upper thoracic level of the spinal cord stained with anti-Proteolipid
Protein antibody (A), used to assess the extent of grey matter demyelination, and Luxol Fast
Blue Cresyl Violet (B - H), used to perform the neuronal counts. Our assessment was restricted
to the anterior horns of the GM, defined as the area ventral to the GM commissure (B - D). E, F
- Measurements of neuronal number and cross-sectional area (panel F, shaded) were made for
all neurons in which the nucleolus was visible within the plane of section. G, H - Neurons were
classified as motoneurons or interneurons according to size criteria; Neurons with a maximum
diameter of at least 30ȝm and a minimum diameter of at least 13.5ȝm were classified as
motoneurons (G); all other neurons were classified as interneurons (H). Scale bars (E - H)
represent 20ȝm.
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Figure 5.2 - Bar charts of the number of interneurons and motoneurons at the upper cervical (A),
upper thoracic (B) and lumbar (C) levels of the spinal cord. Values represent mean ± standard error.
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Figure 5.3
Bar charts of the cross-sectional areas of interneurons (A) and motoneurons (B) at different
levels of the spinal cord. UC=upper cervical; UT=upper thoracic; LUM=lumbar. Values
represent mean ± standard error.
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Chapter 6: The sensitivity of 4.7 Tesla MRI for detecting spinal
cord grey matter demyelination in Multiple Sclerosis - a post-
mortem MRI-histopathological correlative study
6.1 Introduction
Post-mortem studies demonstrate extensive GM demyelination in the brain and spinal cord in
MS132-135. It is feasible that these lesions result in substantial functional impairment secondary
to conduction block, axonal loss and neuronal apoptosis130, 132. For example, it has been
suggested that cortical plaques could contribute to a range of MS-related symptoms including
cognitive dysfunction, seizures, fatigue and depression134, 178-180. However the true clinical
significance of GM demyelination is uncertain, largely because of the poor sensitivity of MRI for
detecting these lesions128, 222, 463.
MRI-histopathological correlative studies demonstrate that GM demyelination in the brain is
grossly underestimated by conventional imaging techniques128, 129, 222, 463. For example
Newcombe et al imaged autopsy material from 17 MS cases at 0.5 Tesla (T), detecting none of
the 39 cortical lesions identified on histology, and only a small proportion of deep GM
lesions463. Similarly, Kidd et al imaged material at 0.6 T; only 2 of the 14 intracortical lesions
and 58 of the 108 juxtacortical lesions were identified on MRI222. Moreover, both of these
studies used histochemical myelin stains to identify GM lesions on histology; they are therefore
likely to have underestimated the extent of GM demyelination, and so overestimated the
sensitivity of MRI for detecting such lesions.
Geurts et al assessed the sensitivity of MRI for detecting GM plaques using myelin protein IHC,
the gold standard staining method for detecting GM demyelination127, 128, 132. T2-weighted
images of autopsy material were acquired at 1.5T; only 22% of mixed GM/WM cortical lesions,
3% of intracortical lesions and 13% of deep GM lesions were detected on MRI128. Employing a
3D FLAIR (fast fluid-attenuated inversion recovery) sequence - a heavily T2-weighted
technique used to suppress the CSF signal so the brain / CSF interface can be better
visualised - resulted in a very modest increase in sensitivity, revealing 5% of intracortical
lesions and 38% of deep GM lesions. When the locations of the histological lesions were
136
revealed to the MRI readers 74% of the type I (i.e. leucocortical) lesions were identified, in
comparison to 66% of intracortical lesions and 63% of deep GM lesions, demonstrating that a
substantial number of GM lesions could not even be identified retrospectively128. Bö et al have
also demonstrated that conventional MRI is particularly poor for detecting subpial lesions129.
A number of studies have attempted to visual GM demyelination in vivo. For example Geurts et
al suggest that cortical lesion detection may be improved by using a double inversion-recovery
sequence to suppress the CSF and WM signals simultaneously464. Bagnato et al scanned 22
MS patients at 1.5T, co-registering multiple T1-weighted images (12 serial scans, obtained
monthly for 1 year) to generate a single mean image with a high signal-to-noise-ratio465. Pure
cortical lesions were detected in 9 of the 22 MS patients examined. However, only 23% of the
cortical lesions were entirely intracortical, suggesting that a great number of subpial lesions
were not detected (i.e. neuropathologic studies indicate that the majority of cortical lesions are
intracortical127, 129, 131-134). MRI-pathology correlative studies are therefore required to assess
the true sensitivity and specificity of these techniques.
In comparison to WM plaques - for which MRI is highly sensitive - cortical lesions show a
reduced inflammatory cell infiltrate130, 135, 222, low degrees of complement deposition137 and an
absence of BBB disruption136. Such modest inflammation may result in little signal abnormality
in the demyelinated cortex, impairing lesion detection. Bö et al studied the extent of CD3+,
CD4+, CD8+, and CD45RO+ T cell infiltration in cortical lesions using autopsy material from 10
MS patients135. The highest density of T cells was found in WM lesions; fewer were found in the
cortical portion of type I lesions, while the lymphocyte density in the intracortical lesions was no
greater than in myelinated MS cortex or control cortex. Similarly, Peterson et al reported that
cortical lesions contain a 13-fold reduction in lymphocytes and a 6-fold reduction in CD68+
microglia / macrophages in comparison with WM lesions130. In addition there were
morphological differences between MHC class II-positive cells in WM lesions (the majority of
which were phagocytic macrophages) and those in cortical lesions (where MHC class II-
positive cells retained the morphology of activated microglia). Brink et al reported that levels of
complement activation products (C1q, C3d and C5b-9) were reduced in the GM portion of type
I cortical lesions in comparison with active, chronic active and chronic inactive WM lesions137.
Pure cortical lesions showed even lower degrees of complement deposition. Furthermore,
while WM lesions show evidence of BBB disruption (deposition of fibrinogen and IgG, indicating
leakage of these proteins from blood vessels into the brain parenchyma) and blood vessel wall
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damage (splitting of the basal membrane, demonstrated by staining for type IV collagen),
similar changes are not detected in cortical lesions136.
Bö et al suggest the apparent paucity of inflammation observed in cortical lesions may simply
reflect an abundance of chronic inactive lesions in autopsy material135. However it is unclear
whether cortical demyelination occurs in the absence of inflammation or if inflammation occurs
transiently, but subsequently resolves. It is feasible that the relatively low myelin content of the
cortex does not incite a prominent inflammatory reaction466. Alternatively neurons within the
GM may secrete neurotrophins and other substances which promote an anti-inflammatory
environment466, 467. Other differences between GM and WM - perhaps related to the BBB - may
also contribute to reduced inflammation in cortical lesions135, 466.
Merkler et al injected the pro-LQIODPPDWRU\F\WRNLQHV71)ĮDQG,1)ȖLQWRWKHFHUHEUDOFRUWH[RI
MOG-immunised Lewis rats producing extensive subpial demyelination (similar in topography
to MS lesions) accompanied by the infiltration of macrophages, perivascular and parenchymal
T cells, and complement deposition240. However this cortical inflammation was short-lived,
resolving within 2 weeks. Interestingly, identical cytokine injections into the WM of the spinal
cord or the corpus callosum resulted in dense inflammatory infiltrates that persisted for several
weeks, indicating that EAE immunopathology strongly depends on the lesion site240, 468. In a
separate study Merkler et al examined inflammation during the acute phase of lesion formation
in marmosets with MOG-induced EAE, another animal model which shows extensive cortical
demyelination466. In comparison to their WM counterparts, cortical lesions contained fewer
inflammatory cells in the parenchyma. WM and GM lesions contained similar numbers of
perivascular inflammatory cells (T- and B-lymphocytes, and MHC-II expressing
macrophages/microglia) although the cortical lesions contained a smaller proportion of
macrophages expressing the early activation marker MRP14. Interestingly, examination of
leukocortical lesions (i.e. mixed GM/WM lesions) revealed that the border between WM and
cortex was strictly respected with regard to the density of inflammatory infiltrates within the
parenchyma, with fewer inflammatory cells being observed in the GM portion of the lesions.
A number of other factors may contribute to the low sensitivity of conventional MRI for detecting
cortical demyelination. Due to its high cellular density and low myelin content, the T2 relaxation
time of the cerebral cortex is higher than that of the WM. Therefore while WM lesions show a
marked increase in T2 relaxation time with respect to the surrounding normal appearing WM,
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only small increases occur in cortical lesions, resulting in poor contrast between normal
appearing GM and cortical lesions128. Particular anatomical features may further hinder the
detection of cortical lesions. The cortex is a thin, highly folded structure, making it difficult to
image193. In addition, some GM lesions may be masked by partial volume effects from sulcal
CSF469. This is likely to be particularly relevant when imaging subpial lesions, which constitute
a large proportion of cortical plaques127.
To our knowledge no imaging study has examined spinal cord GM involvement in MS. We
have demonstrated substantial demyelination in the GM of the spinal cord; it is important to be
able to visualise these lesions radiologically in order to examine the functional consequences of
demyelination in this clinically eloquent site. In this MRI-pathology correlative study we evaluate
the sensitivity of high resolution MRI for detecting GM demyelination in the spinal cord in MS.
6.2 Materials and methods
6.2.1 Clinical material
Human autopsy material was obtained from 11 pathologically confirmed cases of MS and 2
controls. This material comprised all of the cases received by the Netherlands Multiple
Sclerosis Brain Bank between 1998 and 2001. The MS cases (3 males, 8 females), aged 45 
83 years (median 70 years) with disease durations of 7  52 years (median 23 years), had a
post-mortem delay of 5 h 30 min 16 h 45 min (median 8 h 50 min) and a scan delay of 61 
224 days (median 116 days). The controls (2 females, aged 41 and 83 years), had no clinical
or pathological evidence of spinal cord disease. The characteristics of the patients and controls
are summarised in table 6.1. This autopsy material has been used in a previous study470.
6.2.2 MR Imaging Protocol
For each of the MS and control cases material was taken from the cervical or the upper
thoracic levels of the spinal cord. Proton Density (PD) - weighted images (TR (repeat time) / TE
(echo time) : 3000 / 15 ms, 0.1 x 0.1 x 1.0 mm resolution) of this formalin-fixed material - which
was immersed in a non-magnetic oil (Fomblin; perfluorinated polyether, Solvay Solexis, Weesp,
The Netherlands) - were acquired at 4.7 T (Unity Varian, Palo Alto, CA, USA) using a custom-
made solenoidal coil as described by Bot et al470.
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6.2.3 Histological evaluation
Following imaging the specimens were cut at 1cm intervals and embedded in paraffin. Adjacent
5ȝm sections were taken from predetermined levels of these tissue blocks and stained for
MBP, GFAP, and MHC class II.
6.2.4 Immunohistochemistry
Sections were stained for MBP, HLA-DR and GFAP using the EnVision method as described in
Chapter 2.2.3.
6.2.5 Antibodies
The primary antibodies used were mouse anti-MBP (IgG1, dilution 1:150, MAB387, Chemicon
International, Temecula, CA, USA), mouse anti HLA-DR (IgG2b, clone LN3, dilution 1:100,
obtained from Dr. J.H.M. Hilgers, VU University Medical Centre, Amsterdam, the Netherlands)
and rabbit anti-human GFAP (dilution 1:4000, Z0334, DAKO). For the HLA DR-staining the
tissue sections were cooked for 10 minutes in a 10 mM citrate buffer (pH 6.0) for antigen
retrieval, cooled and rinsed with PBS prior to incubation with the primary antibody.
6.2.6 Histological Assessment
Digital photographs of the MBP-stained sections (Nikon D1X 105mm camera, Photoshop CS
software) were used to manually outline the MS lesions (Scion Image image analysis
software). Histopathological lesions were defined as sharply demarcated areas characterised
by either complete myelin loss or markedly reduced myelin density on the MBP-stained
sections (figure 6.1). Areas of demyelinated GM and WM were measured separately as
described previously (figure 3.3). Lesions were identified by two observers (LB and CPG in
consensus; LB was blinded to the MRI results, CPG assessed the histology sections 6 months
after performing the image analysis and did not re-examine the scans prior to the histological
assessment). The cross-sectional areas of the spinal cords and the cross-sectional GM areas
were measured in order to calculate the relative proportions of the GM and WM that were
demyelinated. The MBP-stained sections, examined via microscopy (10x, Olympus BX40
microscope) were used as a reference to help identify the MS lesions and the GM boundaries.
6.2.7 Assessment of lesion activity
WM lesions were categorised as active, chronic active or chronic inactive on the basis of HLA
DR immunoreactivity, using the classification system of Bö et al31. Active lesions are
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characterised by intense staining for MHC class II-positive cells (activated microglia and
macrophages) throughout the lesion. Chronic active lesions show intense staining of MHC
class II-positive cells at the lesion edge, with a paucity of staining in the centre. Chronic inactive
lesions do not show prominent MHC class II staining. Activated microglia and macrophages are
differentiated by morphological criteria; microglia have small perikarya, thin processes and
elongated nuclei whereas macrophages have larger, round perikarya and lack processes.
Mixed GM/WM lesions were staged according to the activity of the WM component of the
lesion. A similar system has been used to classify mixed GM/WM lesions in the cerebral
cortex130.
6.2.8 Image analysis
The tissue sections were matched with the corresponding MR images using anatomical
landmarks such as the morphology of the GM and the MS plaques. The readers (CPG and
JJGG in consensus) scored the MR images for MS lesions, blinded to the histopathology
results. MRI lesions were defined as clearly circumscribed areas of abnormal (hyper-intense)
signal intensity on the PD-weighted image. Areas of WM and GM were scored separately using
the same system described to score the histopathological sections (figure 6.1).
6.2.9 Statistical analysis
In view of the relatively small sample size and the distribution of the data, nonparametric tests
were used (SPSS software  version 11.5, SPSS, Chicago). Wilcoxon Signed Ranks Test for
paired data was applied to compare the proportion of demyelinated WM to the proportion of
demyelinated GM. Spearmans ranked test was used for correlations.
6.3 Results
6.3.1 MBP Staining
The staining pattern of myelin in the control spinal cords was very similar to that observed with
the PLP antibody, with a paucity of myelinated fibres in the Substantia Gelatinosa of the dorsal
horns and in the GM commissure (figure 6.2). Unlike PLP - which is restricted to CNS myelin -
MBP is also present in the myelin of the peripheral nervous system. This is evident on
comparison of figure 6.2 and figure 3.7, which demonstrate staining of the nerve roots with the
anti-MBP, but not the -PLP antibody.
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6.3.2 Lesion counts
In the 32 sections studied from the 11 MS cases, 95 demyelinated lesions (51 completely
demyelinated areas, 44 areas of markedly reduced myelin density) were detected in the WM
and 56 lesions (38 completely demyelinated lesions, 18 areas of markedly reduced myelin
density) were detected in the GM. Only one of the GM lesions was restricted entirely to the GM;
the remainder were mixed GM/WM lesions.
Overall, a mean 31.1% (median 19.3%) of the WM analysed was demyelinated in comparison
with 28.5% (median 10.8%) of the GM. This difference was not statistically significant (p =
0.721). There was a significant correlation between the proportion of demyelinated WM and the
proportion of demyelinated GM (coefficient = 0.72, p = 0.013). The proportion of WM that was
demyelinated did not correlate with patient age (coefficient = 0.20, p = 0.554) or disease
duration (coefficient = 0.20, p = 0.555). Similarly the proportion of GM that was demyelinated
did not correlate with patient age (coefficient = 0.100, p = 0.769) or disease duration (coefficient
= 0.009, p = 0.979). The proportion of demyelinated WM and GM in each of the MS cases is
shown in table 6.1.
6.3.3 MHC class II and GFAP expression
3 active lesions (from two different cases) and 5 chronic active lesions (from a third case) were
detected. The GM portion of these lesions showed reduced MHC class II-positivity in
comparison to the WM portion (figure 6.4). The majority of MHC class II-positive cells in the
WM portion were macrophages, while those in the GM had the morphology of activated
microglia. The remaining lesions were classified as chronic inactive. GFAP expression was
highly variable, both within WM and GM plaques (figure 6.4Q and S).
6.3.4 MRI
The GM and WM of the spinal cord were easily differentiated on the PD-weighted images. In
two cases (case numbers 1 and 9, table 6.1) the MR images were of poor quality and were
excluded from the analysis. MRI analysis of the remaining 9 cases revealed 35 of the 37
completely demyelinated WM lesions that were detected histopathologically (94.6% sensitivity)
and 18 of the 24 WM areas with markedly reduced myelin density (75% sensitivity). In the GM,
28 of the 32 completely demyelinated lesions (87.5% sensitivity) and 4 of the 12 areas of
markedly reduced myelin density (33.3% sensitivity) were detected on MRI (figure 6.5).
Therefore, overall the sensitivity of MRI was 87% for detecting all WM lesions, and 75% for all
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GM lesions. Furthermore the MR images accurately depicted the outline of the GM lesions. All
of the areas of abnormal signal intensity scored on MRI did correspond to an area of
demyelination. The average size of the GM lesions that were visible on MRI (mean 1.7mm2)
was greater than those that were not detected (mean size 0.6mm2).
6.4 Discussion
While post-mortem studies have provided important insights into GM pathology in MS, non-
invasive techniques are required to detect GM lesions in-vivo in order to establish (i) how GM
lesions evolve over time, (ii) their clinical significance and (iii) response to therapeutic
intervention. MRI-pathology correlative studies play an important role in understanding the
pathological substrate of MR abnormalities.
6.4.1 Post-mortem MRI is highly sensitive for detecting spinal cord GM involvement in
MS
To our knowledge this is the first study to assess the sensitivity of post-mortem MRI for
detecting GM lesions in the spinal cord in MS. In contrast to previous work using this autopsy
material we use myelin protein IHC to examine the extent of GM demyelination470. Our results
indicate that post-mortem imaging at 4.7 T is highly sensitive for cord lesions, detecting 87% of
WM lesions and 75% of GM lesions. Furthermore MRI was highly specific for GM
demyelination, with all areas of abnormal signal hyper-intensity corresponding to plaques.
The spinal cord GM lesions that were not detected on MRI were generally very small and may
be beyond the resolution of the scanner. Alternatively they may have been missed due to
inaccuracies in the co-registration of the tissue sections to the MR images. Small lesions
located in the GM commisure and substantial gelatinosa may be expected to go undetected as
these areas appear hyperintense on the PD-weighted images; for example, it is unsurprising
that the single pure GM lesion, which was restricted to the GM commissure, was not detected
on MRI. In contrast to a previous MRI-pathology correlative study, we have not performed a
retrospective, side-by-side comparison of the MR images and tissue sections to look for subtle
signal abnormalities corresponding with the histologically-identified lesions initially missed on
MRI128. Such assessments are subject to bias and it is difficult to evaluate the specificity of the
subtle signal changes that are identified. However, we recognise that the readers skill in
analysing post-mortem MR images may improve with experience. Because of a paucity of
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autopsy material for use in MRI-pathology studies it is difficult to assess this learning effect
although we note that one of the readers (JJGG) has extensive experience in analysing post-
mortem MR images128, 129, 471.
We have previously reported that a number of spinal cord plaques show a distinct morphology
whereby a proportion of the plaque border maintains a strict respect for the GM/WM boundary,
resulting in areas of demyelinated GM with apparent sparing of the adjacent WM. We observe
a similar pattern of demyelination in the current study (figure 6.1I, J). However, within our
relatively small sample, we do not see any lesions that extend along the GM/WM boundary
over large distances. Similarly we only observe a single pure GM lesion, partly reflecting the
fact that these are more commonly seen in the lumbar cord where the GM has a larger cross-
sectional area. Therefore we are unable to comment on the utility of post-mortem MRI for
detecting and defining the morphology of these lesions.
6.4.2 Spinal cord GM plaques may be detected on MRI more readily than brain lesions
In contrast to the current study, a number of previous reports demonstrate that GM
demyelination in the brain is grossly underestimated by conventional MRI128, 222, 463. The higher
sensitivity that we observe is likely to reflect a number of factors:
i. Morphological differences between spinal cord and cortical plaques
The most frequently observed lesions in the cerebral cortex are subpial in location, extending
inwards from the surface of the brain, usually to layers 3 or 4 of the cortex127, 131-134. Detection
of these plaques is potentially hindered by partial volume averaging with the CSF. Furthermore,
the density of myelinated fibres is particularly low in these superficial cortical layers, and is
likely to result in poor contrast between normal appearing GM and subpial lesions on MRI464.
With the exception of the Substantia Gelatinosa and the GM commissure, the GM of the spinal
cord contains more myelin than the superficial cortical layers. This may result in greater
contrast between myelinated and demyelinated areas in the spinal cord, aiding lesion detection
in this area. Areas of high myelin content may also incite a more intense inflammatory reaction,
resulting in even greater signal change and further aiding lesion detection.
The vast majority of spinal cord GM lesions observed in our study were mixed GM/WM lesions.
MRI is more sensitive for detecting mixed GM-WM cortical lesions than pure intracortical
lesions128. Identification of mixed GM/WM lesions is aided by following the plaque border from
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the readily identifiable WM portion of the plaque into the GM. Furthermore, the GM portions of
mixed GM/WM cortical lesions contain more prominent inflammatory changes than pure
intracortical lesions, which may also aid lesion detection135, 137. It is interesting to note that,
despite these factors, Geurts et al only detected 22% of mixed GM-WM lesions on post-mortem
MRI464. In contrast we detect 75% of GM lesions in the spinal cord, most likely reflecting the
higher field strength employed in our study (4.7T versus 1.5T).
ii. Differences in inflammatory cell content
The low inflammatory cell content of cortical plaques is believed to hinder their detection by
MRI130, 135, 222, 464. There may be regional differences in the numbers of inflammatory cells in
GM plaques, as is the case with WM lesions328. It is feasible that, in comparison with cortical
lesions, spinal cord GM plaques show a more fulminant inflammatory reaction, which in turn
aids their detection on MRI.
Animal studies indicate that there are marked differences between the GM of the brain and
spinal cord in terms of their response to injury. Following either traumatic injury or the injection
of pro-inflammatory cytokines (TNFĮ and IL-1ȕ), leucocyte infiltration and BBB breakdown is
more pronounced in the spinal cord GM in comparison to the striatum264, 265. It has been
suggested that these differences reflect, in part, differences in the expression of chemokines in
response to injury472.
As expected in a post-mortem study, we observe relatively few active plaques. Overall, 8 active
or chronic active lesions were detected in three MS cases. It is likely that these do not actually
represent 8 distinct lesions, but rather that some extensive lesions appear on more than one
tissue section. However, our results suggest that the GM portion of these lesions contain fewer
MHC class II-positive cells than the WM portion. Whereas the majority of activated cells in the
WM lesion were macrophages, those in the GM lesions had the morphology of microglia.
Peterson et al made similar observations in relation to mixed GM/WM lesions in the cerebral
cortex130. Further work is required to assess the degree of lymphocyte infiltration, BBB
breakdown and complement deposition in the GM plaques as any of these factors may
influence lesion detection by MRI. We have previously attempted to examine lesion activity in
a larger number of cases, using the autopsy material derived from the Oxford Radcliffe NHS
Trust and used in Chapter 3. MHC class II-expression was examined in 28 sections taken from
13 MS cases (23 sections) and 3 controls (5 sections). Despite using an identical staining
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protocol to that used in the current study, the staining was unsuccessful in the majority of
cases, possibly reflecting the longer fixation times of the Oxford archival material. However a
small number of active plaques were observed, including that shown in figure 6.7 which
illustrates that some spinal cord GM plaques can contain large numbers of inflammatory cells,
and MHC class-II positive cells within these lesions may have a macrophagic morphology.
iii. Gliosis
There appears to be regional variation in the extent of gliosis within GM plaques. We have
used GFAP to examine gliosis in a limitted number of MS cases; further work - using additional
astrocyte markers - is required to characterise gliosis in more detail. However our results
suggest that a proportion of spinal cord GM plaques are associated with a prominent gliotic
reaction (figure 3.10 and figure 6.4). In contrast, Vercellino et al did not observe gliosis within
cortical plaques or lesions in the deep GM structures of the brain132.
iv. Anatomical differences between the brain and spinal cord
Finally, particular anatomical features are also likely to facilitate lesion detection in our study.
The morphology of the spinal cord is relatively simple in comparison with the highly folded
cerebral cortex. The spinal cord GM is not predisposed to partial volume averaging with the
CSF and is less prone to errors in matching the histopathological sections with the
corresponding MR images. Accurate matching of the tissue sections to the MR images is
further aided by imaging formalin fixed material. All of these factors make the spinal cord well
suited for MRI-pathology correlative studies.
6.4.3 Limitations of the study
There are several limitations to our study that require further discussion. Firstly, tissue fixation
may affect the distribution of water within tissue, altering a number of MR parameters222, 473, 474.
However it has been demonstrated through serial imaging of this material that no further
changes in relaxation times occur after 45 days of fixation470. All of the MR images used in this
study were obtained after this time point to minimise possible differences between specimens
caused by the effects of formalin fixation.
There are obvious limitations to extrapolating our work to in vivo MRI. Post-mortem imaging
permits the acquisition of high resolution images owing to the absence of motion artefact and
improved signal-to-noise-ratio through the use of a surface coil and longer scanning times222.
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Currently, poor spatial resolution precludes the use of MR imaging to study spinal cord GM
pathology in vivo in adequate detail. Cord image quality is further compromised by artefacts
related to surrounding bone, fat and CSF, and by motion artefacts related to respiratory and
cardiac movement475. Bergers et al compared post-mortem in situ MRI (i.e. imaging of the
whole-corpse - before the cord was removed - using a clinical scanner) with in-vitro imaging at
high-resolution, demonstrating that in situ MRI underestimated the number and size of spinal
cord plaques475.
6.5 Conclusion
MRI-pathology correlative studies indicate that conventional MRI is insensitive for detecting GM
demyelination in the brain in MS. In contrast we demonstrate that post-mortem imaging at 4.7T
is highly sensitive for detecting spinal cord GM demyelination. This is likely to reflect a number
of factors including the use the improved spatial resolution obtained at 4.7T, anatomical factors
and intrinsic differences between GM lesions in the spinal cord with those in the brain. Our
work suggests that the spinal cord is a promising site to study the functional consequences of
GM lesions, although there are a number of technical challenges related to imaging the GM of
the cord in vivo.
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Figures
Figure 6.1
Paraffin sections from MS spinal cords, immunohistochemically stained with anti-Myelin Basic
Protein antibody. A, B - Sections were scored for lesions characterised by either complete
myelin loss (blue shading) or markedly reduced myelin density (red shading). The grey matter
(GM) / white matter (WM) boundary is outlined (dashed line). This section contains two
completely demyelinated plaques (one restricted to the WM, one mixed GM/WM lesion) and
one plaque characterised by a marked reduction in myelin density (restricted to the WM). C-E -
Areas of GM showing normal myelin density (C), markedly reduced myelin density (D) and
complete myelin loss (E) at high magnification. F-H - Areas of white matter showing normal
myelin density (F), markedly reduced myelin density (G) and complete myelin loss (H). J - A
proportion of lesions maintain a strict respect for the GM/WM boundary. Higher magnification
images from panels I (box) demonstrate complete demyelination of the GM with apparent
sparing of the adjacent WM. The scale bars in C-H represent 50ȝm; in J they represent
500ȝm.
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Figure 6.2
Paraffin sections from control spinal cord, immunohistochemically stained with anti-Myelin
Basic Protein antibody, demonstrating a paucity of myelin in the Substantia Gelatinosa (dashed
box, shown at higher magnification in panel B) and the grey matter (GM) commissure (solid
box, panel C). In contrast to Proteolipid Protein, Myelin Basic Protein is also a component of
myelin in the peripheral nervous system and therefore stains the posterior nerve roots. Scale
bars (B, C) represent 500ȝm.
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Figure 6.3
Paraffin sections from MS spinal cords immunohistochemically stained with anti-Myelin Basic
Protein (A, C, E) antibodies with the corresponding Proton Density-weighted scans of the
autopsy material, imaged at 4.7 Tesla (B, D, F).
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Figure 6.4
Paraffin sections from control (A-D) and MS spinal cords (E-S), immunohistochemically stained
with anti-Myelin Basic Protein (MBP) (A, E, M, R), anti-HLA DR (B-D, F-L, N-P), and anti-GFAP
antibodies (Q-S). A-D - Tissue from control cases show low levels of HLA DR-staining (B),
seen at higher magnification in panels C (grey matter (GM)) and D (white matter (WM)). E, I -
Bilateral mixed WM/GM lesions; the lesion on the left is chronic inactive and that on he right is
acute active. F - Active plaque from panel I (box) at medium magnification demonstrating
prominent HLA DR-staining in the WM portion of the lesion and at the plaque border, which lies
in the GM. G - MHC class II-positive cells, with the morphology of macrophages, are distributed
throughout the WM portion of the acute active lesion. H  the plaque border  in the GM portion
of the lesion - contains MHC class II-positive cells with the morphology of activated microglia.
J. Staining in the core of the GM portion of the lesion is markedly reduced compared to the WM
portion (H), but increased compared to the GM in the chronic inactive lesion (K) and control
GM (C). L - WM in the chronic inactive lesion. M, N - Two chronic active lesions and a chronic
inactive lesion. O - The chronic active lesion in the posterior columns from panel N (box)
contains numerous perivascular macrophages seen at higher magnification in panel P. Q
(corresponding to E and I) - A proportion of GM plaques show clear evidence of gliosis. R, S -
In other cases the gliotic reaction in the GM portion of the plaque is much less pronounced.
The scale bars in F and O represent 500ȝm; in C, D, G, H, J-L and P they represent 50ȝm.
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Figure 6.5
Bar chart illustrating the number of MS plaques detected by histopathological and MRI
analysis. Complete = completely demyelinated lesions. Partial = lesions with markedly
reduced myelin density
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Figure 6.6
Paraffin sections from an MS spinal cord at the Lumbar level, immunohistochemically stained
with anti-Proteolipid Protein (PLP) (A, B) and anti-HLA DR antibodies (C-G). A, C  the mixed
grey matter (GM) / white matter (WM) lesion on the left is acute active, and contains numerous
PLP-laden macrophages in both the GM (panel B, at high magnification, demonstrating
macrophage nuclei (horizontal arrow) and intra-cellular PLP (vertical arrow)) and WM portions
of the plaque. Large numbers of MHC class II-positive cells, with the morphology of
macrophages, are distributed throughout both GM (D) and WM (E) portions of the acute active
lesion. In comparison, much fewer MHC class II-positive cells are observed in the myelinated
GM (F) and WM (G), where they have the morphology of microglia. Scale bars (B, D-G)
represent 50ȝm.
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% Demyelinated Area*
NBB number Age Sex Disease course
Disease duration
(years)
Cause of death
Post-mortem
delay
Scan delay
(days) WM GM
98-176 83 M PP 52 Pneumonia 7 h 5 min 194 28.8 10.8
98-179 60 F SP 36 Intracerebral haemorrhage 8 h 50 min 214 10.3 36.0
98-185 70 F PP 19 Pneumonia 8 h 55 min 178 4.7 8.2
99-051 45 F SP 14 Euthanasia 10 h 55 min 116 44.1 53.0
99-054 58 F SP 20 Euthanasia 8 h 10 min 224 61.1 21.4
99-062 79 F PP 44 Cardiac disease 10 h 0 min 107 18.6 7.1
99-066 69 M SP 46 Ileus 16 h 45 min 66 19.3 4.0
99-073 71 F ND 23 Pneumonia 8 h 20 min 111 94.1 92.7
99-086 71 F SP 31 Respiratory failure 10 h 25 min 129 49.7 71.9
99-109 70 M ND 21 Pneumonia 6 h 25 min 61 11.6 8.9
99-115 57 F PP 7 Euthanasia 5 h 30 min 66 0 0
00-022 83 F Control NA Myocardial infarct 7 h 45 min 144 NA NA
00-025 41 F Control NA Bronchial carcinoma 13 h 30 min 144 NA NA
Table 6.1 - Clinical characteristics of the autopsy cases and the proportion of GM and WM that was demyelinated. * % Demyelinated Area values represent
the pooled results from the three spinal cord levels. Abbreviations: NBB (Netherlands Brain Bank), WM (white matter), GM (grey matter), SP (Secondary
Progressive), PP (Primary Progressive), ND (not determined), NA (not applicable).
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Chapter 7: Summary of Results
MS is the most common chronic disabling neurological disease affecting young people in the
UK. Current therapeutic options offer only modest benefit. A greater understanding of MS
pathogenesis and the mechanisms of disability in the disease are required in order to develop
novel therapeutic agents. MS has traditionally been considered to be a disease of WM, a view
that partly reflects shortcomings in conventional MRI and histological staining techniques -
particularly their lack of sensitivity in detecting demyelination in GM structures127-129. More
recent post-mortem and imaging studies have resulted in an increasing recognition of GM
pathology, with there being some evidence that these changes occur in part independently of
WM demyelination / inflammation129, 133, 183, 193, 315. However this work has focused exclusively
on GM structures in the brain.
We believe our series represents the largest post-mortem examination of spinal cord pathology
in MS. We have chosen to focus on the cord for several reasons: firstly, in comparison with the
cerebral cortex and thalamus, spinal cord GM pathology has received little attention. Secondly
the spinal cord is a well-recognised predilection site for demyelination, with lesions in this
clinically eloquent area frequently resulting in disabling relapses205, 206. Disability in progressive
forms of MS is also often attributed to spinal cord pathology. Thirdly, while not easily amenable
to study via imaging or tissue biopsy, the simple but well characterised anatomy of the spinal
cord lends itself to quantitative neuropathological study using post-mortem material. Finally, in
addition to being a predilection site for demyelination, there is marked axonal loss in the spinal
cord, making it well suited to examine neurodegenerative aspects of MS pathology76-79, 210.
In this thesis we further our understanding of GM involvement in MS by exploring a variety of
aspects of GM pathology in the spinal cord. We have been particularly interested in the factors
that govern plaque morphology  both in terms of the topography of individual plaques
(including their relationship to blood vessels, the CSF and the GM/WM boundary) and regional
differences in the extent of demyelination. Our initial study highlights the extent of
demyelination in the spinal cord GM. This study is the first to use myelin protein IHC  the gold
standard technique for detecting GM demyelination  to compare the extent of both WM and
GM demyelination in the spinal cord with that in intracranial structures (namely the cerebral
cortex, cerebellum and thalamus). We demonstrate that both GM and WM demyelination is
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highest in the spinal cord, although considerable demyelination is also observed in the
cerebellar cortex. Previous studies have highlighted an abundance of lesions in subpial
structure (both in the cerebral and the cerebellar cortex), suggesting a role for CSF- or
meningeal- related factors in mediating this demyelination. It is therefore interesting to note that
even greater demyelination occurs in the spinal cord, where the GM is neither bathed in CSF
nor intimately related to the meninges. The study also demonstrates that demyelination is more
extensive in the GM than in the WM at each of the anatomical sites examined, further
challenging the concept that MS is predominantly a disease of WM.
These novel findings prompted us to examine the extent and pattern of GM demyelination in
the spinal cord in greater detail. We did this using autopsy material from 37 MS cases,
assessing plaque topography at the upper and lower cervical, upper and lower thoracic and
lumbar cord levels. We demonstrate that the proportion of GM that is demyelinated is greater
than the proportion of WM that is demyelinated at all five levels. While WM demyelination is
most prominent at the upper cervical level, there is no significant difference in the extent of GM
demyelination between the various cord levels.
We observe striking morphological differences between GM and WM plaques. The factors
influencing plaque topography in MS are not fully understood. Previous studies suggest the
majority of spinal plaques are perivenular in location, and display a total disregard for
anatomical boundaries21, 24, 204. However we find that the borders of many spinal cord GM
plaques maintain a strict respect for the GM/WM boundary, a pattern of residual plaque
morphology that does not appear to occur in a purely perivenular distribution. In this respect
we have likened these lesions to the type IV lesions of the cerebral cortex and the subpial
lesions of the cerebellar cortex, both of which show extensive demyelination within the GM,
with sparing of the adjacent WM. We have proposed that these lesions may share a common
pathogenic mechanism, possibly reflecting (i) differences in interstitial fluid drainage pathways
between GM and WM, (ii) phenotypical differences between GM and WM or (iii) GM/WM
differences in the ability to remyelinate.
A number of recent studies highlight the extent of axonal and neuronal pathology in MS, which
are likely to represent important substrates for irreversible disability53. We demonstrate
substantial neuronal loss in the spinal cord in MS, observing reductions in both interneuron and
motoneuron numbers. This neuronal loss appears to occur predominantly  if not exclusively -
161
within GM plaques. We also observe reductions in interneuron size, both within plaques and in
the myelinated GM. Despite substantial demyelination in the GM of the spinal cord, and the
considerable neuronal loss associated with this demyelination, the spinal cord GM volume does
not differ significantly between MS and control cases. Atrophy in MS is loosely considered to be
a surrogate marker of tissue loss (that is, axonal loss in the WM and neuronal / axonal loss in
the GM) but our studies demonstrate the complex interaction between tissue loss and atrophy.
When viewed in the context of previous studies examining neuronal loss and GM atrophy in the
brain, this work highlights considerable regional heterogeneity related to (i) the extent of
neuronal loss, (ii) the predominant mechanism of neuronal loss, and (iii) the degree of tissue
atrophy131, 157.
Conclusions and further work
A greater understanding of GM pathology may provide important insight into MS
pathologenesis and mechanisms of disability in the disease, and identify potential targets for
novel therapeutic strategies. We feel that this thesis adds to the current body of literature on
GM histopathology in MS, identifying the spinal cord GM as a predilection site for
demyelination, and highlighting patterns of plaque morphology that have not been reported
previously. In addition, we demonstrate substantial neuronal pathology in the spinal cord.
Further work is required to better characterise these processes.
Such extensive demyelination and neuronal pathology is likely to be of clinical importance, both
in relapsing and progressive MS, contributing to a number of symptoms including motor,
sensory and bladder dysfunction. However, post-mortem studies are unlikely to provide
significant insight into the functional consequences of GM pathology. An understanding of the
clinical correlate of GM pathology (be it demyelination, neuronal loss or atrophy) will only come
with non-invasive in vivo techniques. Improved imaging will also provide invaluable information
on the early stages of lesion formation and an appreciation of the evolution of pathology. In
light of this it is promising that post-mortem MR imaging at 4.7 T is highly sensitive for detecting
spinal cord GM demyelination.
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